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Abstract 
Pharmacological probes for the melanocortin receptors have been utilized for 
studying various disease states including cancer, sexual function disorders, Alzheimer’s 
disease, social disorders, cachexia, and obesity. Of interest to our laboratory is the 
melanocortin system’s role in energy homeostasis that is mediated through the 
melanocortin 3 receptor (MC3R) and melanocortin 4 receptor (MC4R). Specifically, our 
laboratory focuses on the development of novel pharmacological probes to better 
understand the role of the melanocortin receptor system’s effects on energy homeostasis.  
This thesis provides the field with foundational work addressing the functional 
effects of melanocortin bivalent ligands both in vitro and in vivo. In Chapter 3 and 
Chapter 4, traditional homobivalent approaches are utilized.  The synthesis and in vitro 
evaluation of homobivalent ligands are discussed in Chapter 3. Lead ligands (CJL-1-87 
and CJL-1-31) increased binding affinity by 14- to 25-fold and increased cAMP signaling 
potency by 3- to 5-fold compared to their monovalent counterparts depending on the 
specific melanocortin receptor subtype assayed. In Chapter 4, the in vivo effects of lead 
ligand CJL-1-87 is characterized thoroughly. Bivalent ligand CJL-1-87 had noteworthy 
advantages as an anti-obesity probe over its monovalent counterpart in a fasting-refeeding 
in vivo paradigm. Treatment with CJL-1-87 significantly decreased food intake compared 
to CJL-1-14 or saline (50% less intake 2 to 8 hours after treatment). Further energy 
expenditure parameters are explored, and possible mechanisms are discussed.  
In Chapter 5 and Chapter 6, uncommon approaches are attempted to exploit 
melanocortin dimers to elicited undiscovered pharmacological effects. In the Chapter 5, 
v 
we present melanocortin unmatched bivalent ligands (MUmBLs) as tools for studying 
asymmetric function of melanocortin receptor homodimers. MUmBLs contain one agonist 
scaffold and one antagonist scaffold designed to target a melanocortin homodimer pair 
such that one receptor is occupied by an agonist scaffold and the other receptor by an 
antagonist scaffold. Utilizing this design strategy to target the MC4R, first in class biased 
unmatched bivalent ligands (BUmBLs) were discovered. The BUmBLs displayed biased 
agonism in which they potently stimulated cAMP signaling, but resulted in minimal 
activation of the β-arrestin recruitment pathway. 
In Chapter 6, we describe two different approaches that were pursued to further 
study melanocortin bivalent ligands’ structure activity relationship (SAR). Homobivalent 
ligands were designed with 13, 16, 19, 20, and 22 atom linkers to explore the effects of 
linker length. Overall, these studies resulted in a “flat” SAR in which the compounds all 
have similar potencies and efficacies. Bivalent ligands were also designed to include the 
retro-inverso tetrapeptide scaffold DTrp-DArg-Phe-DHis. Although this scaffold lacked 
high binding affinity and potency, it was very metabolically stable. The incorporation of 
this scaffold into bivalent ligands yielded ligands with varying potencies and metabolic 
stabilities.  
The current discoveries may be broadly applicable to other GPCR systems. As the 
physiological relevancy to GPCR oligomerization is elucidated, the current medicinal 
chemistry strategies presented in this thesis should aid in the discovery of probes and 
possible therapeutics for the further understanding of GPCR pharmacology for various 
systems.    
vi 
Table of Contents 
Abstract .............................................................................................................................. iv 
Table of Contents ............................................................................................................... vi 
List of Tables ...................................................................................................................... x 
List of Figures ................................................................................................................... xii 
List of Schemes ............................................................................................................... xvii 
Chapter 1: Introduction: What do GPCR Oligomers, Entropic Cost of Binding, 
Melanocortin Signaling, and the Obesity Epidemic have in Common? ............................. 1 
1.1 Bivalent Ligands targeting G Protein-Coupled Receptors ........................................ 1 
1.2 The Melanocortin Receptor System .......................................................................... 3 
1.3 Multivalent and Bivalent Ligands Targeting the Melanocortin System ................... 7 
1.3.1 Melanocortin Multivalent Ligands .................................................................... 9 
1.3.2 Melanocortin Bivalent Ligands ........................................................................ 13 
1.4 Conclusions ............................................................................................................. 19 
Chapter 2: Materials and Methods .................................................................................... 23 
2.1 Chapter Overview ................................................................................................... 23 
2.2 Solid Phase Peptide Synthesis ................................................................................ 24 
2.3 Resin Splitting Approach ........................................................................................ 27 
2.4 Cell Culture ............................................................................................................. 29 
2.5 Competitive Radioligand Binding Affinity Studies ................................................ 29 
2.6 AlphaScreen® cAMP Functional Bioassay ............................................................. 31 
2.7 ALPHAScreen Assay Data Normalization ............................................................. 33 
2.8 PRESTO-Tango (β-arrestin Recruitment) Assay ................................................... 34 
2.9 Bioluminescence Resonance Energy Transfer (BRET) Studies ............................. 36 
2.10 Serum Stability Studies- ....................................................................................... 38 
2.11 Animals Studies .................................................................................................... 40 
2.12 Cannulation Surgery and Placement Validation ................................................... 41 
2.13 In Vivo Energy Metabolism Studies ..................................................................... 42 
vii 
2.14 Body Composition Studies ................................................................................... 44 
2.15 Luminex Milliplex Hormone Panel Studies ......................................................... 44 
2.16 Data Analysis ........................................................................................................ 45 
Chapter 3: The Design, Synthesis, In Vitro, and In Vivo Investigation of Homobivalent 
Ligands that Display Preferential Binding and Functional Activity for Different 
Melanocortin Receptor Homodimers ................................................................................ 52 
3.1 Chapter Overview ................................................................................................... 53 
3.2 Introduction ............................................................................................................. 53 
3.3 Results and Discussion: .......................................................................................... 57 
3.3.1 Design .............................................................................................................. 57 
3.3.2 Peptide synthesis .............................................................................................. 60 
3.3.3 125I-NDP-MSH Competitive Binding Affinity Studies.................................... 63 
3.3.4 Functional cAMP Accumulation Studies......................................................... 69 
3.3.5 In Vivo ICV Administration Studies ............................................................... 79 
3.4 Conclusion: ............................................................................................................. 82 
Chapter 4: A Direct In Vivo Comparison of The Melanocortin Monovalent Agonist Ac-
His-DPhe-Arg-Trp-NH2 versus The Bivalent Agonist Ac-His-DPhe-Arg-Trp-PEDG20-
His-DPhe-Arg-Trp-NH2: A Bivalent Advantage ............................................................ 105 
4.1 Chapter Overview: ................................................................................................ 105 
4.2 Introduction ........................................................................................................... 107 
4.3 Results and Discussion: ........................................................................................ 111 
4.3.1 In Vitro Mouse Serum Stability Assays......................................................... 111 
4.3.2 The Effect of ICV Administration of CJL-1-14 versus CJL-1-87 on Mouse 
Energy Homeostasis................................................................................................ 113 
viii 
4.3.3 The Effect of ICV Administration of CJL-1-14 and CJL-1-87 on Body 
Composition ............................................................................................................ 119 
4.3.4 The Effect of ICV Administration of CJL-1-14 and CJL-1-87 on Hormone 
Levels ...................................................................................................................... 121 
4.3.5 125I-AGRP Competitive Binding Studies ....................................................... 125 
4.3.6 Bioluminescence Resonance Energy Transfer (BRET) Supports mMC3R-
mMC4R Heterodimerization .................................................................................. 128 
4.3.7 Coexpression of mMC3R and mMC4R effects on Functional Potency ........ 131 
4.3.8 Coexpression of mMC3R and mMC4R Effects on Functional Potency and 
Discussion of Expression Levels ............................................................................ 134 
4.4 Conclusions ........................................................................................................... 135 
Chapter 5: Developing Biased Unmatched Bivalent Ligands (BUmBLs) to Target 
Asymmetrically Signaling Melanocortin-4 Receptor Homodimers ............................... 153 
5.1 Chapter Overview ................................................................................................. 153 
5.2 Introduction ........................................................................................................... 154 
5.3. Results and Discussion ........................................................................................ 158 
5.3.1 Design and Synthesis ..................................................................................... 158 
5.3.2 Biased Signaling at the hMC4R ..................................................................... 161 
5.3.3 Characterization of cAMP Signaling at the Mouse Melanocortin Receptors 168 
5.3.4 125I-NDP-MSH Competitive Binding Assays. ............................................... 173 
5.3.5 Ligand Dependent Modulation of BRET Signal ........................................... 178 
5.3.6 MUmBLs Effects on Energy Homeostasis in Mice ....................................... 181 
ix 
5.4 Conclusions ........................................................................................................... 195 
Chapter 6: Progressing the Structure Activity Relationship (SAR) of Bivalent Ligands: 
Evaluating the Effects of the Linker Length and Pursuing a Retro-Inverso Approach .. 242 
6.1 Chapter Overview ................................................................................................. 242 
6.2 Introduction ........................................................................................................... 243 
6.3 Results and Discussion ......................................................................................... 246 
6.3.1 Synthesis ........................................................................................................ 246 
6.3.2 In Vitro Biological Characterization .............................................................. 246 
6.3.3 In Vitro Mouse Serum Stability Assays......................................................... 255 
6.4 Conclusions ........................................................................................................... 256 
Chapter 7: Advancements Made, Lessons Learned, and Future Directions ................... 269 
Bibliography ................................................................................................................... 273 
Appendix: Summary of Analytical Information and Pharmacology of Compounds ..... 300 
 
  
x 
 
List of Tables 
 
Table 2.1. Competitive radioligand binding assays on the BRET receptor constructs. .... 51 
Table 3.1. Analytical data for peptides synthesized in this Chapter 3. ............................. 97 
Table 3.2. Summary of competitive binding experiments for compounds evaluated at the 
mouse melanocortin receptors .......................................................................................... 98 
Table 3.3 Summary of functional experiments for His-DPhe-Arg-Trp-based compounds 
evaluated at the mouse melanocortin receptors .............................................................. 101 
Table 3.4 Summary of functional experiments for His-DNal(2')-Arg-Trp and the His-
DPhe(p-I)-Arg-Trp based compounds evaluated at the mouse melanocortin receptors . 103 
Table 3.5 Latin-square (Cross-over) paradigm used for in vivo feeding experiments in 
Chapter 3. ........................................................................................................................ 104 
Table 4.1. Summary of the effects of fasting and melanocortin (MC) receptor agonism on 
hormone and cytokine levels from the literature (Lit.) and the current study. ............... 149 
Table 4.2: The experimental compounds were used to displace either 125I-NDP-MSH or 
125I-AGRP in a dose-response manner to calculate the IC50 values. ............................... 151 
Table 4.3: Functional cAMP AlphaScreen® assays were performed to determine in vitro 
potency of compounds to induce cAMP signaling in five cell categories ...................... 152 
Table 5.1: Functional data at the hMC4R. ...................................................................... 232 
Table 5.2. The analytical data for peptides synthesized ................................................. 234 
xi 
Table 5.3: Summary of cAMP functional experiments and competitive binding 
experiments at the mMC1R, mMC3R, mMC4R, and mMC5R. .................................... 235 
Table 5.4: Functional data at the mMC1R, mMC3R, mMC4R, and mMC5R with data from 
Chapter 3 for comparison................................................................................................ 237 
Table 5.5: Summary of competitive binding experiments at the mMC1R, mMC3R, and 
mMC4R with data from Chapter 3 for comparison. ....................................................... 239 
Table 5.6. Table of adverse reactions observed in the current experiments with CJL-5-58 
in wild-type mice, MC3RKO mice, and MC4RKO mice. .............................................. 241 
Table 6.1. The analytical data for peptides synthesized ................................................. 265 
Table 6.2: Functional cAMP signaling data at the mMC1R, mMC3R, mMC4R, and 
mMC5R........................................................................................................................... 266 
Table 6.3: Summary of competitive binding experiments at the mMC1R, mMC3R, and 
mMC4R........................................................................................................................... 268 
Appendix Table A-1. The analytical data for peptides synthesized in this thesis .......... 304 
Appendix Table A-2: Functional data at the mMC1R, mMC3R, mMC4R, and mMC5R.
......................................................................................................................................... 306 
Appendix Table A-3: Summary of competitive binding experiments with  125I-NDP-MSH 
at the mMC1R, mMC3R, and mMC4R. ......................................................................... 308 
 
  
xii 
List of Figures 
Figure 1.1: Structures of classic melanocortin ligands. .................................................... 21 
Figure 1.2. Bivalent and multivalent ligand binding modes. ............................................ 22 
Figure 2.1. Representative radioligand binding curves of the BRET receptor constructs...48 
Figure 2.2. Average results from hPYY cannulation validation experiments. ................. 49 
Figure 2.3: Experimental paradigms used to study energy homeostasis in Chapter 4 ..... 50 
Figure 3.1. Design of ligands in Chapter 3 from selected scaffolds and linkers. ..............81
Figure 3.2. Crude RP-HPLC analytical chromatograms .................................................. 86 
Figure 3.3. Illustrations of the competitive binding experiments ..................................... 87 
Figure 3.4. Proposed binding mode of the bivalent ligands. ............................................ 88 
Figure 3.5. Postulated rationale for linker-dependent preferences at the different 
melanocortin homodimer subtypes. .................................................................................. 90 
Figure 3.6. Illustrations of the in vitro functional pharmacology at the mMC1R, mMC3R, 
mMC4R, and mMC5R of the His-DPhe-Arg-Trp based ligands. .................................... 91 
Figure 3.8. Correlation of IC50 (nM) vs EC50 (nM) at the different receptor subtypes for 
His-DPhe-Arg-Trp based ligands. .................................................................................... 93 
Figure 3.9. AlphaScreen functional Schild analysis at the mMC3R and mMC4R of both 
our synthetically made (CJL-1-20) and the commercially bought analog (Peptides Int) of 
the Ac-His-DPhe(pI)-Arg-Trp-NH2 .................................................................................. 94 
xiii 
Figure 3.10. Cumulative food intake following intracerebroventricular administration of 
either saline (n=16 male; 8 female) or CJL-1-87 in saline (n=8 male; 4 female) in wild 
type mice. .......................................................................................................................... 95 
Figure 4.1. In vitro serum stability of bivalent ligands and control ligands ................... 139 
Figure 4.2. Investigation of 5 nmol bivalent ligand CJL-1-87 ( ) compared to 5 nmol 
monovalent ligand CJL-1-14 ( ) (A) on energy homeostasis in TSE metabolic cages 
following a cross-over nocturnal feeding paradigm ....................................................... 140 
Figure 4.3. Investigation of 5 nmol bivalent ligand CJL-1-87 ( ) compared to 5 nmol 
monovalent ligand CJL-1-14 ( ) (A) and saline ( ) on energy homeostasis in TSE 
metabolic cages following a cross-over paradigm .......................................................... 142 
Figure 4.4. A new cohort of male mice received a single treatment of saline vehicle control 
( , n=10), 5 nmol CJL-1-14 ( , n=11), or 5 nmol CJL-1-87 ( , n=11) in the 
fasting paradigm .............................................................................................................. 145 
Figure 4.5. Bioluminescence resonance energy transfer (BRET) of the mMC3R and 
mMC4R........................................................................................................................... 146 
Figure 4.6. Cell categories for cAMP AlphaScreen® functional assays during coexpression 
experiments ..................................................................................................................... 148 
Figure 5.1. Hypothesized interaction of ligands with asymmetrically signaling 
melanocortin homodimers. ............................................................................................. 201 
Figure 5.2. Different possible binding states of a MUmBL. .......................................... 202 
Figure 5.3. In vitro mouse serum stability assay to aid in the design of the MUmBLs. . 203 
xiv 
Figure 5.4. Illustrations of the in vitro functional pharmacology at the hMC4R of 
MUmBLs, ....................................................................................................................... 204 
Figure 5.5. Illustrations of a previously reported model for allosteric interactions in GPCR 
dimers. ............................................................................................................................. 205 
Figure 5.6. Illustrations of the in vitro functional pharmacology of the MUmBLs at the 
mMC1R, mMC3R, mMC4R, and mMC5R .................................................................... 207 
Figure 5.7. The functional dose response curve of CJL-1-124 ( ) may increase the 
therapeutic window versus traditional dose response curves ( ) .................................... 208 
Figure 5.8: Illustrations of the competitive binding experiments against 125I-NDP-MSH at 
the mMC3R and mMC4R ............................................................................................... 209 
Figure 5.9: Illustrations of the 125I-NDP-MSH competitive binding experiments with 
MUmBLs compared to monovalent tetrapeptide ligands separately and in a mixture at the 
mMC1R........................................................................................................................... 210 
Figure 5.10. Ligand induced response of bioluminescence resonance energy transfer 
(BRET) signal at the mMC4R-NanoLuc and MC4R-HaloTag homodimer. .................. 211 
Figure 5.11. The dose response effect of CJL-5-58 administered ICV on cumulative food 
intake in male and female wild type mice utilizing a fasting refeeding paradigm. ........ 212 
Figure 5.12. The dose response effect of CJL-5-58 administered ICV on change in body 
weight in male and female wild type mice utilizing a fasting refeeding paradigm………213 
Figure 5.13. The effect of CJL-5-58 administered ICV on cumulative food intake in male 
and female wild type mice utilizing nocturnal feeding paradigm. .................................. 214 
xv 
Figure 5.14 The effect of CJL-5-58 administered ICV on change in body weight (g) in 
male and female wild type mice utilizing nocturnal feeding paradigm. ......................... 215 
Figure 5.15. TSE metabolic cage parameters after ICV administration of 5 nmols of CJL-
5-58, or a combination of 5 nmols CJL-1-14 and 5 nmols CJL-1-80 (10 nmols total 
combined peptide) to male wild type mice in a fasting-refeeding paradigm .................. 216 
Figure 5.16 TSE metabolic cage parameters after ICV administration of 5 nmols of CJL-
5-58, or a combination of CJL-1-14 and CJL-1-80 (10 nmols total peptide) to male wild 
type mice in a fasting refeeding paradigm. ..................................................................... 217 
Figure 5.17. TSE metabolic cage parameters after ICV administration of 5 nmols of CJL-
5-58, or a combination of CJL-1-14 and CJL-1-80 (10 nmols total peptide) to male wild 
type mice in a nocturnal feeding paradigm (no fasting). ................................................ 219 
Figure 5.18: TSE metabolic cage parameters after ICV administration of 5 nmols of CJL-
5-58, or a combination of CJL-1-14 and CJL-1-80 (10 nmols total peptide) to male wild 
type mice in a nocturnal feeding paradigm. .................................................................... 220 
Figure 5.19. TSE metabolic cage parameters after ICV administration of 5.0, 2.5, or 1.0 
nmols of CJL-5-58 to male MC3RKO mice in a nocturnal feeding paradigm. ............. 222 
Figure 5.20. TSE metabolic cage parameters after ICV administration of 1.0 or 0.5 nmols 
of CJL-5-58 to male MC3RKO mice in a fasting-refeeding paradigm. ........................ 224 
Figure 5.21. The effect of CJL-5-58 (5 nmols) administered ICV on cumulative food intake 
and body weight in male MC4RKO mice utilizing nocturnal feeding and fasting-refeeding 
paradigm in conventional cages. ..................................................................................... 226 
xvi 
Figure 5.22. TSE metabolic cage parameters after ICV administration of 5.0 or 2.5 nmols 
of CJL-1-124 to male wild type mice in a nocturnal feeding paradigm. ....................... 227 
Figure 5.23. TSE metabolic cage parameters after ICV administration of 5.0 or 2.5 nmols 
of CJL-1-124 to male MC3RKO mice in a nocturnal feeding paradigm. ...................... 229 
Figure 5.24. The effect of CJL-1-124 (5.0 and 2.5 nmols) administered ICV on cumulative 
food intake and body weight in male MC4RKO mice utilizing nocturnal feeding paradigm 
in conventional cages. ..................................................................................................... 231 
Figure 6.1. The chemical structures of selected scaffolds and linkers used in Chapter 6.
......................................................................................................................................... 259 
Figure 6.2. Design of melanocortin bivalent ligands containing retro-inverso scaffolds.
......................................................................................................................................... 260 
Figure 6.3. Illustrations of the competitive binding experiments at the mMC1R (A), 
mMC3R (B), and mMC4R (C) ....................................................................................... 262 
Figure 6.4. In vitro serum stability of linker length bivalent analogs at 24 h (A) and retro-
inverso analogs at 24 h (B) and 72 h (C) ........................................................................ 263 
Appendix Figure A-1. The chemical structures of selected scaffolds and linkers used. 301 
  
xvii 
List of Schemes 
 
Scheme 2.1 General synthesis scheme of split resin approach. ........................................ 46 
Scheme 2.2.  Example of resin splitting synthesis scheme. .............................................. 47 
 
 
  
1 
Chapter 1: Introduction: What do GPCR Oligomers, Entropic Cost of Binding, 
Melanocortin Signaling, and the Obesity Epidemic have in Common? 
Portions of the information presented in this chapter have been published 
previously and are currently being reproduced in part with permission from: Ericson, M. 
D.; Lensing, C. J.; Fleming, K. A.; Schlasner, K. N.; Doering, S. R.; Haskell-Luevano, C. 
Bench-Top to Clinical Therapies: A Review of Melanocortin Ligands from 1954 to 2016. 
Biochim. Biophys. Acta, Mol. Basis Dis. 2017, in press. Copyright (2017) Elsevier B.V.1 
The primary section being reproduced from this work is Section 1.3 and was principally 
written by the current author, Cody J. Lensing, with contributions from the coauthors. 
Figure 1.1 was made by and used with permission from Mark D. Ericson.1  
1.1 Bivalent Ligands targeting G Protein-Coupled Receptors  
Approximately 30-40% of pharmaceutics target G protein-coupled receptors 
(GPCRs) making them a highly sought-after drug target.2, 3 Because of their therapeutic 
significance, novel methods of targeting GPCRs that are distinct from classical approaches 
are desirable. Classically, ligands targeting GPCRs were designed to bind to orthosteric 
sites in a monomeric fashion. One alternative to this approach would be to design ligands 
that target multiple GPCR orthosteric sites through multivalent binding. There has been 
increasing evidence that GPCRs can form dimers with themselves (homodimers) and with 
other GPCRs (heterodimers) as well as higher order oligomers.4 These oligomers may 
represent new drug targets with unique exploitable functions compared to their monomeric 
receptor forms. Therefore, the development of chemical probes to study GPCR 
oligomerization is of great interest.  
2 
Bivalent ligand design strategies have been developed and used to study various 
GPCR dimer systems including: the opioid,5-12 gonadotropin-releasing hormone,13, 14 
adenosine,15 cannabinoid,16, 17 serotonin,18-20 dopamine,21, 22 chemokine,10, 23 oxytocin,24 
and melanocortin receptor systems.25-40 Bivalent ligands are comprised of two 
pharmacophores separated by a linker or spacer. The two pharmacophores are designed to 
target two different binding sites, such as the two orthosteric binding sites of interacting 
GPCRs in a dimer. This bivalent ligand approach to study GPCR dimerization was 
pioneered by Portoghese and coworkers studying the opioid system.7, 12 Since their 
inception, bivalent ligands have been reported to have a variety of unique pharmacological 
effects that are distinct form their monovalent counterparts including: increasing or 
decreasing binding affinity,19, 21, 33 positively or negatively changing functional 
responses,15, 17, 20, 26, 41 altering receptor subtype selectivity,8, 21 changing receptor 
trafficking,42-44 and creating tissue selectivity.5, 10 Specifically, heterobivalent ligands 
featuring pharmacophores for two different receptor types have been utilized to exploit 
allosteric interactions within heterodimers. This allowed for the development of ligands 
with novel pharmacological profiles, tissue selectivity, and different functional effects.10, 
11, 44-48 
Of particular interest to the development of future therapeutics, there are reports 
indicating that bivalent ligands may avoid the undesirable side effects exhibited by classic 
monovalent ligands.10, 11, 44, 46 A previous study of heterobivalent ligands targeting the δ 
and µ opioid receptor heterodimers resulted in a ligand with 50-fold higher opioid agonist 
potency, but devoid of tolerance commonly seen with monovalent opioid ligands.11 
Bivalent melanocortin ligands may, therefore, be able to circumvent undesirable side 
3 
effects seen with classic monovalent ligands. To discover possibly novel biological 
functions of ligands created using a bivalent ligand design strategy and to investigate their 
utility as probes to study GPCR dimerization, this thesis work explores the application of 
this design strategy on the melanocortin GPCR system. 
1.2 The Melanocortin Receptor System 
The melanocortin receptor system is involved in various physiological functions 
including pigmentation,49, 50 sexual behavior,51 blood pressure modulation,52 memory,53-55 
and energy homeostasis.56-59 Therefore, ligands targeting the melanocortin GPCRs have 
been utilized as probes or investigated as potential therapeutics for Alzheimer’s disease,60-
62 cancer targeting,6, 28, 63-65 sexual function,51, 66 social disorders,67, 68 cachexia,69-73 and 
obesity.56, 74-76 The system contains five Gαs protein-coupled receptor subtypes (MC1-5R) 
that stimulate the cAMP signal transduction pathway upon agonist binding.49, 77-82 The 
melanocortin-1-receptor (MC1R) is expressed in the skin and is primarily involved in 
pigmentation. 49, 77 The melanocortin-2 receptor (MC2R) is expressed in the adrenal cortex 
and is involved in steroidogenesis.49 The centrally expressed melanocortin-3 and 
melanocortin-4 receptors (MC3R and MC4R) are linked to energy homeostasis. 56, 57, 83-87 
Additionally, the MC4R has a role in sexual function. 88, 89 While the exact role of the 
melanocortin-5 receptor (MC5R) has not been elucidated, 90, 91 it has been linked to 
exocrine function  in mice. 92 
In addition to the receptors involved, the melanocortin system is comprised of both 
endogenous agonists and antagonists (Figure 1.1A and B).1 The naturally occurring 
agonists are derived from the proopiomelanocortin (POMC) gene transcript and include 
adrenocorticotropic hormone (ACTH), β-melanocyte stimulating hormone (β-MSH), γ-
4 
MSH, and α-MSH (Figure 1.1A).93 All of these ligands contain the common tetrapeptide 
sequence His-Phe-Arg-Trp tetrapeptide sequence. This common signal sequence has been 
the center of many structure activity relationship (SAR) campaigns to discover synthetic 
agonists (e.g. NDP-MSH and MTII) and antagonists (e.g. SHU9119) (Figure 1.1C).94-99 
The existence of endogenous antagonists is uncommon for GPCR systems. Melanocortin 
endogenous antagonists include agouti (ASP) and agouti-related protein (AGRP) (Figure 
1.1B).100-102 Additionally, agouti and AGRP possess inverse agonist activity in some 
organisms, 103, 104 directly decreasing levels of cAMP within a cell.  
The melanocortin system’s role in energy homeostasis is of particular interest to 
both academic and industrial researchers due to the current obesity epidemic. 
Approximately one third of Americans are clinically obese.105 It is estimated that the US 
spends $209.7 billion each year on obesity-related diseases.106 Obesity is associated with 
an increased risk of developing type 2 diabetes, cancer, hypertension, osteoarthritis, 
asthma, depression, and myocardial infarction.106 These health and economic implications 
demand an integrative approach of public policy, education, preventative programs, and 
pharmaceutical intervention to treat obesity. Melanocortin-related effects on energy 
homeostasis are largely thought to be mediated through the MC3R and MC4R located in 
the hypothalamus.57, 76, 107 Therefore, ligands that target the MC3R or MC4R may provide 
a pharmaceutical therapy to overcome the current obesity epidemic.  
Initial evidence of the role of the MC4R came from the knockout (KO) mouse 
model.57 Female MC4R KO mice were two times heavier as their wild-type counterparts 
after 15 weeks. Male MC4R KO mice were one and a half times heavier than their wildtype 
counterparts.57 Importantly, these genetic trends of the MC4R’s role in obesity are 
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observed in human epidemiological studies as well. Individuals with a loss of function 
mutation in the MC4R accumulate more body mass compared to normal (wild type) 
patients as seen in their body mass index (BMI).108, 109 The difference in BMI was ~8-9 
kg/m2 for females and ~4-5 kg/m2 for males.108, 109 In another study, 5.8% of patients 
(n=500) with severe childhood obesity were identified to have a mutation in the MC4R.110  
Although the MC3R has been identified to play a role in energy homeostasis, there 
is less known about it. The MC3RKO mice, MC4RKO mice, and double 
MC3RKO/MC4RKO mice all displayed different phenotypes indicating non-redundant 
roles for the MC3R and MC4R.58, 111 The MC3RKO mice at 4-6 months of age were 
reported to have increased fat mass and reduced lean mass, but were hypophagic. The 
MC3RKO mice were also reported to be hyperleptinemic and mildly hyperinsulinemic.58 
The double MC3RKO/MC4RKO mice become significantly heavier than either the 
MC4RKO mice or MC3RKO mice. This result may indicate a synergistic effect between 
the two receptors.58, 111  
Further evidence of the melanocortin system’s roles in energy homeostasis can be 
observed in pharmacological data. Central administration of MC3R and MC4R agonist 
ligands results in decreased food intake and increased energy expenditure, and therefore, 
agonists represent potential therapeutics for metabolic disorders resulting from net positive 
calorie consumption (e.g. obesity).25, 56, 57, 76, 107, 112 In contrast, central administration of 
MC3R and MC4R antagonist ligands result in increased food intake, and therefore, 
antagonists represent potential therapeutics for metabolic disorders resulting from a calorie 
deficit (e.g. cachexia and anorexia).56, 69, 76  Teasing out the exact effects of the MC3R 
compared to the MC4R has been challenging. Intracerebroventricular (ICV) administration 
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of mixed MC3R/MC4R endogenous antagonist/inverse agonist AGRP in both MC3R and 
MC4R male knockout mice results in increased food intake.76, 113  Similarly, administration 
of the MC3R/MC4R agonist melanotan-II (MTII) results in decreased food intake in both 
MC3R and MC4R knockout mice suggesting both receptors are possible therapeutic 
targets.111  
Based on both genetic and pharmacological reports, many pharmaceutical 
companies initiated melanocortin ligand discovery programs. However, reports of 
cardiovascular side effects associated with MC4R ligands in humans52 coupled with an 
increase in mergers within the pharmaceutical industry led to diminished industrial 
investment in melanocortin ligands. Despite these setbacks, melanocortin ligands have 
continued to be advanced to clinical trials.114-117 To date, no melanocortin ligands have 
been FDA-approved to treat metabolic disorders. The major identified limitations of 
melanocortin ligands as anti-obesity therapeutics is still their undesirable effects of 
modulating blood pressure52, 118 and inducing male erections.66  
Various strategies to overcome these limitations have been proposed in the field. 
One approach has been attempting to identify ligands that are MC3R selective over the 
MC4R with the hypothesis that MC3R ligands would not possess the cardiovascular 
effects. This has proven challenging, but ligands with some selectivity have been 
reported.119 Other strategies that may be hypothesized include identifying allosteric 
modulators, biased agonist, tissue specific ligands, or other unique pharmacologies not 
currently reported in the literature. To identify novel pharmacologies, melanocortin ligands 
based on new scaffolds and different targeting strategies are needed. Therefore, we pursued 
utilizing bivalent ligand design strategy to target the melanocortin receptor system.  
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As stated above, bivalent ligands have been demonstrated to have unique functional 
characteristics compared to monovalent counterparts including: increasing or decreasing 
binding affinity,19, 21, 33 positively or negatively changing functional responses,15, 17, 20, 26, 41 
altering receptor subtype selectivity,8, 21 changing receptor trafficking,42-44 and creating 
tissue selectivity.5, 10 Due to these unique characteristics, bivalent ligands may offer distinct 
advantages over the classical monomeric approaches or allow for the discovery of new 
biological functions or pharmacologies. The ideal pharmacology for an anti-obesity probe 
would be a melanocortin bivalent agonist ligand that has reduced effects on sexual 
behavior51 and blood pressure52 while maintaining the desirable effect of decreasing food 
intake.56-58, 74, 76 However, any novel pharmacology discovered will allow for further 
understanding of the melanocortin system.  
1.3 Multivalent and Bivalent Ligands Targeting the Melanocortin System  
Before and during this current thesis’s work, research, and preparation; bivalent 
and multivalent ligand design strategies targeting the melanocortin receptors have been 
utilized. Mainly, bivalent and multivalent ligands were used only to achieve high binding 
affinity ligands and often functional effects on signaling pathways were not evaluated. To 
give an adequate introduction and review of the current state of this field (as of May 2017), 
we will supply a short review of reports to date. Hopefully, this will allow a thorough 
understanding of the current work, its context in the established literature, and its 
contribution to the field.  
A major benefit of bivalent or multivalent ligand binding strategies is the lowered 
entropic cost of binding by allowing multiple binding interactions per ligand resulting in 
cooperative binding affinity (Figure 1.2 A-C).7, 120-124 Recent studies have suggested the 
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presence of melanocortin receptor dimers (or higher-order oligomers) for every known 
melanocortin subtype.125-132 Furthermore, radiolabeled ligand binding studies suggested 
that there are two side by side receptor binding sites (indicative of homodimerization) each 
with different binding properties on cells expressing the melanocortin receptors. 133, 134 This 
suggests targetable dimers that may be functionally relevant.133, 134 The reported bivalent 
and multivalent ligands are likely taking advantage of the dimerization or oligomerization 
of multiple melanocortin receptors together on the cell membrane (Figure 1.2 D-E).  
A large portion of the prior work into bivalent and multivalent melanocortin ligands 
has been as probes to study melanoma. Since melanoma cells often express elevated levels 
of the MC1R, it was hypothesized that ligands with high MC1R affinity could be 
conjugated to dyes or other labels and utilized as imagining or diagnostic tools.135-139 These 
high affinity ligands might also be used to deliver therapeutics selectively to melanoma 
cells. However, this targeting strategy has been criticized because stimulation of the MC1R 
has been shown to increase melanocyte proliferation and, therefore, could possibly lead to 
melanoma growth.140, 141 The use of melanocortin ligands as diagnostic tools has been 
reviewed previously, and is not the focus of the current thesis work.135-139 The current work 
is focused on studying the effects of melanocortin bivalent ligands on energy homeostasis. 
This introduction will focus on updating the medicinal chemistry approaches that have 
been applied to bivalent and multivalent melanocortin ligands in general. Multivalent 
ligands possessing more than two pharmacophores will be reviewed first, followed by 
bivalent ligands containing exactly two pharmacophores. 
One difficulty in understanding the pharmacology of bivalent and multivalent 
ligands is discerning whether the effects are from a cooperative synergistic binding mode, 
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or due to the effect of increasing the pharmacophore concentration without synergy effects. 
Large increases in binding affinity compared to the monovalent controls (>10-fold) are 
hypothesized to be due to a cooperative synergistic bivalent or multivalent binding mode 
(Figure 1.2). While melanocortin bivalent ligands have been shown to enhance binding 
affinity, rarely additional pharmacophores beyond two have been reported to result in 
further binding affinity gains at the melanocortin receptors as discussed below. 28, 123  
1.3.1 Melanocortin Multivalent Ligands 
Multivalent ligands are defined as ligands that feature more than two 
pharmacophores for the melanocortin receptors, ranging from three to several hundred. 
Conjugates of multiple copies α-MSH derivatives to larger biomolecules were reported 
starting in 1977.142, 143 Eberle and coworkers reported conjugating α-MSH to human serum 
albumin at a ratio of four and six α-MSH hormones to one molecule of albumin and showed 
approximately equal activity to non-conjugated α-MSH analogs in testing on Rana pipiens 
(i.e. frogs). Schwyzer and coworkers reported loading the tobacco mosaic virus (TMV) 
with approximately 400-600 molecules of α-MSH analogs, resulting in enhanced potency, 
affinity, resistance towards enzymatic degradation, and prolonged activity at target 
cells.144-149 Sharma and coworkers developed a class of multivalent fluorescent 
melanotropin-macromolecule conjugates.150, 151 They used a polyvinyl alcohol (PVA) 
scaffold that had an approximate molecular weight of 110,000 and 2500 hydroxyl groups 
available for derivation. The hydroxyl groups were conjugated to introduce 10-16 
molecules of a melanocortin pharmacophore (based on NDP-MSH) and 10-16 molecules 
of a fluorophore (fluorescein isothiocyanate or FTIC) to create macromolecular conjugates 
(MSH-PVA-FITC). These conjugates possessed increased binding affinity and increased 
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levels of melanocortin receptor detection in labeling experiments comparing different cells 
that did or did not express the melanocortin receptors.150, 151 Sharma and coworkers also 
developed both latex bead and polyamide bead conjugates to NDP-MSH analogs and 
achieved similar results as Schwyzer and coworkers.152-154 The latex beads were considered 
microspheres (~1 µm in diameter) and the polyamide beads were classified as 
macrospheres (40 to 100 µm in diameter). Electron and light microscopy imaging indicated 
that mutiple latex microspheres were bound to B16/F10 mouse melanoma cells (~10-15 
µm in diameter). The larger polyamide macrospheres were bound to multiple cells, a 
difference presumed to be due to the relative sizes of the conjugated beads and the cells. 
 In 2007, Newton and coworkers engineered and fused α-MSH analogs to phages 
and used these multivalent phage constructs to image B16-F1 mouse melanoma in vitro 
and in vivo.155 In 2011 and 2013, Barkey and coworkers attached hMC1R selective α-MSH 
analogs to stabilized triblock polymer micelles through Cu-catalyzed click chemistry.65, 156 
Though the ligand decreased binding affinity of the polymer micelles after attachment, it 
increased specificity for the hMC1R over the hMC4R and hMC5R.64 Further cross-linking 
the targeted polymer micelles generated constructs that were used as delivery systems for 
contrast-enhancing gadolinium complexes of texaphyrin (Gd-Tx).65 These agents were 
efficacious at penetrating and delivering the contrast agent into xenografted tumors in mice 
with minimal accumulation in healthy tissues, including the kidney and liver.65  
 Besides conjugated multivalent ligands, additional research has focused on the 
design of smaller, synthetic ligands. One design strategy to create trivalent ligands has been 
to incorporate a lysine into the linker of bivalent ligands, providing an additional chemical 
handle to add another pharmacophore. This method of creating trivalent ligands has 
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resulted in ligands that possessed increased binding affinity over bivalent and monovalent 
ligands at the hMC4R, but the results were reported to not be indicative of trivalent 
binding.157 In a different design strategy in 2011, Brabez and coworkers reported a series 
of trivalent melanocortin ligands with increased binding affinity in support of a trivalent 
cooperative binding mode. They found the optimal distance between His-DPhe-Arg-Trp 
tetrapeptide pharmacophores to be 24 ± 5 Å when targeting the hMC4R.28 In competitive 
binding experiments with HEK293 cells expressing the hMC4R, the monovalent, bivalent, 
and trivalent analogs had IC50 values of 4900, 310, and 14 nM, respectively. The increased 
affinity with each valency suggested that three receptors were involved in a trivalent 
cooperative binding mechanism with the trivalent ligand.28, 123 The authors noted that 
although cAMP signaling potency increased with each valency, the levels of cAMP 
signaling corresponded to receptor occupancy independent of valency. This suggested that 
the ligands activated cAMP signaling in a monovalent fashion and no allosterism or 
synergy in function was detected.28 In a follow-up study, the authors conjugated multiple 
trivalent ligands together resulting in ligands with 6 and 9 pharmacophores.158 The 6- and 
9-valent compounds decreased binding affinity 3-fold at the hMC4R compared to the 
trivalent analog, but were approximately 100-fold more potent than the monovalent 
compound. These data suggest the 6- and 9- pharmacophore ligands achieved cooperative 
binding but three or fewer receptors were involved. The cAMP signaling was also 
independent of the number of pharmacophores present, as previously described. They 
reported that all compounds were internalized within 90 minutes, suggesting these 
constructs could potentially be used for drug delivery purposes.158 
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Solanesol-derived and sucrose-derived scaffolds were utilized to make both 
bivalent and tetravalent ligands attached to the His-DPhe-Arg-Trp tetrapeptide 
sequence.159, 160 Moderate improvement in binding affinity at the hMC4R was observed, 
likely due to proximity effects and increasing the moles of pharmacophore present, but not 
indicative of cooperative or multivalent binding. The authors hypothesized their ligands 
may not possess the correct linker length or improperly presented the pharmacophores for 
cooperative binding.159, 160 
A unique strategy to synthesize multivalent ligands featuring the His-DPhe-Arg-
Trp tetrapeptide was reported by Dehigaspitiya and coworkers in 2015. Linear ligands that 
had up to eight His-DPhe-Arg-Trp units were synthesized and separated by a (Pro-Gly)3 
linker. The binding affinities for the hMC4R were slightly enhanced in competitive binding 
experiments when adjusted for pharmacophore concentrations, suggesting the observed 
enhancement were not from cooperativity or multivalent binding.161 
In 2015, Elshan and coworkers presented trivalent scaffolds featuring the His-
DPhe-Arg-Trp tetrapeptide pharmacophore and compared them to monovalent bivalent 
ligands. The bivalent ligands increased binding affinity 10- to 30-fold, indicating 
synergistic bivalent binding affinity at the hMC4R. The trivalent ligands were reported to 
be only marginally better binders (~2-fold) than the bivalent ligands. This indicated that 
the benefits in binding for the trivalent ligands are derived from a bivalent binding mode, 
but that true trivalent binding was not achieved with these ligands.162 Their results 
suggested the optimal linker length to bridge two receptors is between 17 and 23 Å. 
However, considering a third receptor did not appear to be utilized, it is likely that the third 
pharmacophore linker is not optimized to achieve trivalent binding.162 Dehigaspitiya and 
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coworkers reported similar results when comparing monovalent, bivalent, trivalent and 
tetravalent ligands featuring the tetrapeptide His-DPhe-Arg-Trp in different scaffolds.163 
All multivalent compounds possessed 30- to 40-fold higher binding affinities at the 
hMC4R compared to monovalent controls, although valencies beyond two did not result in 
further affinity gains. This finding is consistent with bivalent binding to putative 
melanocortin receptor dimers, without evidence for trivalent or tetravalent binding. They 
also reported the optimal distance between pharmacophores was between 17 and 23 Å, as 
previously reported.162, 163 
1.3.2 Melanocortin Bivalent Ligands 
Bivalent ligands are the simplest form of multivalent ligands featuring two 
pharmacophores separated by a linker or spacer. The two pharmacophores are intended to 
target two different binding sites.  Bivalent ligands were first reported in the clinic by Barb 
and coworkers as diagnostic tools. 164-167 A subclass of bivalent ligands is bitopic ligands, 
which target both an orthosteric and an allosteric binding site on the same receptor. To the 
author’s knowledge, there are no known bitopic melanocortin ligands. Therefore, in this 
thesis the term bivalent ligand will be used exclusively for ligands that target two 
orthosteric binding sites on two different receptors.  
Orthosteric bivalent ligands are commonly split into two classes: homobivalent 
ligands and heterobivalent ligands. Homobivalent ligands contain the same pharmacophore 
on each side of the linker. Heterobivalent ligands contain two different pharmacophores 
for two different GPCR types on each side of the linker. Heterobivalent ligands that contain 
one melanocortin pharmacophore have been developed as probes for targeting melanoma 
or other cancers.6, 168-173 These ligands feature a pharmacophore for the melanocortin 
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receptors and a pharmacophore for a different receptor system (including opioid receptors 
or cholecystokinin). Monovalent binding occurs to cells expressing one receptor subtype. 
However, synergistic bivalent binding occurs only on cells expressing both receptor types.6, 
168-173 If appropriate receptor pairs are selected that are co-expressed in cancer cells but not 
in normal cells, the synergistic bivalent binding will selectively happen on cancer cells. A 
fluorescent label can be conjugated in the inert linker region, resulting in high affinity 
ligands that can be used for cancer imagining and diagnostics. Replacement of the 
fluorescent label with a chemotherapeutic can result in a highly selective drug targeting 
strategy.6, 168-173 This heterobivalent ligand targeting strategy has been validated both in 
vitro and in vivo.6, 168-172 In 2012, Xu and coworkers synthesized heterobivalent ligands 
containing a melanocortin pharmacophore and a cholecystokinin pharmacophore separated 
by a fluorescently-labeled synthetic linker. They observed the ligands had up to a 12-fold 
higher specificity for tumors co-expressing both receptors than for tumors expressing one 
receptor, providing a proof-of-principle for future studies.6 Although these ligands do hold 
promise, the current thesis will focus on bivalent ligands that target only the melanocortin 
receptor system.  
This work focuses mainly on homobivalent ligands (containing two of the same 
pharmacophores). These are discussed in Chapter 3, Chapter 4, and Chapter 6. A class 
of bivalent ligands that are comprised of two different pharmacophores, but both targeting 
the melanocortin receptors, will also be discussed in Chapter 5 and Chapter 6. The key 
differentiator between previously described heterobivalent ligands and the bivalent ligands 
described in Chapter 5 and 6, is that the ligands herein are comprised of one agonist 
pharmacophore and one antagonist pharmacophore on each side of the linker that both 
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target the same receptor. In order to differentiate from heterobivalent ligands that target 
two different GPCR types, we have titled this class of ligands “melanocortin unmatched 
bivalent ligands,” which is abbreviated MUmBLs. 
  Carrithers and Lerner developed one of the earliest series of homobivalent 
melanocortin ligands in 1996 to target two separate melanocortin receptors by crosslinking 
them. They utilized either an agonist pharmacophore based on α-MSH or the 
pharmacophore Met-Pro-DPhe-Arg-DTrp-Phe-Lys-Pro-Val tethered by a poly-lysine 
linker.26, 174 They demonstrated that the agonist bivalent ligand increased functional 
activity 5- to 7-fold. In the frog melanocyte dispersion assay utilized, the Met-Pro-DPhe-
Arg-DTrp-Phe-Lys-Pro-Val-based monovalent ligand was reported to antagonize α-MSH 
mediated dispersion in a dose-dependent manner. At high concentrations, the bivalent 
ligand based on Met-Pro-DPhe-Arg-DTrp-Phe-Lys-Pro-Val resulted in an agonist 
functional response. 175 This was the first report demonstrating increased functional activity 
with melanocortin bivalent ligands targeting putative dimers.  
 After the above report, homobivalent ligand development primarily focused on 
increasing the binding affinity at the hMC4R through various bivalent ligand design 
strategies, 28, 120, 123, 157, 161-163, 176-180 with some reports focusing on the MC1R and in vivo 
imaging. 40, 180-182 While high affinity ligands are desirable for biological responses, the use 
of low affinity pharmacophores in bivalent ligand design allows the greatest detection of 
synergistic binding 28, 40, 120, 122, 124, 157, 176, 179. Therefore, analogs with lower initial 
monovalent binding affinities result in the greatest observable fold enhancements via a 
bivalent design strategy. Research programs primarily utilized different analogs of the 
agonist NDP-MSH (Figure 1.1). These included the tetrapeptide His-DPhe-Arg-Trp,28, 120, 
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123, 157, 161-163, 176, 178, 180 six residue analogs,157, 181, 182 seven residue analogs, 40, 177, 179 and 
full length NDP-MSH. 120, 176, 178 Antagonist analogs in which the DPhe was replaced with 
DNal(2’) have been utilized as well to produce antagonist analogs with increased binding 
affinity.179, 180 There has also been one report to date in which a melanocortin agonist 
pharmacophore was attached to an antagonist pharmacophore via a linker that also resulted 
in increased binding affinity, but functional activity was not assayed.179 
 In the reports to date, linker optimization has been a primary goal of melanocortin 
homobivalent ligand design. The optimal linker length must be long enough to bridge or 
crosslink two receptors, but not too long to eliminate entropic gains. Various linker systems 
have been incorporated including poly-lysine,175, 177 polyethylene glycol,157, 163, 177-180 Ala-
Gly,157 Pro-Gly,157, 161, 177, 179, 180 rigid amino acids,176 squalene,120 glycerol,163 D-
mannitol,163 phloroglucinol,162 tripropargylamine,162 1,4,7-triazacyclononane,162 others,28, 
40, 123 and mixtures of these different linker systems together. Improper linker design may 
result in some increased binding affinity (<10-fold) that can be attributed to simply 
doubling the pharmacophore concentration.157, 176, 177 Greater fold enhancements (>10-
fold) are observed with linkers that appear to bridge two receptors resulting in cooperative 
synergistic binding (Figure 1.2 A-C). An optimal linker length of approximately 23 ± 5 Å 
has been suggested by multiple studies at the hMC4R.28, 162, 163, 177, 179 
 An assumption in the field prior to this thesis work was that a bivalent ligand 
optimized for the MC4R would be effective as a diagnostic tool for melanoma (that highly 
expresses the MC1R), as long as a non-selective pharmacophore was incorporated. As a 
result, the majority of studies only investigated in vitro pharmacology using HEK293 cells 
overexpressing the hMC4R, which resulted in ligands optimized for the hMC4R. This 
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thesis work challenges this assumption by providing evidence that the linker systems, 
independent of the binding pharmacophore, displayed preferential patterns for different 
melanocortin receptor subtypes.180 Similar trends for other GPCR systems have been 
reported,183-185 highlighting the importance of optimizing the linker and pharmacophore for 
a specific receptor subtype if high affinity and specificity is desired. Our work on 
investigating bivalent ligands’ preferential binding affinities and functional activities for 
the different melanocortin receptor homodimers is discussed in detail in Chapter 3.  
 Binding affinity is usually the optimized parameter in melanocortin bivalent 
designs, but there are a few reports discussing bivalent ligand effects on functional potency. 
As described above, Carrithers and Lerner observed a 5- to 7-fold enhancement relative to 
the monovalent ligand in a functional frog-melanocyte dispersion assay (presumably 
through the MC1R).175 Another study by Brabez and coworkers compared the effects of 
monovalent, bivalent, and trivalent ligands on cAMP signaling in HEK293 cells expressing 
the hMC4R and observed increased cAMP signaling corresponding to increased valency.28 
It was reported in work resulting from this thesis that although bivalent ligands increased 
binding affinity (14- to 25-fold), more moderate increases in cAMP signaling potency were 
observed (3- to 5-fold) (see Chapter 3). Considering that at least a doubling in functional 
potency would be expected due to doubling the pharmacophore concentration, these 
increases suggested minimal synergy in function due to bivalent ligand design.180 Several 
hypotheses have been proposed for the possible divergences between binding affinity and 
functional potency, including unique βγ subunit signaling, potency masking, auxiliary 
binding sites, signal amplification events, and asymmetric dimer signaling.28, 175, 180 Given 
the limited reports of bivalent ligands’ functional effects, this thesis work sought to further 
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expand the characterization of the functional activities of melanocortin bivalent ligands. 
Our work on homobivalent ligands’ functional effects both in vitro and in vivo are 
discussed in Chapter 3 and Chapter 4. Then in Chapter 5, we characterize the functional 
effects of the designed MUmBLs to explore possible reasons for the divergences between 
binding affinity and functional potency. In Chapter 6, further structure activity 
relationships (SAR) are examined by exploring linker length and the incorporation of a 
retro-inverso pharmacophore DTrp-DArg-Phe-DHis into the bivalent ligand design. 
Most of the previous in vivo studies on melanocortin homobivalent ligands have 
focused on their utility as diagnostic tools, and not on their functional efficacy.40, 135, 136, 164, 
165, 181, 182 As noted above, the use of high affinity ligands for the MC1R coupled to dyes or 
radiolabeled have been identified as possible imagining tools, diagnostic tools, or targeting 
molecules for melanoma. To our knowledge, there were no reports of the functional effect 
of melanocortin bivalent ligands in vivo prior to our report in 2016 as presented in Chapter 
3.25 We reported that the ICV administration of melanocortin homobivalent ligand CJL-1-
87 (Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-Arg-Trp-NH2) in mice resulted in dose-
dependent decrease in food intake.25 However, comparison to the monovalent ligand Ac-
His-DPhe-Arg-Trp-NH2 suggested little improvement in a nocturnal feeding paradigm.25, 
132, 186 To further elucidate the in vivo effects, we performed studies to compared the effects 
of CJL-1-87 to its monovalent counterpart CJL-1-14 (Ac-His-DPhe-Arg-Trp-NH2) 
utilizing our in-house TSE metabolic cage system. These studies showed significant 
differences between CJL-1-87 and CJL-1-14 after ICV administration in a fasting-
refeeding paradigm in mice.132 Administration of CJL-1-87 resulted in 50% less food 
intake than the monovalent 2 to 8 hours post-treatment. Treatment also resulted in 
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significantly lowered respiratory exchange ratio (RER) as well as significantly decreased 
insulin, C-peptide, leptin, and resistin plasma levels compared to the monovalent ligand 
Ac-His-DPhe-Arg-Trp-NH2.132 Further details and conclusions from these studies are 
presented in Chapter 4. In Chapter 5, in vivo data will be presented about the MUmBL 
compounds.  
1.4 Conclusions 
In summarizing the reports to date about bivalent and multivalent ligand designs 
for the melanocortin receptors, two key observations can be made. First, in order to observe 
synergistic effects, the proper pharmacophore must be used. In almost all cases, the use of 
tetrapeptide His-DPhe-Arg-Trp was observed to result in the greatest-fold affinity 
enhancements, presumably due to synergistic binding. This is likely due to the lower initial 
binding affinity of the monovalent tetrapeptide compared to longer analogs, which 
therefore allows easier detection and observation of the bivalent synergistic binding mode. 
The second key is the design of proper linker length to bridge putative melanocortin dimers. 
The greatest-fold enhancements were with linkers of approximately 23 ± 5 Å. One 
difficulty in estimating the exact length is that the linkers used are flexible and therefore 
nearly impossible to measure precisely. The estimated range for the optimal melanocortin 
linker is similar to that of other GPCR systems including the oxytocin (~25 Å),187 opioid 
(~22 Å),11, 184, 188 and dopamine receptors (~25 Å).185 This provides strong evidence for a 
common design of bivalent ligands targeting various GPCR systems and suggests this 
length may be the result of a common GPCR phenomenon (dimerization or high-order 
oligomerization). We utilized these observations from the literature as guiding principles 
in the bivalent ligand design throughout the current thesis.  
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Prior to this thesis bivalent melanocortin ligands’ increased binding affinity 
supported their use as diagnostic tools, imaging probes, and drug delivery vehicles for 
melanoma, but their functional effects required further investigation. The purpose of this 
thesis was to provide the field with foundational work addressing the functional effects of 
melanocortin bivalent ligands both in vitro and in vivo, and to study in more detail their 
effects on energy homeostasis. Chapter 3 and Chapter 4 use traditional homobivalent 
approaches to help further advance the field. Chapters 5 and Chapters 6 take uncommon 
approaches in attempts to exploit melanocortin dimers to elicited undiscovered 
pharmacological effects. It seems likely that the current discoveries may be broadly 
applicable to various other GPCR systems. As the physiological relevancy to GPCR 
oligomerization is elucidated, the current medicinal chemistry strategies presented in this 
thesis should aid in the discovery of probes and possible therapeutics for the further 
understanding of GPCR pharmacology for various systems.  
To address the question posed in the chapter title: “What do GPCR Oligomers, 
Entropic Cost of Binding, Melanocortin Signaling, and the Obesity Epidemic have in 
Common?” They are all key components in the goal of this thesis: To use bivalent ligands 
to target GPCR oligomers to decrease entropic cost of binding and elicit novel 
melanocortin signaling patterns in hopes of finding a solution to the obesity epidemic and 
other metabolic disorders. 
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Figure 1.1: Structures of classic melanocortin ligands. (A) POMC-derived naturally 
occurring agonists (the common His-Phe-Arg-Trp tetrapeptide is highlighted in red). (B) 
The sequences of endogenous antagonists AGRP and ASP (the active Arg-Phe-Phe 
tripeptide is highlighted in blue). (C) The synthetic ligands NDP-MSH, MTII and 
SHU9119 (hypothesized pharmacophore region highlighted in red). This figure was made 
by Mark D. Ericson and reproduced with permission from Ericson, M. D.; Lensing, C. J.; 
et. al. Bench-Top to Clinical Therapies: A Review of Melanocortin Ligands from 1954 to 
2016. Biochim. Biophys. Acta, Mol. Basis Dis. 2017, in press. Copyright (2017) Elsevier 
B.V. 1  
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Figure 1.2. Bivalent and multivalent ligand binding modes. (A) The bivalent ligand first 
binds a receptor with one pharmacophore in a monovalent fashion. (B) The second 
pharmacophore is tethered in close proximity to the second binding site. (C) The second 
pharmacophore can bind the second receptor with reduced entropic cost. Similar binding 
mode may exist for multivalent ligands with more than two pharmacophores. (D) 
Monovalent ligands bind monomers, dimers, and higher-order oligomers equally. (E) 
Bivalent ligands bind dimers and higher-order oligomers in a cooperative synergistic 
fashion. (F) Multivalent ligands bind GPCR clusters in a cooperative synergistic fashion. 
This figure was reproduced with permission from Ericson, M. D.; Lensing, C. J.; et. al. 
Bench-Top to Clinical Therapies: A Review of Melanocortin Ligands from 1954 to 2016. 
Biochim. Biophys. Acta, Mol. Basis Dis. 2017, in press. Copyright (2017) Elsevier B.V.1, 
25 
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Chapter 2: Materials and Methods 
Portions of the methods described in this chapter have been previously published, 
and it is being reproduced here with permission from: Lensing, C. J.; Freeman, K. T.; 
Schnell, S. M.; Adank, D. N.; Speth, R. C.; Haskell-Luevano, C. An in Vitro and in Vivo 
Investigation of Bivalent Ligands That Display Preferential Binding and Functional 
Activity for Different Melanocortin Receptor Homodimers. J. Med. Chem. 2016, 59, 3112-
3128. 25  Copyright (2016) American Chemical Society. Also it is being reproduced with 
permission from: Lensing, C. J.; Adank, D. N.; Wilber, S. L.; Freeman, K. T.; Schnell, S. 
M.; Speth, R. C.; Zarth, A. T.; Haskell-Luevano, C. A Direct In Vivo Comparison of The 
Melanocortin Monovalent Agonist Ac-His-DPhe-Arg-Trp-NH2 versus The Bivalent 
Agonist Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-Arg-Trp-NH2: A Bivalent Advantage. 
ACS Chem. Neurosci. 2017, in press.132 Copyright (2017) American Chemical Society. 
And finally it is being reproduced with permission from: Lensing, C. J.; Adank, D. N.; 
Doering, S. R.; Wilber, S. L.; Andreasen, A.; Schaub, J. W.; Xiang, Z.; Haskell-Luevano, 
C. Ac-Trp-DPhe(p-I)-Arg-Trp-NH2, a 250-Fold Selective Melanocortin-4 Receptor 
(MC4R) Antagonist over the Melanocortin-3 Receptor (MC3R), Affects Energy 
Homeostasis in Male and Female Mice Differently. ACS Chem. Neurosci. 2016, 7, 1283-
1291.189 Copyright (2016) American Chemical Society. 
2.1 Chapter Overview  
In the pursuit of designing, synthesizing, and evaluating melanocortin bivalent 
ligands many different techniques and experimental paradigms were utilized. These 
techniques and assay paradigms included: solid phase peptide synthesis, cell culture, cAMP 
Alpha Screen technology, competitive radioligand binding studies, PRESO-Tango (β-
24 
arrestin recruitment) assays, bioluminescence resonance energy transfer (BRET) studies, 
in vitro serum stability studies, mouse breeding, ICV administration of compounds to mice, 
metabolism studies, hormone level studies, and more. The methods and materials for each 
of these techniques will be presented below. I would like to thank all my teachers, mentors, 
coworkers, and colleagues for their support by either teaching me these techniques or 
performing these experiments. I would specifically like to thank those that were or are in 
the Haskell-Luevano laboratory including Carrie Haskell-Luevano, Katie Henning 
(Freeman), Danielle Adank, Stacey Wilber, Branden Smeester, Sathya Schnell, Skye 
Doering, Katlyn Fleming, Katie Schlasner, Mark Ericson, Michael Powers, Mary Lunzer, 
Zoe Koerperich, Srinivasa Tala, and Anamika Singh. I would also like to thank those that 
contributed to the work from other laboratories including Adam Zarth, Erika Dahl, 
Radleigh Santos, and Robert Speth.  
2.2 Solid Phase Peptide Synthesis 
All experimental ligands were synthesized using standard solid-phase peptide 
synthesis. Specifically, a fluorenyl-9-methoxycarbonyl (Fmoc) methodology was 
utilized.190, 191 A CEM Discover SPS manual microwave peptide synthesizer was used to 
expedite couplings and deprotections especially where common sequences were present. 
A semi-automated synthesizer (LabTech, Louisville, KY) without the use of a microwave 
was also used for parallel synthesis. The 4-(2’,4’-dimethoxyphenyl-Fmoc-
aminomethyl)phenoxyacetyl-MBHA resin [Rink-amide-MBHA (200-400 mesh), 0.35-
0.37 meq/g substitution], 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU), and Fmoc-protected amino acids [Fmoc-Pro, Fmoc-Gly, 
Fmoc-His(Trt), Fmoc-DPhe, Fmoc-Arg(Pbf), Fmoc-Trp(Boc), and Fmoc-DNal(2’)] were 
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purchased from Peptides International (Louisville, KY, USA). The O-(N-Fmoc-3-
aminopropyl)-O'-(N-diglycolyl-3-aminopropyl)-diethyleneglycol [Fmoc-NH-(PEG)2-
COOH (20atoms) or Fmoc-NH2-PEDG20-COOH] was purchased from Novobiochem® 
EMD Millipore Corp (Billerica, MA, USA). The N,N-diisopropylethylamine (DIEA), 
triisopropylsilane (TIS), 1,2-ethanedithiol (EDT), piperidine, pyridine, and trifluoroacetic 
acid (TFA) were purchased from Sigma-Aldrich (St. Louis, MO). Acetonitrile (MeCN), 
N,N-dimethylformamide (DMF), acetic anhydride, dichloromethane (DCM), and methanol 
(MeOH) were purchased from FischerScientific. All reagents were ACS grade or better 
and were used without further purification. 
Peptides were assembled on the Rink-amide-MBHA resin in a fritted 
polypropylene reaction vessel (25 mL CEM reaction vessel). After resin was swelled in 
DCM for at least one hour, it was continually mixed by bubbling nitrogen. Subsequently, 
a two-step cycle of deprotection with 20% piperidine in DMF, followed by amide coupling 
with the Fmoc-amino acid, HBTU, and DIEA was repeated until the final peptide was 
synthesized on resin. Excess reagents were removed by 3-5 washes of DMF between steps. 
A Kaiser/ninhydrin test was utilized after each deprotection or coupling step (except with 
Pro residues) to indicated the presence or lack of a free primary amine.192  For Pro residues, 
the presence or lack of a free secondary amine was indicated by a chloranil test.191, 193 
Removal of the Fmoc group was achieved in a two-step process using a deprotection 
solution of 20% piperidine in DMF. An initial two minute deprotection was performed 
outside of the microwave. The deprotection solution was removed by vacuum. A second 
aliquot of 20% piperidine was added and further deprotection was assisted by microwave 
heating (75ºC, 30 W, 4 min).  
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Microwave assisted amide coupling was achieved by addition of 3.1-fold excess 
Fmoc-protected amino acids (5.1-fold for Arg) and 3-fold excess of HBTU (5-fold for Arg) 
dissolved in DMF added to the deprotected elongating peptide on the resin. The coupling 
reaction was initiated via addition of 5-fold excess of DIEA (7-fold for Arg) and the 
reaction was heated in the microwave synthesizer (75ºC, 30 W or 50ºC, 30 W for His) for 
five minutes (10 min for Arg at 75ºC, 30 W). Fmoc-NH-(PEDG20)-COOH was 
incorporated into the peptide using the standard microwave protocol except it was allowed 
to cool for at least one hour post coupling to ensure the reaction went to completion.  
The semi-automated synthesizer couplings were achieved by splitting dry resin 
with the Fmoc protected elongating peptide chain (~0.2 nmols) into a 16-well Teflon 
reaction block. The resin and peptide swelled for two hours in DCM, and then were 
deprotected by addition of 20% piperidine in DMF for two minutes. The deprotection 
mixture was removed, then a second aliquot of 20% piperidine was added and mixed for 
18 minutes. Following a positive Kaiser test, the coupling was initiated by addition of 
reagents as described above. The reaction was then mixed for at least two hours at room 
temperature.  
All N-terminal acetylated peptides were acetylated on resin after the final Fmoc 
deprotection by addition of 3:1 mixture of acetic anhydride to pyridine and were mixed 
(with a nitrogen bubbler) for 30 minutes at room temperature. After syntheses were 
completed, all peptides were washed with DCM at least 3 times and dried overnight in a 
desiccator. Simultaneous side chain deprotection and resin cleavage was accomplished via 
addition of 8 mL of a cleavage cocktail (91% TFA, 3% EDT, 3% TIS, 3% water) for 1.5-
3 hours. The crude peptides and cleavage solution were filtered into a pre-weighed 50 mL 
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conical tube. The cleaved resin was rinsed with an additional 2 mL of cleavage cocktail to 
remove residual peptides. Peptides were precipitated using cold (4ºC) anhydrous diethyl 
ether. The turbid mixture was vortexed and centrifuged at 4ºC and 4000 RPMs for 4 
minutes (Sorval Super T21 high-speed centrifuge swinging bucket rotor). The supernatant 
was decanted leaving the crude peptide pellet. This was then washed with cold (4ºC) 
diethyl ether and centrifuged. This process was repeated at least 3 times until no thiol aroma 
was present and the peptide was dried overnight in a desiccator.  
A 5-20 mg sample of crude peptide was purified by RP-HPLC using a Shimadzu 
chromatography system with a photodiode array detector and a semipreparative RP HPLC 
C18 bonded silica column (Vydac 218TP1010, 1 cm x 25 cm). The solvent system for 
purification was either acetonitrile (MeCN) or methanol (MeOH) in water with 0.1% TFA. 
After purified fractions were collected, peptides were concentrated in vacuo and 
lyophilized. A purity of greater than 95% was confirmed by analytical RP-HPLC in two 
diverse solvent systems (10% MeCN in 0.1 % TFA/water and a gradient to 90% MeCN 
over 35 min; and 10% MeOH in 0.1 % TFA/water and a gradient to 90% MeOH over 35 
minutes). The correct molecular mass was confirmed by ESI-MS (University of Minnesota 
Department of Chemistry Mass Spectrometry Laboratory). 
2.3 Resin Splitting Approach  
A split resin technique to allow rapid diversification was used as previously 
described (Scheme 2.1).25, 30 Although the specific design of the bivalent ligands will be 
described in detail in each chapter, in general, bivalent ligands consist of two tetrapeptide 
pharmacophore scaffolds connected by a linker (e.g. Ac-His-DPhe-Arg-Trp-PEDG20-His-
DPhe-Arg-Trp-NH2). Therefore, the synthesis of these ligands can be split into three 
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components: synthesis of the C-terminal pharmacophore, synthesis of the linker, and 
synthesis of the N-terminal pharmacophore. In the split resin approach, the initial common 
four amino acid residues that comprise the C-terminal pharmacophore scaffold were added 
to the resin. Then, the resin was split so that different linkers or spacers could be added to 
the C-terminal pharmacophore scaffold. Then, the resin was split further before adding the 
N-terminal pharmacophore for completion of the bivalent ligand. At each step along the 
way, the peptide could also be cleaved to provide control ligands such as the tetrapeptides 
used as pharmacophore scaffolds, and the tetrapeptides plus addition of the linker on to the 
N-terminus (Scheme 2.1A). The linker could be added directly to the resin to provide the 
tetrapeptide plus the linker on the C-terminus (Scheme 2.1B). When splitting resin, often 
a semi-automated synthesizer without the use of microwave was utilized to aid in the 
synthesis so that peptides could be synthesized in parallel.  
The best example of this method in use was the synthesis scheme utilized for 
ligands in Chapter 3, Chapter 4, and Chapter 5 (Scheme 2.2). In the idealized version 
of this method, the C-terminal tetrapeptide (e.g. His-DPhe-Arg-Trp) was added to the resin. 
An aliquot of the resin was taken, acetylated, and cleaved to yield control tetrapeptide (e.g. 
Ac-His-DPhe-Arg-Trp-NH2). The rest of the resin was split into two additional aliquots. 
To one aliquot the PEDG20 linker was added and to the other the (Pro-Gly)6 linker was 
added. A portion of these resins was cleaved for tetrapeptide plus linker control ligands 
[e.g. (Pro-Gly)6-His-DPhe-Arg-Trp-NH2 and PEDG20-His-DPhe-Arg-Trp-NH2]. To 
uncleaved aliquots of the resin, a second N-terminal tetrapeptide scaffold was added. Then 
it was acetylated and cleaved to yield the final bivalent ligands (e.g. Ac-His-DNal(2’)-Arg-
Trp-PEDG20-His-DPhe-Arg-Trp-NH2 and Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-
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Arg-Trp-NH2) (Scheme 2.2A). In order to synthesize the C-terminus linked controls, first 
the linker was added to the resin. Then this was split to add different tetrapeptide 
pharmacophores to yield the linker controls (Scheme 2.2B). 
It should just be mentioned that compounds synthesized early in this thesis work 
were synthesized linearly without splitting the resin to ensure the bivalent ligand synthesis 
was easily amendable to the laboratory’s techniques, and for me to learn the proper 
techniques. For later synthesis schemes like those in Chapter 6, this type of synthesis plan 
allowed for rapid synthesis and diversification.  
2.4 Cell Culture 
All cells assays were performed with female HEK293 cells. Cells were maintained 
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% newborn calf 
serum (NCS), and 1% penicillin/streptomycin in humidified atmosphere of 95% air and 
5% CO2 at 37ºC. Stable cell lines were generated with wild type mMC1R, mMC4R, 
mMC5R, Flag-mMC3R, Flag-hMC4R DNA in pCDNA3 expression vector (20 µg) using 
the calcium phosphate transfection method.194 Stable populations were generated using 
G418 selection (0.7-1.0 mg/mL) and used in bioassays unless indicated otherwise. 
Experimental ligands were dissolved to a 10-2 M stock in DMSO and stored at -20ºC. 
Subsequent dilutions were performed in the stated assay buffer to achieve the final 
concentration in the well. The ligands were assayed as TFA salts. 
2.5 Competitive Radioligand Binding Affinity Studies 
The binding affinities of bivalent ligands in Chapters 3-6 were evaluated by 
performing competitive radioligand binding assays at the mMC1R, mMC3R, and mMC4R. 
The mMC5R was excluded from study as its functional has not yet been fully elucidated 
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and our efforts are focused on understanding the melanocortin system’s role in energy 
homeostasis.  Human AGRP(87-132) or NDP-MSH peptides were radioiodinated using 
Na125I following the chloramine T procedure by Robert Speth.25, 132, 195  
Monoradioiodinated peptide was isolated from unlabeled or diradioiodinated peptide by 
HPLC using a C18 column. It was eluted isocratically in a mobile phase of 24% acetonitrile 
and 76% triethylamine phosphate (pH 3.0).   
HEK293 cells stably expressing the mMC1R and mMC4R were maintained as 
described above in Section 2.4. Binding experiments on the mMC3R were performed on 
transiently transfected HEK293 cells. Transfection was performed two days prior to the 
binding experiment in 10 cm plates using FuGene6 transfection reagent (15 µL/plate; 
Promega), Opti-Mem medium (1.7 mL/ plate; Invitrogen), and Flag-mMC3R DNA (3.33 
µg/plate). One or two days preceding the experiment, cells were plated into 12-well tissue 
culture plates (Corning Life Sciences, Cat. # 353043) and grown to 90-100 % confluency. 
On the day of the assay, medium was aspirated and the cells were treated with a freshly 
diluted aliquot of non-labeled compound at the concentration being tested (ranging from 
10-12 to 10-4 M as appropriate) in assay buffer (DMEM and 0.1% bovine serum albumin 
(BSA)) and a constant amount of 125I-NDP-MSH or 125I-AGRP (100,000 cpm/well). Cells 
were incubated at 37º C for one hour. After which, media was gently aspirated and cells 
were washed gently once with assay buffer.  
Buffer was gently aspirated and cells were lysed with NaOH (500 µL; 0.1M) and 
Triton X-100 (500 µL; 1%) for at least 10 minutes. Cell lysate was transferred to 12x75 
mm polystyrene tubes and radioactivity was quantified on WIZARD2 Automatic Gamma 
Counter (PerkinElmer). Experiments were performed with duplicate data points and 
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repeated in at least two independent experiments. Each experiment included unlabeled 
NDP-MSH or AGRP(87-132) as a positive control. Non-specific values were obtained 
using a 10-6 M unlabeled NDP-MSH or AGRP(87-132), corresponding to the respective 
125I-labeled peptide. Data was analyzed using the PRISM program (v4.0; GraphPad Inc.). 
Dose-response curves and IC50 values were generated and analyzed by a nonlinear 
regression method. The standard error of the mean (SEM) or standard deviation (SD) was 
derived from the IC50 values from at least two independent experiments.  
2.6 AlphaScreen® cAMP Functional Bioassay  
Agonist stimulation of all known melanocortin receptors results in the activation of 
the cAMP signaling pathway through the Gαs subunit. Melanocortin agonist activity is 
commonly quantified by measuring cAMP signaling.25, 96, 132, 196, 197 Therefore in Chapter 
3-6, the AlphaScreen® cAMP technology (PerkinElmer Life Sciences, Cat #6760625M) 
was utilized to measure cAMP signaling after ligand stimulation in HEK293 cells stably 
expressing the mMC1R, mMC3R, mMC4R, and mMC5R. The AlphaScreen® assay was 
performed as described by the manufacturer and described previously by our lab.25, 132, 197 
It is also described briefly below.  
Cells were 70-95% confluent on the day of the assay. Cells were removed from 10 
cm plates with Gibco® Versene solution. Cells were pelleted by centrifugation (Sorvall 
Super T21 high speed centrifuge, swinging bucket rotor) at 800 rpm for five minutes at 
room temperature. Medium was aspirated and cells were resuspended in Dulbecco’s 
phosphate buffered saline solution (DPBS 1X [-] without calcium and magnesium chloride, 
Gibco ® Cat # 14190-144). A 10 µL aliquot was removed for manual cell counting. After 
the addition of a Trypan blue dye solution (BioRad) to the cell aliquot (1:1 by volume), 
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cells were counted manually using a hemocytometer. Cells were again pelleted at 800 rpm 
for 5 minutes and DPBS was gently aspirated. The pelleted cells were then resuspended in 
a solution of freshly made stimulation buffer (Hank’s Balanced Salt Solution [HBSS 10X 
[-] sodium bicarbonate] and [-] phenol red, Gibco®], 0.5 mM isobutylmethylxanthine 
[IBMX], 5 mM HEPES buffer solution [1M, Gibco®], 0.1% bovine serum albumin [BSA] 
in Milli-Q water, pH=7.4) and anti-cAMP acceptor beads (1.0 unit per well, 
AlphaScreen®). This resuspended cell/acceptor bead solution was added manually to a 384 
well microplate (OptiPlate-384; PerkinElmer). The final concentration was 10,000 
cells/well and 1.0 Unit of anti-cAMP beads/well. The equal mixture of stable mMC3R cells 
and stable mMC4R cells described in Chapter 4 was 5,000 cells/well of each cell type for 
a total of 10,000 cells/well. Cells were stimulated for two hours in a dark laboratory drawer 
with ligand diluted in stimulation buffer from 10-13 to 10-4 M.  
During incubation, a three-component biotinylated cAMP/streptavidin donor bead 
working solution was made with streptavidin donor beads (1 Unit/well, AlphaScreen®), 
biotinylated cAMP (1 Unit/well, AlphaScreen®), and lysis buffer (10% Tween-20, 5 mM 
HEPES buffer solution [1M, Gibco®], 0.1% bovine serum albumin [BSA] in Milli-Q 
water, pH=7.4). After the incubation, the biotinylated cAMP/streptavidin donor bead 
working solution was added and mixed into each well in the 384-well plate under green 
light and mixed well by pipetting up and down. Cells were incubated for another two hours 
at room temperature in the dark. The plate was read using a pre-normalized assay protocol 
set by the manufacturer on an EnSpire™ Alpha plate reader. All assays were performed in 
at least three independent experiments with duplicate data points. Each plate contained a 
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control ligand dose response (10-6 M to 10-12 M  of NDP-MSH, α-MSH, or ɣ2-MSH), a 10-
4 M forskolin positive control, and a no ligand assay buffer negative control.  
Data was analyzed using the PRISM program (v4.0; GraphPad Inc.). Dose response 
curves and potency EC50 values (concentration that caused 50% maximal signal) were 
generated and analyzed by a nonlinear regression method. Because the AlphaScreen® assay 
is a competition assay and to be consistent with functional data being represented as an 
increasing response with increasing concentration, a transformation was carried out for 
illustration purposes to normalize data to control compounds and flip data curves. A 
detailed explanation of the transformation can be found in Section 2.7.  
Compounds that showed partial receptor activation at 100 µM at the mMC3R or 
mMC4R were analyzed for antagonist properties using a Schild regression analysis.198 
Ligands were tested in a dose-dependent manner to inhibit NDP-MSH agonist receptor 
stimulation and the pA2 values were calculated [pA2=-log(Ki)].198 The standard error of the 
mean (SEM) was derived from the potency values and pA2 from at least three independent 
experiments. 
2.7 ALPHAScreen Assay Data Normalization 
The AlphaScreen® assay is a competition assay between biotinylated cAMP which 
is part of the assay kit and intracellular cAMP which is produced by the cells in response 
to agonist ligands. Because the AlphaScreen® assay is a competition assay, it results in 
decreasing signal with increasing cAMP functional response due to receptor activation. 
This is inconsistent with standard functional assays which result in increasing signal with 
increasing receptor activation. Therefore, data was normalized to “flip” data curves to be 
consistent with the literature as previously described. 25, 197  Of note, the ligand potency 
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values reported were obtained prior to data normalization. Data normalization was only 
used for illustration purposes only and did not influence the ligand potency values. 
Data was normalized by taking the raw value of each well, subtracting the averaged 
maximal response of NDP-MSH (normally responses at 10-6 and 10-7 M). This value was 
then divided by the maximal response subtracting the average minimal response (Basal 
values and/or values of NDP-MSH at 10-12). This value was then subtracted from 1 to “flip” 
the response and multiplied by 100 to result in % response of NDP-MSH. The equation is 
as follows:  
 
% Response of NDP-MSH = 1- [[(Raw Value)-(Average Max Response)]/[(Average 
Minimal Response)-(Average Max Reponses)]] X 100 
 
2.8 PRESTO-Tango (β-arrestin Recruitment) Assay 
Melanocortin agonist stimulation is also known to result in β-arrestin recruitment 
and receptor desensitization.199-201 In order to characterize melanocortin ligand stimulated 
β-arrestin recruitment and to evaluate biased agonism, the PRESTO-Tango β-arrestin 
recruitment assay was performed on cells expressing the hMC4R in Chapter 5. The 
PRESTO-Tango assay was developed by Kroeze and coworkers for identifying 
biologically activate compounds by the rapid screening for most of the entire druggable 
GPCRome.202, 203 The plasmids and assay technology were kindly provided by the Bryan 
Roth laboratory (University of North Carolina at Chapel Hill) and are now available 
through ADDGENE (Kit # 1000000068). Briefly, HTLA cells (HEK293 cells that stably 
express a tTA-dependent luciferase reporter and a β-arrestin 2 –TEV fusion gene and were 
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kindly provided by Richard Axel203) were maintained in DMEM supplemented with 10% 
FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, 2 µg/mL puromycin, and 100 µg/mL 
hygromycin B in humidified atmosphere of 95% air and 5% CO2 at 37 ºC.  
On the first day of the assay, HTLA cells were plated at approximately 1x106 cells 
per 10 cm plate and grown to 20-40% confluency. The second day cells were transiently 
transfected using the calcium phosphate method with 4 µg/plate of hMC4R PRESTO-
Tango plasmid construct and incubated 15-24 hours in humidified atmosphere of 97% air 
and 3% CO2 at 35 ºC.194, 202 On the third day, cells were removed from 10 cm plates using 
Gibco® Versene solution and pelleted by centrifugation (Sorvall Super T21 high speed 
centrifuge, swinging bucket rotor) at 800 rpm for five minutes at room temperature. Cells 
were manually counted on a hemocytometer and resuspended in 1% dialyzed FBS and 1% 
penicillin/streptomycin in DMEM to a final concentration of 400,000 cells/mL. Cells were 
plated into 384-well white wall and clear bottom microplate (ViewPlate-384 TC, 
PerkinElmer Cat # 6007480) for a final concentration of 20,000 cells/well and incubated 
in 5% CO2 at 37 ºC. On the fourth day, cells were stimulated by ligands diluted to the 
appropriate in well concentrations (i.e. 10-12 to 10-5 M) in filter-sterilized assay buffer (20 
mM HEPES, 1x HBSS, water, titrated to pH 7.4 with 1 N NaOH). Stimulated cells were 
incubated for 18 hours in 5% CO2 at 37 ºC. On the fifth day, the assay buffer and cell 
medium was removed by aspiration. Then 20 µL of Bright-Glo (Promega, Cat # N1661) 
diluted 20-fold in assay buffer was added to each well and incubated for 15-20 minutes at 
room temperature. After incubation, luminescence was read on an EnSpireTM Alpha plate 
reader using a pre-normalized assay protocol for luminescence set by the manufacturer. 
Dose response curves were analyzed using the PRISM program (v4.0; GraphPad Inc.). 
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Potency EC50 values (concentration that caused 50% maximal signal) were calculated by a 
nonlinear regression method. 
2.9 Bioluminescence Resonance Energy Transfer (BRET) Studies 
It has been supported by a variety of techniques that all known melanocortin 
receptors homodimerize and heterodimerize. 125, 127, 129-131, 204-209 However, to our 
knowledge prior to this thesis work, no evidence has supported the existence of a MC3R-
MC4R heterodimer.132 Based on expression patterns of mRNA in the brain and the double 
MC3R-MC4R KO mouse model, it was hypothesized that the MC3R-MC4R heterodimer 
may exist and may have functional relevancy. 58, 81, 132, 210-212   Furthermore, there has been 
evidence supporting that bivalent ligands can modulate existing dimers or induce 
dimerization.213, 214  Therefore, to study the hypothesized MC3R-MC4R heterodimer, as 
well as to study the effects of bivalent ligands on MC4R homodimers, bioluminescence 
resonance energy transfer (BRET) studies were performed. This technique was utilized in 
Chapter 4 and Chapter 5. 
Specifically, a NanoBRET™ Protein:Protein Interaction System was utilized 
according to manufacturer’s instructions to examine the association and proximity of the 
melanocortin receptors. Plasmids were constructed to incorporate the NanoLuc® fusion 
protein and the HaloTag® fusion protein onto the C-terminus of both the mMC3R and 
mMC4R of the plasmids described above. Competitive binding assays with 125I-NDP-MSH 
demostrate proper cell membrane expression and ligand binding (Figure 2.1, Table 2.1). 
On the first day, cells were plated in the morning into 6 well plates. In the afternoon of the 
same day, cells were transiently transfected with melanocortin receptor by adding FuGene6 
Transfection (8 µL/well, Promega), DNA (2 µg/well) in OptiMem medium (Invitrogen) at 
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a total volume of 100 µL/well. The 100 µL/well aliquot was added to the current media in 
each well of the plated cells. The ratio of donor NanoLuc® to acceptor HaloTag® DNA 
was optimized in preliminary experiments and a ratio of 1 Receptor-NanoLuc® plasmid: 
4 Receptor-HaloTag® plasmid was utilized for all following experiments. Cells were 
incubated with transfection reagent overnight at 37˚ C at 5 % CO2. One day after the 
transfection, cells were re-plated into 96-well black clear bottom plates (Cat # 3603, 
Corning Life Sciences) at 30,000 cells in 100 µL of assay buffer (4% FBS in OptiMem). 
As a negative control, a mixture of mMC4R-NanoLuc® cells and mMC3R-HaloTag® cells 
was made by mixing 15,000 cells of each cell type together. In these experimental 
conditions, the mMC4R-NanoLuc® and mMC3R-HaloTag® should not associate since 
they are on separate cell membranes resulting in low BRET signal. 
To each well, 1 µL of 0.1 mM HaloTag® NanoBRET™ 618 ligand was added and 
incubated 18-24 h at 37˚ C at 5 % CO2. As a negative control, each assay also included; 
“no acceptor controls” in which 1 µL of DMSO was added instead of the HaloTag® 
NanoBRET™ 618 ligand rendering the BRET relay system incomplete (providing the 
background signal). This background signal was subtracted from the final experimental 
signal. Plates were then developed 48 to 60 hours after transfection. To develop plates, 25 
µL of 5x solution of NanoBRET™ Nano-Glo® Substrate in Opti-MEM® was added to 
each well. Plates were then read within 10 min on a FlexStation® 3 plate reader (Molecular 
Devices) at the donor emission wavelength (460 nm) and acceptor emission wavelength 
(618 nm). The milli BRET Units (mBUs) were calculated by dividing the acceptor 
emission of 618 nm by the donor emission at 460 nm and multiplying it by 1000.  All 
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assays were performed in at least three independent experiments with 3 to 5 replicates wells 
in each experiment. 
In Chapter 5, the same protocol was followed except cells were plated in 90 µL of 
assay buffer instead of 100 µL to test the effects of ligands. Then, 2 hours before the plates 
were developed, 10 µL of a 10X aliquot of the ligand was added to each well to yield the 
final in well concentration (10-5, 10-7, or 10-9 M) of each compound. 
2.10 Serum Stability Studies-  
One critique often asserted about peptidic ligands is that they can have poor 
metabolic stability. Also, it has been reported that the endogenous melanocortin peptide 
ligand α-MSH is rapidly degraded in blood serum.74 In order to ensure that results obtained 
in in vivo studies were due to the parent compound, it is necessary to demonstrate adequate 
metabolic stability of lead ligands. Furthermore, if the bivalent ligands are rapidly split into 
two monovalent ligands upon in vivo administration, the bivalent ligand design cannot be 
evaluated. Therefore, the lead ligands’ mouse serum stability was measured in vitro to 
obtain an indication of the metabolic stability. These results are presented in Chapter 4-6. 
The experimental ligands at an initial concentration of 10 µM in mouse serum (Cat # 
M5905; Sigma-Aldrich) were incubated at 37 ᵒC on an orbital shaker. At the time points 0, 
0.5, 1.5, 3, 6, 8, 24, 48, and 72 h time points, a 50 µL aliquot was taken and the reaction 
was quenched with 150 µL of cold (4 ᵒC) 66% aqueous acetonitrile. Samples were 
incubated in a bucket of wet ice for 10-15 min, then centrifuged at 12900 rpm at 4 ᵒC. The 
supernatant was collected into pre-labeled tubes and stored at -80 ᵒC until liquid 
chromatography-positive electrospray ionization-tandem mass spectrometry (LC-ESI+-
MS/MS) analysis was performed. Liquid chromatography was carried out with a reverse-
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phase linear gradient and a flow rate of 15 µL/min on a 0.5 × 150 mm Zorbax SB-C18 5 
µm column (Agilent, Santa Clara, CA). The gradient was from 95% aqueous TFA (0.1%) 
and 5% acetonitrile to 35% aqueous TFA (0.1%) and 65% acetonitrile in 15 min. This was 
followed by a washout and re-equilibration period at initial conditions. 
Mass spectrometry was performed on a Finnigan TSQ Quantum Discovery MAX 
triple quadrupole mass analyzer (Thermo Scientific, Waltham, MA). Selected reaction 
monitoring (SRM) mass transitions were optimized for each compound from the MS/MS 
product ion spectra of the initial control sample. Collision energy was 35 eV and scan width 
was 1.0 amu. The following SRM transitions were monitored for each compound: NDP-
MSH, m/z 824.2 → 136.1; α-MSH, m/z 555.9 → 136.1 and 833.3 → 136.1; CJL-1-14, m/z 
343.9 → 110.1 and 686.7 → 180.1; CJL-1-87, m/z 544.9 → 110.2 and 816.3 → 110.0; 
CJL-5-35-4, m/z 503.1 → 110.1; CJL-1-116, m/z 482.1 → 156.1 and 321.9 → 156.1; 
CJL-1-31, m/z 746.8 → 179.9; CJL-5-35-1, m/z 806.4 → 172.0 and 806.4 → 152.0; CJL-
1-41, m/z 785.6 → 445.1 and 524.2 → 195.1; CJL-5-127-7, m/z 343.6 → 159.1 and 343.7 
→ 110.1; CJL-5-119-1, m/z 550.0 → 110.1 and 550.0 → 152.1; CJL-5-119.2, m/z 544.2 
→ 152.0 and 816.0 → 180.1; CJL-5-119-3, m/z 535.2 → 152.1 and 535.2 → 110.1; CJL-
9-22-4, m/z 561.0 → 152.1 and 841.0 → 180.0; CJL-5-119-5, m/z 544.2 → 159.1 and 
544.2 → 110.1; CJL-5-127-2, m/z 544.3 → 110.1 and 816.0 → 154.7; and CJL-5-127-5, 
m/z 544.2 → 228.8 and 816.0 → 110.0. All samples were run in two technical replicates. 
The signal intensity at time point 0 h was arbitrarily set as 100% and the % intact peptide 
at each time point was calculated relative to this signal. Data was graphed and half-lives 
were calculated using PRISM software (v 4.0; GraphPad Inc.). Mass spectrometry was 
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carried out in the Analytical Biochemistry Shared Resource at the University of Minnesota 
Masonic Cancer Center. 
2.11 Animals Studies 
The transition of in vitro assay results to in vivo effects is an important translational 
step to understand the physiological and pharmacological relevancy of newly discovered 
ligands. Therefore, to better understand the in vivo physiology of the bivalent ligands and 
their potential as in vivo probes, compounds were administered intracerebroventricular 
(ICV) to mice in Chapters 3-5. All studies were performed in accordance with the 
Institutional Animal Care and Use Committee (IACUC) of the University of Minnesota. 
The mice used were male and female wild type, MC3RKO, or MC4RKO mice with a 
mixed genetic background from the C57BL/6J and 129/Sv inbred strains derived for the 
in-house breeding colonies as previously reported.25, 59, 76, 107, 132, 189, 215 25, 132, 189, 215 The 
specific sex and genotype is stated in the description of each assay paradigm. All mice 
were maintained on a reversed 12 h light/dark cycle (Lights out was at 11:00 AM) in a 
temperature controlled room (23-25 ᵒC) with free access to tap water. Excluding when a 
fast occurred prior to injection, mice had free access to normal chow (Harlan Teklad 2018 
Diet: 18.6% crude protein, 6.2% crude fat, 3.5% crude fiber, with energy density of 3.1 
kcal/g). The hPYY validation experiments and the Luminex Multiplex hormone panel 
experiments (see below) took place in standard mouse polycarbonate conventional cages 
provided by the University of Minnesota’s Research Animal Resources (RAR). All cages 
were changed weekly by lab research staff. The compounds used for animal studies were 
dissolved in sterile saline (0.9%; Hospira, Lake Forest, IL) to a stock solution of 10-2 M 
unless specifically stated otherwise. 
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2.12 Cannulation Surgery and Placement Validation 
Cannulation surgeries were performed to place a cannula into the lateral cerebral 
ventricle as previously reported.25, 76, 132, 189, 216  All mice were age matched to have 
surgeries at 8-10 weeks old. Mice were anesthetized with a mixture of xylazine (5 mg/kg) 
and ketamine (100 mg/kg) administered intraperitoneally (IP). Mice were placed in a 
stereotaxic apparatus (David Kopf Instruments), which was used to guide the cannula 
placement. A 26-guage cannula (Cat # 8IC315GS4SPC; PlasticsOne, Roanoke, VA) was 
placed into the lateral cerebral ventricle at the coordinates 1.0 mm lateral and 0.46 mm 
posterior to bregma and 2.3 mm ventral to the skull.217 Dental cement (C&B-Metabond 
Adhesive Cement Kit # S380) followed by Lang’s Jet™ Denture Repair Kit (Jet Denture 
Repair Powder, Ref #1220; Jet Liquid, Ref # 1403) was used to secure the cannula. Flunixin 
meglumine (FluMegluine, Clipper Distribution Company) and 0.5 mL of 0.9% saline 
(Hospira, Lake Forrest, IL) was administered subcutaneously after surgery to aid in 
recovery. Mice were given at least seven days to recover before cannula validation. Mice 
were housed individually after surgery and for the remainder of the experiments. 25, 76, 132, 
189, 216    
Cannula placement was verified by evaluating the increase in feeding after the ICV 
administration of 2.5 µg of human (h)PYY3-36 (Cat # H8585; Bachem) as described 
previously.25, 76, 107, 132, 189, 216 Each mouse received a saline treatment and a hPYY treatment 
on different days separated in a cross-over design nocturnal feeding paradigm. There was 
at least a 3-day washout period between administration to ensure that normal feeding 
patterns and body weight returned as hPYY is well documented to have only an acute 
response. In the nocturnal feeding paradigm utilized in this entire thesis, compound or 
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saline is administered two hours prior to lights out (t = 0 h) with free access to food and 
water throughout the entire experiment. Food intake and body weight were manually 
measured 2, 4, and 6 hours after hPYY or saline administration. A mouse with a validated, 
properly placed cannula consumed at least 0.75 g more food after hPYY administration 
compared to saline administration at the 4 h time point. Data from a standard validation 
experiment is provided in (Figure 2.2). This validation experiment was performed for the 
TSE metabolic cage studies described in Chapter 4. In this experiment an average mouse 
ate 0.4 ± 0.1 g at the 4 h time point after saline administration compared to 1.6 ± 0.1 g after 
hPYY administration 
2.13 In Vivo Energy Metabolism Studies 
A TSE PhenoMaster metabolic cage system was utilized to study more thoroughly 
the effects of bivalent ligands on energy homeostasis. Normally, the effects on food intake 
and body weight were first characterized in standard mouse polycarbonate conventional 
cages. Then, a new cohort of mice with validated cannula placement were transitioned into 
sealed metabolic home cages and allowed one week to acclimate to the TSE cages and 
environment. The TSE PhenoMaster metabolic cage system (TSE Systems, Berlin 
Germany) was configured to measure food intake, water intake, oxygen uptake, carbon 
dioxide production, and locomotor activity (beam break) in 15 minute bins. After the 
acclimation period, the indicated amount (nmols) of compound in 3 µL of saline was 
delivered two hours prior to lights out (t=0 hr) through the implanted cannula using an 
infusion internal cannula (Cat# 8IC315IS4SPC; PlasticsOne, Roanoke, VA) in either a 
satiated nocturnal feeding paradigm or a fasting refeeding paradigm as described above.25, 
132, 189, 215, 218  
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All experiments followed a cross-over paradigm in which the mouse received saline 
and compound on different days with a washout period in between. In Chapter 4, a three-
group crossover design paradigm was utilized to assess the differences between CJL-1-14, 
CJL-1-87, and saline (Figure 2.3A). The nocturnal paradigm is described above. In the 
fasting-refeeding paradigm utilized throughout this thesis, food was removed from the 
mice at the start of the lights out on the previous day (t = -22 h) for a 22-hour fast. Two 
hours before lights out on the day of the assay (t = 0 h), mice received the indicated dose 
(nmols of compound or saline vehicle control) and food was returned to the cage (Figure 
2.3B). After compound administration (t=0 h), TSE cages were “resumed” to collect data 
in 15 minute intervals until the conclusion of the experiment.  
 The cumulative food and water intakes were reported in two hour increments. The 
energy expenditure and RER were calculated from the oxygen uptake and carbon dioxide 
production. The oxygen uptake, carbon dioxide production, and locomotor activity were 
recorded in 15-minute bins. The RER of four 15-minute recordings were averaged for each 
reported hourly RER. Similarly, the four 15-minute energy expenditure readings (kcal/h) 
were normalized to the animals’ pre-treatment weight (kcal/kg/h) and were then averaged 
into one-hour bins. Activity measurements were the ambulatory activity (XA) defined as 
consecutive beam breaks of two different X-axis beams. Activity readings of the four 15-
minute intervals were summed for each one-hour bin. Figures were made using PRISM 
software (v 4.0; GraphPad Inc.). Statistical analysis was performed using SPSS V23 
software (IBM) utilizing a multivariate general linear model followed by a Bonferroni post 
hoc test. Statistical significance was defined as p < 0.05. Results are presented as Mean ± 
SEM. 
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2.14 Body Composition Studies 
In Chapter 4, the effects of lead bivalent ligand CJL-1-87 and its monovalent 
counterpart CJL-1-14 is evaluated for its effects on lean and fat mass and on metabolic 
hormones.132 In these studies an additional cohort of 32 male age matched littermate mice 
(saline, n=10; 5 nmol CJL-1-14, n=11; 5 nmol CJL-1-87, n=11) remained in standard 
mouse polycarbonate conventional cages. This cohort was used for both body composition 
analysis and Luminex Milliplex assays in a block design. Food intake and body weight 
were manually measured using a standard top-loading laboratory balance at time points -
22, 0, 2, 4, and 6 hours. The amount of lean body mass and fat mass was measured using 
an EchoMRI-100H™ (Echo Medical Systems LLC, Houston TX, USA) at time points -22, 
0, and 6 hours. The lean body mass percentage and body fat mass percentage were 
calculated based on the amount of lean mass or fat mass measured divided by the manually 
recorded weight immediately prior to the MRI measurements. Results are presented as the 
Mean ± SEM.  
2.15 Luminex Milliplex Hormone Panel Studies 
A Luminex Milliplex assay was utilized to assess the effects of lead compound 
CJL-1-87 on metabolic hormone regulation in Chapter 4. Trunk blood of the second 
cohort was collected six hours after treatment using 1.5 mL EDTA-K2 coated tubes 
(Milian, USA) and placed on ice. To prevent hormone degradation, a series of inhibitors 
was added to each EDTA-K2 coated tube. DPPIV (Cat. No. DPP4, EMD Millipore 
Corporation, Billerica, MA) was added at a concentration of 10 µL/mL of whole blood. 
Pefabloc/AEBSF (Product No. 11873601001, Roche, Indianapolis, IN) was added at 1 
mg/mL of whole blood. Protease Inhibitor Cocktail (Part No. P8340, Sigma-Aldrich, St. 
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Louis, MO) was added at 10 µL/mL of whole blood. Aprotinin (Part No. A6279, Sigma-
Aldrich, Indianapolis, IN) was added at 500 KIU/mL of whole blood. The total whole blood 
collected per tube was about 500 µL. Whole blood samples were spun at 10,000 rpm for 
10 minutes at 4 oC. Plasma was collected from the supernatant and aliquoted to avoid 
multiple freeze/thaw cycles. The samples were then frozen at -20 oC until they were 
assayed. Plasma hormone levels were measured in duplicate from a 10 µL serum sample 
using the Mouse Metabolic Hormone Magnetic Bead Panel Milliplex Kit (Cat. No. 
MMHMAG-44K, EMD Millipore Corporation, Billerica, MA), which is commercially 
available. Hormone levels were read and acquired using Magpix instrument and Luminex 
xPonent 4.2 software (Cat. No. 40-072, EMD Millipore Corporation, Billerica, MA). Data 
was analyzed using GraphPad Prism. 
2.16 Data Analysis  
All in vitro data was analyzed utilizing PRISM program (v 4.0; GraphPad Inc.). 
The in vivo data was analyzed utilizing SPSS (v 23; IBM), but was graphed using the 
PRISM program. Statistical significance was considered p < 0.05. Data analysis is 
discussed in more detail at the end of each assays’ experimental section.  
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Scheme 2.1 General synthesis scheme of split resin approach. A) As a bivalent ligand 
is synthesized, the resin can be split at various points to produce control ligands including 
the tetrapeptide scaffold by itself and the tetrapeptide with the N-terminus linker. Also, the 
resin can be split such that a different linker can be added and/or a different second 
pharmacophore scaffold can be added.   B)  The C-terminus linker controls must be 
synthesized separately. The resin can still be split to add different pharmacophores onto 
the same linker.  (a) 20 % piperidine in DMF (b) Fmoc-NH-AA-COOH or Fmoc-NH-
PEDG20-COOH, HBTU, DIEA in DMF. Repeat (a) and (b) to achieve desired sequence. 
When Fmoc-NH-PEDG20-COOH was incorporated, reaction was allowed to proceed for 
an extra hour at room temperature. (c) 75% acetic anhydride/ 25% pyridine. (d) Cleavage 
with 91% TFA, 3% EDT, 3% TIS, 3% water for 1.5-3 hours.
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Scheme 2.2. Example of resin splitting synthesis scheme. This scheme was utilized to make ligands in Chapter 3, Chapter 4, and 
Chapter 5. (A) The synthesis of N-terminal linker controls and bivalent ligands by microwave synthesis. (B) Synthesis of C-terminal 
linker controls using a semi-automated synthesizer (a) 20 % piperidine in DMF (b) Fmoc-NH-AA-COOH or Fmoc-NH-PEDG20-
COOH, HBTU, DIEA in DMF. Repeat (a) and (b) to achieve desired sequence. When Fmoc-NH-PEDG20-COOH was incorporated, 
reaction was allowed to proceed for an extra hour at room temperature. (c) 75% acetic anhydride/ 25% pyridine. (d) Cleavage with 91% 
TFA, 3% EDT, 3% TIS, 3% water for 1.5-3 hours. This scheme has been adapted with permission from Lensing, C.J. et al, J. Med. 
Chem. 2016, 59, 3112-3128. 25  Copyright (2016) American Chemical Society.   
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Figure 2.1. Representative radioligand binding curves of the BRET receptor constructs. 
Unlabeled NDP-MSH was used to displace 125I-NDP-MSH in a dose-response manner to 
calculate the IC50 values. The reported errors are the standard error of the mean (SEM) 
determined from two replicate wells in a single experiment. This figure has been 
reproduced with permission from Lensing, C. J. et. al, ACS Chem. Neurosci. 2017, in 
press.132 Copyright (2017) American Chemical Society. 
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Figure 2.2. Average results from hPYY cannulation validation experiments. This 
experiment was performed to identify validated mice for use in TSE metabolic cage studies 
described in Chapter 4. Mice were administered 2.5 µg of human (h)PYY3-36 two hours 
before lights out. Food intake was measured manually. Validated mice ate at least 0.8 g 
more food after hPYY administration compared to saline administration at the 4 h time 
point. On average mice ate 0.4 ± 0.1 g at the 4 h time point after saline administration 
compared to 1.6 ± 0.1 g after hPYY administration in this experiment. Statistical analysis 
not shown. This figure has been reproduced with permission from Lensing, C. J. et. al, ACS 
Chem. Neurosci. 2017, in press.132 Copyright (2017) American Chemical Society. 
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Figure 2.3: Experimental paradigms used to study energy homeostasis in Chapter 4. A) 
Head to head three-way crossover design of experimental groups. Similarly, a two-way 
cross-over was also used in this thesis work. B) Fasting-refeeding experimental paradigm 
used throughout this thesis work. This figure has been reproduced with permission from 
Lensing, C. J. et. al, ACS Chem. Neurosci. 2017, in press.132 Copyright (2017) American 
Chemical Society. 
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 NDP-MSH IC50 (nM) 
 Mean±SEM 
mMC3R-NanoLuc® 1.1±0.7 
mMC3R-HaloTag® 3.1±1.4 
mMC4R-NanoLuc® 2.8±1.1 
mMC4R-HaloTag® 2.5±1.8 
 
Table 2.1. Competitive radioligand binding assays on the BRET receptor constructs. 
Unlabeled NDP-MSH was used to displace 125I-NDP-MSH in a dose-response manner to 
calculate the IC50 values. The reported errors are the standard error of the mean (SEM) 
determined from at least two independent experiments. This table has been reproduced 
with permission from Lensing, C. J. et. al, ACS Chem. Neurosci. 2017, in press.132 
Copyright (2017) American Chemical Society. 
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Chapter 3: The Design, Synthesis, In Vitro, and In Vivo Investigation of 
Homobivalent Ligands that Display Preferential Binding and Functional Activity 
for Different Melanocortin Receptor Homodimers 
Portions of the studies presented in this chapter have been previously published and 
are currently being reproduced with permission from: Lensing, C. J.; Freeman, K. T.; 
Schnell, S. M.; Adank, D. N.; Speth, R. C.; Haskell-Luevano, C. An in Vitro and in Vivo 
Investigation of Bivalent Ligands That Display Preferential Binding and Functional 
Activity for Different Melanocortin Receptor Homodimers. J. Med. Chem. 2016, 59, 3112-
3128.25 Copyright (2016) American Chemical Society. All peptides were designed, 
synthesized, purified, and analytically characterized by Cody Lensing under the 
supervision of Carrie Haskell-Luevano. The in vitro pharmacology studies were performed 
by Cody Lensing, Katie Freeman, and Sathya Schnell, all members of the Haskell-Luevano 
lab group. In vivo studies were performed by Cody Lensing and Danielle Adank. Katlyn 
Fleming aided in the interpretation of the pharmacology of CJL-1-20 (Ac-His-DPhe(pI)-
Arg-Trp-NH2) and presented the following poster at the Chemistry and Biology of Peptides 
Gordon Research Conference: Fleming, K. A.; Doering, S. R.; Lensing, C. J.; Freeman, K. 
T.; Tala, S. R.; Haskell-Luevano, C. “A Parallel Comparison of the Functional Efficacy of 
Melanocortin Peptides in Two Diverse In Vitro Assays.” Radiolabeled 125I-NDP-MSH was 
prepared by Robert Speth.  
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3.1 Chapter Overview 
Pharmacological probes for the melanocortin receptors have been utilized for 
studying various disease states including cancer, sexual function disorders, Alzheimer’s 
disease, social disorders, cachexia, and obesity. This study focused on the design and 
synthesis of bivalent ligands to target melanocortin receptor homodimers. Lead ligands 
(CJL-1-87 and CJL-1-31) increased binding affinity by 14- to 25-fold and increased 
cAMP signaling potency by 3- to 5-fold compared to their monovalent counterparts. 
Unexpectedly, different bivalent ligands showed preferences for particular melanocortin 
receptor subtypes depending on the linker that connected the teatrapeptide scaffolds 
suggesting structural differences between the various dimer subtypes. Homobivalent 
compound CJL-1-140 possessed a functional profile that was unique from its monovalent 
counterparts providing evidence of the discrete effects of bivalent ligands.  
3.2 Introduction 
As stated in Chapter 1,1 the melanocortin receptor system is involved in various 
physiological functions including pigmentation,49, 50 sexual behavior,51 blood pressure 
modulation,52 memory,53-55 and energy homeostasis.56-59 The system contains five Gαs 
protein-coupled receptor subtypes (MC1-5R) that stimulate the cAMP signal transduction 
pathway upon agonist binding.49, 77-82 Ligands targeting the melanocortin G protein-
coupled receptors (GPCRs) have been utilized as probes, and investigated as potential 
therapeutics for Alzheimer’s disease,60-62 cancer targeting,6, 28, 63-65 sexual function,51, 66 
social disorders,67, 68 cachexia,69-73 and obesity.56, 74-76 Due to the wide range of 
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pharmacological effects, the development of ligands with new scaffolds, unique functional 
properties, or more selective profiles are needed as in vitro and in vivo probes for the 
various melanocortin dependent functions. 
Bivalent ligands have been shown to offer access to properties and pharmacological 
profiles which are unique from classic monovalent ligands. The growing acceptance of 
GPCR dimers as pharmacological targets has fostered the development of bivalent ligands 
to target them. There have been several reports establishing that all known subtypes of 
melanocortin receptors form homodimers.125, 127, 129-131, 204, 206 Competitive binding studies 
suggested that melanocortin receptors have two side by side binding sites (presumably on 
different receptors) each with different binding properties which may indicate targetable 
homodimers.205, 219 Bivalent ligands offer a potential avenue to target melanocortin GPCR 
dimers and investigate their functional effects both in vitro and in vivo. Since Portoghese 
and coworkers pioneered bivalent ligands targeting GPCRs,7 bivalent ligands have been 
developed for various GPCR systems including the opioid,5, 7-9, 11 serotonin,18-20 
adenosine,15 cannabinoid,16, 17 chemokine,23 dopamine,21 and melanocortin receptors.26-37 
Bivalent ligands have been demonstrated to have a variety of different pharmacological 
effects as compared to their monovalent counterparts including: increasing or decreasing 
binding affinity,19, 21, 33 positively or negatively changing functional responses,15, 17, 20, 26, 41 
altering receptor subtype selectivity,8, 21 changing receptor trafficking,42-44 and creating 
tissue selectivity.5, 10 Due to these unique characteristics, bivalent ligands can offer distinct 
advantages and/or disadvantages over the classical monomeric approach. 
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Melanocortin bivalent ligands with various designs and linkers have increased 
binding affinity for human (h)MC4R expressed in HEK293 cells.27, 29-37 There had not 
previously been a report of bivalent ligands’ pharmacologies using the cloned MC1R, 
MC3R, and MC5R cell lines prior to this thesis work.25 Studying bivalent ligands’ effects 
at each receptor subtype is important for understanding ligand selectivity and for 
transitioning molecules to more complicated whole animal models that are expressing 
multiple receptor isoforms. Furthermore, there has been no investigation of bivalent 
ligands’ effects on the cloned mouse receptors prior to this thesis work.25, 132 Results 
obtained from the cloned mouse receptors are advantageous to inform the use of 
melanocortin bivalent ligands in the developed mouse models56-59  and represent an 
important translational step in the development of bivalent ligands as pharmacological 
probes.  
 Reports of melanocortin bivalent ligand’s effects on functional activity have been 
limited. The early functional activity study showed effects on frog-melanophore cells and 
used an unoptimized linker.26 In this system, an agonist bivalent ligand increased agonist 
signal. They also reported a bivalent ligand based on an antagonist monovalent 
pharmacophore that unexpectedly became a full agonist at high concentrations.26 Another 
report described bivalent ligands as having increased potency in cAMP accumulation 
assays in HEK293 cells expressing the hMC4R.28 To the best of our knowledge, these were 
the only two functional studies of bivalent ligands at the melanocortin receptors reported 
prior to this thesis work.26, 28 While these preliminary studies with frog melanophores and 
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hMC4R cell lines illustrate the uniqueness and utility of melanocortin bivalent ligands, 
further functional studies such as the one presented in this chapter at other receptor 
subtypes would help advance melanocortin bivalent ligands as potentially selective and 
potent pharmacological probes.25 
Given the lack of studies reporting bivalent ligands’ effects at different 
melanocortin receptor subtypes, there had been little understanding of how different linkers 
and design strategies affect binding and functional selectivity between the different 
melanocortin receptor isoforms. One objective of this study in this chapter was to 
investigate receptor subtype preference patterns by screening in parallel the different 
melanocortin receptors (the MC2R was excluded since it is reported to only be stimulated 
by ACTH)49 with bivalent ligands using different design strategies. Furthermore, in order 
for the bivalent ligands to be suitable in vivo functional probes for mouse studies, their 
effects must be characterized at the mouse melanocortin receptors otherwise interpretation 
of in vivo mouse studies would be confounding. The current study reports the design and 
synthesis of a library of agonist, partial agonist, and antagonist melanocortin homobivalent 
ligands which underwent in vitro binding and functional evaluation at the mouse 
(m)MC1R, mMC3R, mMC4R, and mMC5R subtypes. It also gives, to the best of our 
knowledge, the first in vivo functional evaluation of a melanocortin bivalent ligand.25 
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3.3 Results and Discussion: 
3.3.1 Design 
It was hypothesized that appropriately designed bivalent ligands can be used to 
target melanocortin receptor dimers, and that there may be differences in the receptor 
subtype homodimer pharmacological profiles. Our approach throughout this thesis was to 
target receptor homodimers by creating bivalent ligands comprised of two pharmacophore 
scaffolds connected with two different linkers (Figure 3.1). The previously reported 
tetrapeptides Ac-His-DPhe-Arg-Trp-NH2,96, 98 Ac-His-DNal(2’)-Arg-Trp-NH2,97, 220 and 
Ac-His-DPhe(pI)-Arg-Trp- NH2,97, 220 were selected as the scaffold templates to 
incorporate into the bivalent ligands. These tetrapeptides are based on His-Phe-Arg-Trp 
which is the minimal messaging sequence of the endogenous melanocortin hormones.96, 99, 
221, 222 Truncation studies of the potent and enzymatically stable peptide NDP-MSH (Ac-
Ser-Tyr-Ser-Nle-Glu-His-DPhe-Arg-Trp-Gly-Lys-Pro-Val-NH2) have previously shown 
the tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 to be the most active fragment.96  
The Ac-His-DPhe-Arg-Trp-NH2 peptide has previously been reported to have a 
high nanomolar to low micromolar binding affinity at the melanocortin receptors.98 Herein, 
it is postulated that the incorporation of the His-DPhe-Arg-Trp scaffold into bivalent 
ligands would retain the relatively potent agonist functional effects, but would have a lower 
binding affinity than bivalent ligands containing longer peptides scaffolds would. This is 
an important consideration in the design strategy presented, since bivalent ligands based 
off of low affinity scaffolds often allow easier detection of synergistic binding effects as 
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discussed in Chapter 1.1, 27, 122, 223 This allows for detection of larger increases in binding 
affinity which is characteristic of bivalent ligands targeting dimers.7, 31, 47 Incorporation of 
the tetrapeptide His-DPhe-Arg-Trp into bivalent ligands had already been reported to 
significantly increase binding at the hMC4R.33 This thesis’ design and experiments 
advance the field by examining the binding and functional effects of bivalent ligands based 
on this tetrapeptide with different linkers at the various melanocortin receptor subtypes. 
The previous report studied bivalent ligands that contained 14 atom, 19 atom, and 38 atom 
linkers separating the two His-DPhe-Arg-Trp scaffolds;33 the design herein utilizes 20 
atom, 36 atom, and 40 atom linkers connecting the same scaffolds. The small extensions 
in our design can significantly change activity, as bivalent ligands are quite sensitive to 
linker length.10, 11, 224, 225 For example, single atom linker extensions previously resulted in 
noteworthy changes (>500-fold) in the in vivo potency in a series of bivalent ligands tested 
for antinociception.10 A two-atom linker extension in a bivalent ligand previously increased 
potency by 1100-fold.225 
Carrithers and Lerner reported that bivalent ligands containing antagonist 
monomers yields an agonist bivalent ligand at high concentrations in a functional frog 
melanocyte dispersion assay.26 This result leads to the present hypotheses that bivalent 
ligands based on antagonist and partial agonist monomers may result in unique 
pharmacological profiles with general activity trends that could be exploited in future 
bivalent ligand design. In order to study the effects of antagonist and partial agonist based 
bivalent ligands, the DPhe in the agonist scaffold was substituted to a DNal(2’) or a 
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DPhe(pI) to yield the His-DNal(2’)-Arg-Trp and Ac-His-DPhe(pI)-Arg-Trp-NH2 
tetrapeptide scaffolds. The His-DNal(2’)-Arg-Trp tetrapeptide has previously been 
reported to be a mMC3R/mMC4R antagonist, with partial activity at the mMC3R, and full 
agonist activity at the mMC1R and mMC5R.97, 220 To our knowledge, the binding affinity 
of this tetrapeptide had not been previously reported, but it was assumed that the binding 
affinity would be similar to Ac-His-DPhe-Arg-Trp-NH2 in that it would have a low enough 
affinity to detect synergistic binding modes when used in homobivalent ligands. The Ac-
His-DPhe(pI)-Arg-Trp-NH2 tetrapeptide was reported to be a full double digit to single 
digit nanomolar agonist at the mMC1R, mMC4R, and mMC5R, but an antagonist (pA2 = 
7.25±0.18) with some agonist activity (40% receptor activation at 100 µM) at the mMC3R. 
97, 220 Of note, the reported pharmacology of these compounds was from a CRE/β-
galactosidase reporter gene assay,97, 196, 220 but most of the studies in this thesis utilize an 
AlphaScreen cAMP technology to measure receptor activation. There were some assay 
differences between compounds that will be discuss more thoroughly below in Section 
3.3.4.1.  
Both a polyethylene diamine diglycolyic acid (PEDG, but also referred to in the 
literature as PEGO or PEG2) and an alternating proline-glycine (Pro-Gly) linker system 
were selected for this study based upon previous work of Hruby and coworkers 
demonstrating these linker systems enhance binding affinity at the hMC4R.30, 31, 33, 168, 170 
It was hypothesized that different linker systems and lengths may have varying effects at 
the different receptor homodimer subtypes. The PEDG linker is flexible with good 
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solubility. Both a 20 atom PEDG20 linker and a 40 atom PEDG20-PEDG20 linker have 
previously been reported to have increased binding affinity at the hMC4R when joining 
seven residue analogs of the NDP-MSH scaffold.31 The Pro-Gly linker is a semi-rigid 
linker system with the Pro giving the linker rigidity and the Gly giving the linker flexibility. 
A linker system of 36 atoms based on six repeats of Pro-Gly has been shown to be an 
effective linker system for targeting the hMC4R.30, 31, 168 The PEDG20, PEDG20-PEDG20, 
and (Pro-Gly)6 have previously been estimated to be 4-18 Å, 8-36 Å, and 10-20 Å, 
respectively.31, 63 The PEDG20 linker was selected for the Ac-His-DNal(2’)-Arg-Trp-NH2 
series and Ac-His-DPhe(pI)-Arg-Trp- NH2 series based on solubility, ease of synthesis, 
and preliminary functional results. Although the metabolic stability was not tested at the 
time of the current study, it has previously been shown that adding polyethylene glycol to 
a peptide can increase metabolic stability.226, 227 By incorporating the polyethylene glycol-
like PEDG20 into our design, we hypothesized it may increase the likelihood of identifying 
a suitable in vivo probe. Serum stability assays examining the effects of linker design were 
performed later, validating this hypothesized design strategy, and will be discussed in detail 
in Chapter 4 and Chapter 6.132 
3.3.2 Peptide synthesis 
All compounds were synthesized on Rink-amide-MBHA resin using standard 
Fmoc-chemistry and solid phase synthesis methodology utilizing both a semi-automated 
synthesizer and a microwave synthesizer as described in Chapter 2.190, 191, 228 Similar to a 
strategy previously employed,30 the resin was split at various points in the synthesis to 
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produce the desired linker controls (Scheme 2.1 and 2.2). This strategy allowed the 
production of the desired control ligands (i.e. the tetrapeptides and the tetrapeptides with 
the linker attached) in route to the synthesis of the bivalent ligands. This strategy was also 
used to derivatize control ligands with the linker attached to the N-terminus of the DPhe, 
DNal(2’), and DPhe(pI) compounds. The control compounds synthesized in this fashion 
also served as controls for the MUmBL compounds discussed in Chapter 5. 
Peptides were cleaved off of the resin using triisopropylsilane, 1,2-ethanedithiol, 
and water in trifluoroacetic acid (TFA). A cleavage time of 3 hours caused significant 
degradation of CJL-1-116. Interestingly, the major degradation product and pure CJL-1-
116 had the same retention time by analytical RP-HPLC in acetonitrile and aqueous TFA 
(0.1%) (Figure 3.2A), but clear peak separation could be seen by analytical RP-HPLC in 
methanol and aqueous TFA (0.1%) (Figure 3.2B) illustrating the importance of using two 
diverse solvent systems (e.g. acetonitrile and methanol) when assessing compound purity. 
Mass spectrometry revealed the mass of the desired product (mass of 961.6) and the mass 
of the impurity (mass of 685.4). The impurity peak possessed the same mass and had 
similar retention times as the parent tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 that could 
indicate the degradation of the linker. Co-injection of purified CJL-1-14 with crude sample 
of CJL-1-116 from the 3-hour cleavage resulted in increased relative intensity of the 
impurity peak demonstrating the similar retention times of CJL-1-14 and the impurity 
(Figure 3.2C). A shorter cleavage time of 1.5 hours resulted in minimal degradation 
products of CJL-1-116 as seen by analytical HPLC in methanol and aqueous TFA (0.1%) 
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(Figure 3.2D). A shorter cleavage time was also used for CJL-1-132 and minimal 
degradation was observed. The remaining peptides reported were synthesized with little 
difficulty. All final ligands were purified to greater than 95% pure and their mass was 
confirmed by ESI-MS (Table 3.1). Further details can be found in the in Chapter 2.  
Although bivalent CJL-5-64, Ac-His-DPhe(pI)-Arg-Trp-(PEDG20)-His-
DPhe(pI)-Arg-Trp-NH2, was synthesized and purified, it could not be successfully 
dissolved after lyophilization. Attempted solvents to dissolve the peptide included DMSO, 
water, 20% Solutol®HS (Sigma, Cat # 42966) in water, neat acetic acid, and mixtures of 
these solvents. Compound CJL-5-64 did seem to dissolve in large amounts of methanol or 
acetonitrile but these solvent systems would not be applicable to the current whole cell 
assays or in vivo assays. The reason for the lack solvation of CJL-5-64 was never 
understood completely. Retention times in HPLC were similar to readily dissolvable 
compounds (K’MeCN = 6.0, K’MeOH= 10.5) indicating it was not an issue of hydrophobicity. 
The current hypothesis is that a noncovalent “side-on” interaction of the negatively charged 
I atom with the electropositive aromatic plane that results in polymerization or 
aggregation.229 This would need to be experimentally validated and tested. Because of the 
solubility issues and the assay differences observed with Ac-His-DPhe(pI)-Arg-Trp-NH2 
(CJL-1-20) that will be discussed below, CJL5-64 was excluded from the bioassays and 
any further development. It will, therefore, not be discussed further. 
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3.3.3 125I-NDP-MSH Competitive Binding Affinity Studies 
The ligands’ ability to competitively displace 125I-NDP-MSH was studied in 
HEK293 cells signally expressing each of the melanocortin receptors. The results are 
summarized in Table 3.2 and illustrated in Figure 3.3. The varying effects of the linker, 
pharmacophore, and receptor subtype are summarized below.  
3.3.3.1 Linker effects  
The addition of the linker to the monovalent tetrapeptide scaffold affected binding 
of the ligand depending on the type of linker, site of addition (N- or C-terminus), and 
receptor subtype. At the mMC1R, the linkers had minimal effects on binding (Figure 3.3A 
and D) and the difference between control ligand CJL-1-14, CJL-1-80, or CJL-1-20 and 
their corresponding linker control ligands are within experimental error. Changes less than 
3-fold were considered to be within experimental error associated with the assay (in our 
hands). At the mMC3R, the addition of a linker to the tetrapeptides resulted in equal or 
increased binding affinity (Figure 3.3B and E). Most notable was the addition of the 
PEDG20 to the C-terminus and (Pro-Gly)6 to the N-terminus of the Ac-His-DPhe-Arg-Trp-
NH2 scaffold in compounds CJL-5-35-4 and CJL-1-41. The addition of this linker resulted 
in increased mMC3R binding affinity of ca. 6- and 9-fold, respectively, as compared to its 
monovalent counterpart CJL-1-14 (Table 3.2). The addition of the PEDG20 to the N-
terminus of Ac-His-DPhe(p-I)-Arg-Trp-NH2 in compound CJL-5-009 resulted in a 3-fold 
increase in binding affinity compared to its monovalent counterpart CJL-1-20. At the 
mMC4R, the (Pro-Gly)6 linker reduced the binding affinity by 4-fold compared to CJL-1-
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14 when added to the C-terminus in compound CJL-5-35-1 (Figure 3.3C and F). In 
contrast, the PEDG20 linker when added to the C-terminus in CJL-5-35-4 resulted in a 3-
fold increased binding affinity compared to CJL-1-14. All other linker control compounds 
resulted in less than 3-fold changes at the mMC4R compared to their monovalent 
counterpart.  
It is worth noting that there were changes in binding affinity when the linker was 
added to the C-terminus of the peptide, which has been seldom investigated when studying 
melanocortin bivalent ligands. The present SAR study demonstrated that the site of linker 
addition to either the C-terminus or N-terminus is an important consideration when 
designing bivalent ligands. 
3.3.3.2 Bivalent Ligands 
All His-DPhe-Arg-Trp based bivalent ligands had increased binding affinity (3- to 
25-fold) compared to the parent tetrapeptide CJL-1-14.  The SAR of the His-DPhe-Arg-
Trp based bivalent ligands at the different receptor subtypes was an intriguing finding. At 
the mMC1R, the most enhanced compound was the (Pro-Gly)6 linked compound CJL-1-
31 (Figure 3.3A). Its binding affinity increased by 14-fold compared to monovalent ligand 
CJL-1-14. The PEDG20 linked compounds CJL-1-87 and CJL-5-72 resulted in a 6- and 
3-fold increased binding affinity, respectively. At the mMC3R, the (Pro-Gly)6 and 
PEDG20 linkers had the greatest effect (Figure 3.3B). It was observed that CJL-1-31 and 
CJL-1-87 possessed c.a. 25- and 23-fold increased binding affinity, respectively, 
compared to CJL-1-14. Compound CJL-5-72 resulted in an 8-fold increased binding 
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affinity compared to CJL-1-14. At the mMC4R, the PEDG20 linked bivalent ligand CJL-
1-87 increased binding affinity 22-fold as compared to the monovalent counterpart CJL-
1-14 (Figure 3.3C). Compounds CJL-1-31 and CJL-5-72 possessed 6- and 4-fold 
increased binding affinity, respectively, as compared to CJL-1-14. 
In the Ac-His-DNal(2’)-Arg-Trp-NH2 series, bivalent ligand CJL-1-140 resulted 
in 4-fold increased binding affinity at both the mMC1R and mMC3R as compared to its 
monovalent counterpart CJL-1-80 (Figure 3.3D and E). The binding affinity of 
compound CJL-1-140 was within experimental error of the binding affinity of CJL-1-80 
at the mMC4R (Figure 3.3F). It was postulated that no increase in binding affinity was 
observed at the mMC4R because of the potent binding affinity of Ac-His-DNal(2’)-Arg-
Trp-NH2 scaffold that potentially masked multivalent interactions.27, 122, 223 The lower 
binding affinity of the Ac-His-DPhe-Arg-Trp-NH2 scaffolds allows easier detection of the 
enhancements in the binding affinity. As Kiessling and Lamanna explain, an “increase in 
apparent affinity of a multivalent display of middle-affinity epitopes quickly exceeds 
measurable binding constants and is indistinguishable from multivalent scaffolds of high-
affinity ligands. In contrast, the increase in functional affinity between multivalent displays 
of weakly versus more weakly interacting epitopes falls within a range discernible by most 
biological systems.”223    
The increased binding affinity (14- to 25-fold) of the lead bivalent ligands in the 
Ac-His-DPhe-Arg-Trp-NH2-based series support the hypothesis that these ligands are 
binding in a synergistic bivalent mode utilizing a second binding site.  The second binding 
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site could be either an auxiliary binding site on the same receptor or an orthosteric binding 
site on a neighboring receptor.223, 230  The use of Occam’s razor directs us to the latter 
possibility since it has been observed that melanocortin receptors dimerize,125, 127, 129-131, 204, 
206 and therefore, a neighboring orthosteric binding site should be readily accessible for 
synergistic binding versus an unknown auxiliary binding site for the His-DPhe-Arg-Trp 
pharmacophore. 
In the proposed bivalent binding mode, the first binding interaction of one 
pharmacophore is postulated to tether the second pharmacophore to the receptor surface. 
If the linker has the correct properties (e.g. length, flexibility) to orientate the second 
pharmacophore into a tandem binding site (i.e. a GPCR dimer), the second binding 
interaction proceeds with lowered entropic cost (Figure 3.4).7, 230 Based on these results, 
the PEDG20-PEDG20 linker in compound CJL-5-72 may be too long to tether the second 
pharmacophore in the correct location of the second binding site, and therefore, loses the 
entropic gains of the bivalent design reflected in the lower fold changes in binding affinity 
at all receptor subtypes.7 These results helps validate the use of this design strategy in 
Chapters 4-6. 
An interesting trend observed was the differential effects of the (Pro-Gly)6 and 
PEDG20 linkers at the melanocortin receptor subtypes. Compound CJL-1-31 with the 
(Pro-Gly)6 linker resulted in the greatest fold increase in ligand binding affinity at the 
mMC1R (14-fold) and notable fold increase at the mMC3R (25-fold), but lower fold 
changes at the mMC4R (6-fold). Ligand CJL-1-87 with the PEDG20 linker resulted in the 
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greatest fold increase in binding affinity at the mMC4R (22-fold) and notable fold increase 
at the mMC3R (23-fold), but lower fold increase at the mMC1R (6-fold). In this study, it 
was identified that the mMC1R has a preference for the (Pro-Gly)6 linker, the mMC4R has 
preference for the PEDG20 linker, and the mMC3R bound well with both of the two linkers 
(Figure 3.5). 
The receptor subtype differences observed with compounds CJL-1-31 and CJL-1-
87 are not due to the binding scaffold or the binding pocket since these remain constant 
when comparing the bivalent ligands to the monovalent counterparts at each receptor 
subtype. In addition, the tetrapeptide plus linker control ligands resulted in minimal 
increased binding affinity (<4-fold) at the mMC1R and mMC4R suggesting that the linker 
by itself is not the driving factor for the bivalent ligands increased activity. At the mMC3R, 
the linker control ligands did result in increased binding affinity (≤ 9-fold), but their 
affinities were lower than the affinities of the lead bivalent ligands and are likely not the 
primary driving factor for the increased mMC3R binding affinities of the bivalent ligands. 
Instead the bivalent ligand-receptor differences are conjectured to be due to differences in 
the physiochemical nature of the linker (e.g. flexibility, length, ect.) and how these may 
change the presentation of the pharmacophore to the tandem binding site.  
Based upon these results it can be postulated that there are differences how the 
tandem binding sites of different melanocortin homodimer subtypes present themselves. 
For example, if the mMC1R homodimer has more distance between the two binding sites 
than a mMC4R homodimer, the (Pro-Gly)6 linker (36 atoms, ~8-36 Å31, 63), that is 
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hypothesized to be longer based on atom length than the PEDG20 linker (20 atoms, ~4-18 
Å31, 63), would favor the mMC1R homodimer and the PEDG20 would favor the mMC4R. 
To be consistent with the data, the mMC3R homodimer would have an intermediate 
distance between their two binding sites compared to the mMC1R and mMC4R 
homodimers, and therefore would show enhanced binding with both linker systems 
(Figure 3.5). It should be noted that the flexibility of the linkers makes prediction of their 
exact lengths in solution difficult, and this is just a hypothesis to explain the trends 
observed. 
This idealized situation only accounts for the distance between tandemly arranged 
binding pockets and the linker’s length. Other factors including the linker’s other 
physiochemical properties, the two pharmacophores’ orientations, and the binding pockets’ 
accessibility may play a role in the binding affinity preferences observed. Nevertheless, 
these data suggest bivalent ligands could be exploited to achieve selectivity between the 
different melanocortin homodimers. This is, to our knowledge, the first indication of ligand 
preference patterns (albeit not selectivity) between the melanocortin homodimer-subtypes; 
however this phenomenon has been observed in several other bivalent ligand systems 
targeting GPCR systems.8, 21 For example, Kuhhorn and coworkers previously observed 
different linker systems connecting bivalent ligands resulted in varying dopamine receptor 
subtype specificity.21 In addition, Portoghese and coworkers synthesized bivalent ligands 
with different selectivity profiles for the µ, κ, and δ opioid receptors based on single glycyl 
unit linker extensions.8 Given these three examples of differential binding of bivalent 
69 
 
ligands, it suggests that ligand selectivity between different receptor homodimer subtypes, 
as opposed to monomer orthosteric selectivity, may be a general phenomenon among 
GPCRs. However, more investigation into melanocortin receptor homodimerization (or 
higher-order oligomerization) will be necessary. The current study reports foundational 
work and results in novel chemical probes for future studies for both melanocortin GPCR 
homodimers and heterodimers.  
3.3.4 Functional cAMP Accumulation Studies 
The AlphaScreen® cAMP Assay Technology was utilized to examine the ligands 
ability to stimulate intracellular cAMP signaling in live HEK293 cells stably expressing 
the mMC1R, mMC3R, mMC4R, and mMC5R. Compounds which did not produce full 
activation at 100 µM (compared to maximal NDP-MSH signal) were analyzed for 
antagonist properties via a Schild analysis at the mMC3R and mMC4R.198 The results of 
the studies are summarized in Tables 3.2 and 3.3 as well as illustrated in Figures 3.6 and 
3.7.  
As anticipated, compounds with greater binding affinity tended to have greater 
functional potency. However, plotting the EC50 values versus IC50 values of His-DPhe-Arg-
Trp ligands suggested that binding affinity does not correlate linearly to function at the 
mMC1R and mMC3R with R2 values of 0.22 and 0.75, respectively (Figure 3.8). At the 
mMC4R, it does appear to correlate linearly (R2 value of 0.95) such that a ligand’s EC50 
potency is approximately 10-fold more potent compared to its IC50 binding affinity. 
Although some of the poor correlation could be due to inherent experimental error, these 
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data show that binding affinity and cAMP accumulation functional potency observed do 
not necessarily correlate within receptor isoforms highlighting the importance of studying 
both a ligand’s binding affinity and functional potency in complementary assays. A more 
detailed description of the functional activity with the linker control compounds and the 
bivalent compounds is discussed below. 
3.3.4.1 Discrepancies between cAMP Functional Assays 
Comparison of the current studies to past literature results reported by our 
laboratory revealed some discrepancies between the functional potency and efficacy of 
monovalent tetrapeptides presumably due to differences in the assay paradigms. In the 
literature studies, a CRE/β-galactosidase reporter gene assay was utilized to evaluate the 
pharmacology instead of the AlphaScreen® cAMP Assay Technology currently used.97, 220 
Compound CJL-1-14, Ac-His-DPhe-Arg-Trp-NH2, was a strong agonist and gave 
comparable results to previous reports using the CRE/β-galactosidase reporter gene assay 
by our laboratory (Table 3.3).97, 220 Furthermore, the other control agonist compounds (i.e. 
NDP-MSH, α-MSH, and γ-MSH) presented currently have comparable activities compared 
previous literature reports in the CRE/β-galactosidase reporter gene assay.97, 220 
The results obtained with compound CJL-1-80, Ac-His-DNal(2’)-Arg-Trp-NH2 at 
the mMC1R and mMC3R were similar to literature values reported (Table 3.4). 97, 220 At 
the mMC4R, CJL-1-80 resulted in a very similar pA2 value to those reported pervious, but 
it resulted in some agonist activity at 100 µM that was not previously observed.97, 220 This 
agonist activity at high concentrations is likely not physiologically relevant as 
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concentrations exceeding 10 µM are unlikely to be achieved in the brain. This also could 
be an assay artifact from some sort of assay interference observed at high concentrations. 
This hypothesis that it is an assay artifact was supported by the preliminary work of Katie 
Henning (Freeman) utilizing the AlphaScreen™ TruHits™ assay kit (data not shown). 
However, a major pharmacological difference was observed with CJL-1-80 at the 
mMC5R. In the current AlphaScreen Assay, CJL-1-80 resulted in only 75% receptor 
activation at 100 µM relative to NDP-MSH. In previous studies using the CRE/β-
galactosidase reporter gene assay, CJL-1-80 was reported to be a double-digit nanomolar 
agonist.97 This suggests that these results are not solely due to assay artifacts and that these 
two assays are not completely equivalent. Our laboratory is primarily interested in the 
mMC3R and mMC4R and its role in energy homeostasis. However, if designing ligands 
for the mMC5R, this discrepancy must be included in data interpretation.  
Compound CJL-1-20, Ac-His-DPhe(pI)-Arg-Trp-NH2, resulted in comparable 
pharmacology at the mMC1R, mMC3R, and the mMC5R as previous literature reports.97, 
220 However, compound CJL-1-20 was a nanomolar antagonist (pA2= 8.6 ± 0.1) with some 
partial activity. In previous reports, Ac-His-DPhe(pI)-Arg-Trp-NH2 was reported to be a 
nanomolar agonist at the mMC4R in the CRE/β-galactosidase reporter gene assay.97, 220  
This contrast of CJL-1-20 being an agonist in the CRE/β-galactosidase reporter gene assay 
but an antagonist in the AlphaScreen assay warranted further investigation.  
In order to investigate, Ac-His-DPhe(pI)-Arg-Trp-NH2 was purchased from 
Peptides International for a direct comparison to the synthesized compound, CJL-1-20. 
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The two compounds were then assayed in parallel in the AlphaScreen Assay to compare 
the cAMP signaling results directly (Figure 3.9).  A very similar pharmacological profile 
was observed with both compounds. Also the compounds had matching masses and 
retention times by analytical RP-HPLC. This confirmed that the compound differences 
between the reported pharmacology,97, 220 and the observed current results are not due to 
our synthesis of the compound. It seems likely that the discrepancy is due to an assay 
difference between the CRE/β-galactosidase reporter gene assay and the cAMP 
AlphaScreen assay. 
In order to understand why there may be assay-dependent differences, it is 
necessary to understand how the assays work. In the CRE/β-galactosidase reporter gene 
assay, the receptor is stimulated which activates adenylate cyclase. The adenylate cyclase 
amplifies the signal by converting ATP to cAMP. Then cAMP activates protein kinase A 
(PKA) which then phosphorylates cAMP response element binding protein (CREB) 
resulting in further signal amplification. In the CRE/β-galactosidase reporter gene assay, 
cells are transfected with a plasmid with five CRE promoters that drives β-galactosidase 
expression in another amplification step. In a final amplification step after cell lysis, the β-
galactosidase cleaves the colorless ortho-nitrophenyl-β-galactoside (ONPG) into galactose 
and brightly yellow colored ortho-nitrophenol. A dose-dependent increase in color 
conversion can be analyzed as a functional curve.196 In contrast, the AlphaScreen assay 
measures cAMP by direct competition for a cAMP antibody such that binding disrupts a 
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signal relay system. Increased cAMP production by the cell results in decreased signal due 
to disruption in a dose-dependent manner. 
Due to the inherit differences in the assay, several hypotheses can be proposed to 
explain the discrepancies between the two assays. First, the several additional signal 
amplification steps may result in greater signal from weak or partial agonists allowing them 
to reach maximal signal and be observed as full agonists. Second, the AlphaScreen has 
only a 2-hour compound stimulation whereas the CRE/β-galactosidase reporter gene assay 
has a 6-hour compound stimulation. The differences observed may be time-dependent 
differences. Third, the cAMP AlphaScreen should only be affected by the Gαs-coupled 
signaling pathway. In addition to Gαs-coupled signaling pathway, the CRE/β-galactosidase 
reporter gene assay is known to be stimulated through the Gαq-coupled signaling pathway 
that also results in CREB phosphorylation.196 Discrepancies could be a result of this 
alternative signaling cascade (possibly through biased agonsim). Fourth, if any compound-
dependent assay interference was occurring in either assay, it may be different between the 
two assays considering the assay conditions are different (e.g. room temperature vs 37o C, 
gain of function versus loss of function, incubation times, gene reporter vs bead reporter). 
Further research into the reason for the exact assay discrepancies is warranted. In 
the current thesis, we treated the two assays as complementary. Therefore, consistent 
results in the two assays was treated as a way of confirming compound pharmacology at 
that receptor subtype. Compounds based off CJL-1-14 (Ac-His-DPhe-Arg-Trp-NH2) and 
CJL-1-80 (Ac-His-DNal(2’)-Arg-Trp-NH2), especially at the mMC3R and mMC4R, 
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normally resulted in consistent results in both assays and, therefore, were the focus of the 
current thesis work. Compounds that were inconsistent between the two assays were treated 
as suspect and, therefore, were avoided for further study and inclusion in design. These 
included compounds designed based on CJL-1-20 (Ac-His-DPhe(pI)-Arg-Trp-NH2). 
However, some in vitro work was performed with compounds that contain the His-
DPhe(pI)-Arg-Trp pharmacophore were included in this chapter and in Chapter 5 to aid 
in future efforts to understand the assay discrepancies and melanocortin ligand design (See 
the Appendix for pharmacology information). After all, hindsight is 20/20.  
3.3.4.2 Linker Effects 
There were five situations in which the addition of a linker to the tetrapeptide 
scaffold resulted in noteworthy changes in agonist activity. Changes less than 3-fold were 
considered to be within the intrinsic experimental error associated with this functional 
assay (in our hands). The attachment of the (Pro-Gly)6 linker to the C-terminus in CJL-5-
35-1 decreased the potency of the Ac-His-DPhe-Arg-Trp-NH2 by 5-fold at the mMC4R 
and mMC5R (Table 3.3, Figure 3.6G and H). In contrast, at the mMC5R the attachment 
of PEDG20 to the C-terminus in CJL-5-35-4 resulted in 5-fold increased functional 
potency (Table 3.3, Figure 3.6H). Also attachment of the PEDG20 to the C-terminus of 
His-DPhe(pI)-Arg-Trp as seen in compound CJL-5-35-6 resulted in a 10-fold increase in 
agonist potency at the mMC5R. Compound CJL-5-35-6 also resulted in a 3-fold increase 
in antagonist potency at the mMC3R (Table 3.4).  
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These data indicated that the C-terminus of His-DPhe-Arg-Trp is amendable to 
changes, but sensitive to modifications. These findings reinforced the importance of 
including C-terminal linker controls in bivalent ligand studies. 
3.3.4.3 Bivalent Ligands 
At the mMC1R, the bivalent ligand CJL-1-31, based off of the His-DPhe-Arg-Trp 
scaffold, resulted in 3-fold increased agonist potency as compared to its monovalent 
counterpart CJL-1-14 (Figure 3.6A). At the mMC3R, ligands CJL-1-87 and CJL-1-31 
(that possessed 23- and 25-fold increased binding affinity) resulted in 5- and 3-fold 
increased agonist potency, respectively, as compared to CJL-1-14 (Figure 3.6B). At the 
mMC4R, bivalent ligand CJL-1-87 resulted in 4-fold increased potency as compared to 
the parent tetrapeptide CJL-1-14 (Figure 3.6C). At the mMC5R, bivalent ligand CJL-1-
87 resulted in a 3-fold increased potency as compared to the monovalent control CJL-1-
14 (Figure 3.6D). However, this data was confounded by the 5-fold increased potency of 
linker control compound CJL-5-35-4 compared to CJL-1-14 (Figure 3.6H). It is therefore 
hard to interpret whether increased potency at this receptor subtype is due to the addition 
of the linker or because of the bivalent design.  
At the mMC1R, bivalent ligand CJL-1-140, derived from the His-DNal(2’)-Arg-
Trp tetrapeptide, decreased agonist potency 5-fold as compared to the monovalent 
counterpart CJL-1-80 (Figure 3.7A). This is the only bivalent ligand that displayed a 
decreased potency; an unanticipated result since the binding affinity of this ligand was 
increased as compared to its monovalent counterpart CJL-1-80. At the mMC3R, ligand 
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CJL-1-140 increased receptor efficacy relative to NDP-MSH, resulting in an 80% maximal 
signal at 100 µM compared to monovalent ligand’s 45% signal (Figure 3.7B). The ligand 
was analyzed via a Schild analysis for antagonist activity but showed no change in 
antagonist potency as compared to the monovalent ligand CJL-1-80 (Table 3.4). At the 
mMC4R, bivalent ligand CJL-1-140 showed increased receptor efficacy showing 85% 
maximal signal at 100 µM relative to NDP-MSH compared 40% maximal signal by the 
monovalent ligand CJL-1-80 (Figure 3.7C). The ligand was also analyzed by a Schild 
analysis, but showed minimal change in antagonist potency compared to the monovalent 
ligand CJL-1-80 (Table 3.4). At the mMC5R, ligand CJL-1-140 displayed full agonist 
pharmacology (EC50 = 790 nM) and increased receptor efficacy as compared to CJL-1-80 
that showed 75% agonist signal at 100 µM relative to NDP-MSH (Figure 3.7D). 
A thought-provoking pattern with the bivalent ligands based on the His-DNal(2’)-
Arg-Trp scaffold was observed: compound CJL-1-140 increased efficacy at the mMC3R, 
mMC4R, and mMC5R as compared to the monovalent control ligand CJL-1-80. This trend 
observed of a monovalent scaffold that possessed relatively low agonist efficacy and potent 
antagonism being converted to a bivalent ligand showing increased agonist efficacy at high 
concentrations was previously seen by Carrithers and Lerner.26 They observed this trend in 
a frog skin melanocyte dispersion assay with a bivalent ligand that consisted of the 
nonapeptide antagonist scaffold Met-Pro-DPhe-Arg-DTrp-Phe-Lys-Pro-Val174 linked with 
a polylysine linker.26 The current study extends this finding by showing a similar trend at 
the individually cloned mMC3R, mMC4R, and mMC5R subtypes. Interestingly, bivalent 
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ligand CJL-1-140 also showed decreased agonist potency at the mMC1R despite an 
increased binding affinity. The ligand had a receptor functional profile different than the 
original monovalent ligand CJL-1-80 in which its agonist potency increased at the 
mMC3R, mMC4R, and mMC5R yet decreased at the mMC1R. Since the region of the 
ligand which purportedly binds the receptor is not changing from the monovalent ligand, 
the pharmacology of CJL-140 is a result of joining the two scaffolds.  
This SAR is unique from classical monovalent ligand SAR and demonstrates that 
bivalent ligands can create unique pharmacologies. The conversion observed at the 
mMC3R and mMC4R of monovalent scaffolds with relatively low agonist efficacy and 
potent antagonism to a bivalent ligand with increased agonist efficacy, yet similar 
antagonism, may be just one potential functional consequence of bivalent compounds 
targeting the melanocortin receptors. Furthermore, the observation that CJL-1-140 
possessed increased binding affinity at the mMC1R but decreased functional potency once 
again emphasizes the importance of studying both the binding and function of bivalent 
ligands.  
It should be noted that the fold increases observed in functional potency (3- to 5-
fold) were not as pronounced as the fold increases observed in binding affinity (14- to 25-
fold). There are several possibilities for why the increased binding affinities did not 
translate to larger increases in functional potency. First, similar to discussion above about 
the smaller fold increases observed with Ac-His-DNal(2’)-Arg-Trp-NH2 based 
compounds’ binding affinity, the Ac-His-DPhe-Arg-Trp-NH2 scaffold’s potent nanomolar 
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agonist efficacy could be masking functional increases. Second, binding affinity is a 
molecular recognition event whereas functional potency is a signaling transduction event 
and is dependent on a conformational change of the receptor. The tethered bivalent ligands 
could cause a change in the orientation of the second pharmacophore in the second binding 
pocket in which it can still bind to the receptor, but it does not activate the cAMP signal 
transduction pathway as effectively. Third, the bivalent ligand could be binding in an 
auxiliary binding site that has minimal functional effects. Fourth, the lower fold changes 
in functional potency could be a result of asymmetric signaling of the two receptors present 
in the dimer. It could be postulated that the first binding event activates cAMP signal 
transduction through the first receptor, but the second binding event does not activate the 
cAMP pathway. The second binding could result in no conformational change of the 
second receptor, or a different conformational change that results in biased signaling 
through a different pathway (e.g. β-arrestin recruitment). This would result in a lack of 
increase in functional activity in spite of increased bivalent ligand binding. This type of 
asymmetry in GPCR dimers was previously observed by Han and coworkers.231 They 
observed that an agonist binding a single dopamine D2 receptor resulted in maximal 
functional activation, while an agonist binding the second receptor in the GPRC dimer 
blunted signaling.231 This final hypothesis lead to the design of the MUmBLs that will be 
discussed in Chapter 5.  
 
 
79 
 
3.3.5 In Vivo ICV Administration Studies  
Although there have been reports of melanocortin bivalent ligands as in vivo 
imaging tools,38-40 to the best of our knowledge, the in vivo functional effects of 
melanocortin bivalent ligands had not been reported prior this thesis work.25, 132 Given the 
unique characteristics of bivalent ligands compared to their monovalent counterparts that 
were not explicitly tested (e.g. altering receptor trafficking42-44 and creating tissue 
selectivity5), it is important to demonstrate that the in vitro pharmacology translated to the 
in vivo pharmacology.  
In order to better understand the functional effects of melanocortin bivalent ligands 
and their potential as in vivo probes, the intracerebroventricular (ICV) administration of 
bivalent ligand CJL-1-87 was performed in mice. The central administration of 
melanocortin ligands has previously been used to study their effect on the centrally located 
MC3R and MC4R. Specifically, ICV administration of melanocortin agonists has been 
reported to decrease food intake and antagonists to increase food intake.56, 76, 107 Compound 
CJL-1-87 was selected for study since it showed the greatest potency and binding affinity 
at the mMC3R and mMC4R. 
Treatment of mice with CJL-1-87 was well tolerated and resulted in a dose 
dependent decrease in food intake after ICV administration as anticipated for an agonist 
compound (Figure 3.10). The treatment strategy followed a cross-over paradigm described 
in Chapter 2 (Table 3.5). A significant decrease in food intake was observed in male mice 
2, 4, 6, and 8 hours after 5 nmols of CJL-1-87 was administered (Figure 3.10A). No 
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significant effect in male mice was seen for later time points (24-72 hours) (Figure 3.10C). 
No significant differences were observed in female mice at 2, 4, 6, and 8 hour time points 
(Figure 3.10B). A significant decrease in food intake was observed 24 hours post-
treatment in female mice (p<0.05), but no significant effect was observed at the 48 and 72 
hour time points (Figure 3.10D). No significant effect on body weight was observed in 
either female or male mice.  
These data are consistent with the in vitro data that CJL-1-87 acts as a melanocortin 
agonist at the centrally expressed melanocortin receptors. The monovalent counterpart, Ac-
His-DPhe-Arg-Trp-NH2, was previously shown to decrease food intake 3, 4, 5, 6, 16, and 
24 hours after administration of a 2 nmol dose.76  An interesting observation between the 
two studies is the longer-lasting effect previously reported with Ac-His-DPhe-Arg-Trp-
NH2 at 24 hours which was not observed with CJL-1-87 in male mice in the current study. 
This may indicate a difference in the physiological effects of the compound in vivo and 
may be due to any number of reasons including increased receptor desensitization, 
increased compensation pathways, changes in hormone signaling, or increased metabolic 
degradation of the compound. Additional experiments were performed to examine 
differences observed in these preliminary experiments, and are the focus of Chapter 4. 
A previous study showed that Ac-His-DPhe-Arg-Trp-NH2 at the 2.0 nmol dose had 
similar results to CJL-1-87 at the 5 nmol dose at 4 and 6 hours after administration. These 
results would indicate that the in vitro functional results (as opposed to binding results) are 
more indicative of the in vivo effects in the current nocturnal satiated feeding paradigm. 
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However, there are key differences between the current study and the previous study that 
should be mentioned. Firstly, the food intake after saline administration in the previous 
study was significantly lower than in the current study at the 6 and 24 hour time points 
(p<0.05). Secondly, different mouse chow was used. The previous study utilized Harlan 
Teklad 8604 containing 4% fat and 3.30 kcal/g digestible energy, whereas, Harlan Teklad 
2018 containing 6.2 % fat and 3.1 kcal/g digestible energy was used in the current study. 
This difference in chow may have been responsible for the differences in saline food intake, 
since a mouse eating Harlan Teklad 8604 would need to consume less chow to achieve the 
same caloric intake. There were also varying environment factors including the animal 
facilities, the lab staff, frequency of measurements, and type of nesting material. Subtle 
changes in experimental conditions have been shown to result in differences in animal 
behavior.232-235 Given these factors, a direct head to head comparison study of the 
monovalent CJL-1-14 and the bivalent ligand CJL-1-87 would be necessary to draw more 
definitive conclusions.  This was performed and will be discussed in detail in Chapter 4. 
The current report advanced the field by indicating that melanocortin bivalent 
ligands are suitable to probe for melanocortin effects in vivo. In the current study, there 
does not appear to be a dramatic advantage between monovalent ligand CJL-1-14 and 
bivalent ligand CJL-1-87. However, only one experimental paradigm of food intake was 
evaluated. Since bivalent ligands show increased binding affinity compared to their 
monovalent counterparts, they may be beneficial in conditions that the ligand is competing 
with the natural antagonist AGRP for binding such as in a fasting state which was indeed 
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the case when evaluated in Chapter 4. The bivalent ligands developed currently may also 
be exploited as imaging tools as described previously,6, 38-40, 63 but for the centrally located 
receptors. This would be especially useful if bivalent ligands featuring selective scaffolds 
for different melanocortin receptor subtypes were used for imaging the isoforms’ locations 
in the brain. Bivalent ligands are also uniquely poised to study melanocortin receptor 
dimerization in vivo. The use of CJL-1-87 to decrease food intake in mice demonstrates 
its utility as a probe for metabolic diseases such as obesity. Additionally, the current study’s 
finding that melanocortin bivalent are well tolerated and functionally active in vivo 
indicates that they will also be useful probes for other disease states in which the 
melanocortin system plays a role including Alzheimer’s disease,60, 61 sexual function,51, 66 
and social disorders.67, 68 In deed, this preliminary study laid the groundwork for the more 
comprehensive study performed in Chapter 4.132 
3.4 Conclusion: 
This thesis chapter validated that melanocortin bivalent ligands can be utilized to 
increase receptor binding affinity and functional potency. It also identified a preference of 
the receptor subtypes for different bivalent ligand linkers indicating differences in the 
homodimer subtypes. It laid the foundational work that was used in Chapter 5 and 
Chapter 6 in which different medicinal chemistry design strategies were utilized to further 
the SAR of melanocortin bivalent ligands. Furthermore, compound CJL-1-87 resulted in 
significant decreased feeding in vivo upon ICV administration which was consistent with 
its agonist in vitro pharmacology. We utilized these preliminary in vivo results to design 
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and perform a more thorough assessment of CJL-1-87’s in vitro and in vivo pharmacology 
in Chapter 4. This foundational work can also be applied to the various fields in which 
melanocortin ligands are currently under investigation as pharmacological probes and 
potential therapeutics. Specifically, our in vivo results indicate bivalent ligands’ utility in 
studying melanocortin-dependent metabolic disease states. It also serves as a foundation 
for the development of melanocortin bivalent ligands as functional pharmacological probes 
for melanocortin receptor homodimers and heterodimers (as discussed further in Chapters 
4-6).  
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Figure 3.1. Design of ligands in Chapter 3 from selected scaffolds and linkers. This figure 
has been adapted with permission from Lensing, C.J. et al, J. Med. Chem. 2016, 59, 3112-
3128.25 Copyright (2016) American Chemical Society. 
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Figure 3.2. Crude RP-HPLC analytical chromatograms at 214 nm of CJL-1-116 (mass of 
961.6) in a gradient from 10% to 90% MeCN or MeOH in water containing 0.1 % 
trifluoroacetic acid at a flow rate of 1.5 mL/min over 35 minutes (5 to 20 minutes are 
shown) using an analytical Vydac C18 column (Vydac 218TP104). (A) Analytical HPLC 
trace in MeCN of crude peptide CJL-1-116 after a three hour cleavage which shows only 
one major peak. A major impurity peak (mass of 685.4) is masked in this chromatogram. 
(B) Analytical HPLC trace in MeOH of crude peptide CJL-1-116 after a three hour 
cleavage which identifies both the desired product and an impurity peak masked in MeCN 
chromatogram. (C) Co-injection of crude CJL-1-116 from three hour cleavage with 
purified CJL-1-14 (mass of 685.4) increases the intensity of the impurity peak 
demonstrating similar retention times. (D) A shorter cleavage time of 1.5 hours diminishes 
degradation product giving better crude peptide purity. This figure has been adapted with 
permission from Lensing, C.J. et al, J. Med. Chem. 2016, 59, 3112-3128.25 Copyright 
(2016) American Chemical Society. 
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Figure 3.3. Illustrations of the competitive binding experiments at the mMC1R, mMC3R, and mMC4R. Top figures shows the His-
DPhe-Arg-Trp-based ligands. The bottom figures show the His-DNal(2’)-Arg-Trp-based ligands.This figure has been adapted with 
permission from Lensing, C.J. et al, J. Med. Chem. 2016, 59, 3112-3128.25 Copyright (2016) American Chemical Society.
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Figure 3.4. Proposed binding mode of the bivalent ligands. (A) First pharmacophore 
engages GPCR dimer or two neighboring binding sites. (B) The first binding event tethers 
the second pharmacophore in close proximity to the second binding site significantly 
increasing the likelihood of the second binding event. (C) The second pharmacophore 
binds with low entropic cost. This figure has been reproduced with permission from 
Lensing, C.J. et al, J. Med. Chem. 2016, 59, 3112-3128.25 Copyright (2016) American 
Chemical Society. 
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Figure 3.5. Postulated rationale for linker-dependent preferences at the different 
melanocortin homodimer subtypes. The different linker systems had varying effects on 
enhancing binding or functional responses depending on which receptor subtype was 
expressed. Since the linkers connect the same pharmacophore, it appears the difference are 
due to the linkers’ physicochemical properties such as linker length. These differences 
suggest that there are differences between the various subtypes of melanocortin receptor 
dimers such as the distance between tandem binding sites (see text). The figure 
demonstrates how different distances between tandem binding sites would show preference 
for the different length linker systems. This figure has been reproduced with permission 
from Lensing, C.J. et al, J. Med. Chem. 2016, 59, 3112-3128.25 Copyright (2016) American 
Chemical Society. 
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Figure 3.6. Illustrations of the in vitro functional pharmacology at the mMC1R, mMC3R, mMC4R, and mMC5R of the His-DPhe-Arg-
Trp based ligands. Top figures show the bivalent ligands compared to the control peptide CJL-1-14. The bottom figures show the effects 
of the linkers plus pharmacophore compared to control peptide CJL-1-14. This figure has been adapted with permission from Lensing, 
C.J. et al, J. Med. Chem. 2016, 59, 3112-3128.25 Copyright (2016) American Chemical Society. 
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Figure 3.7. Illustrations of the in vitro functional agonist pharmacology at the mMC1R, mMC3R, mMC4R, and mMC5R of the His-
DNal(2’)-Arg-Trp based ligands. This figure has been adapted with permission from Lensing, C.J. et al, J. Med. Chem. 2016, 59, 3112-
3128.25 Copyright (2016) American Chemical Society.
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Figure 3.8. Correlation of IC50 (nM) vs EC50 (nM) at the different receptor subtypes for 
His-DPhe-Arg-Trp based ligands. The mMC4R had a relatively linear correlation between 
receptor activation and ligand binding. At the mMC1R there appears to be relatively little 
correlation. The lack of correlation stresses the importance of studying ligands’ binding 
affinity and functional effects in complementary assays.  Data is shown as mean ± SEM. 
This figure has been reproduced with permission from Lensing, C.J. et al, J. Med. Chem. 
2016, 59, 3112-3128.25 Copyright (2016) American Chemical Society. 
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Figure 3.9. AlphaScreen functional Schild analysis at the mMC3R and mMC4R of both 
our synthetically made (CJL-1-20) and the commercially bought analog (Peptides Int) of 
the Ac-His-DPhe(pI)-Arg-Trp-NH2. The pharmacology matches for both CJL-1-20 and 
the Peptides International bought version confirming the pharmacology discrepancies 
were not a result of improper synthesis. All structural analysis performed also confirmed 
the proper structure. Data is shown as mean ± SEM calculated from two independent 
experiments.  
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Figure 3.10. Cumulative food intake following intracerebroventricular administration of 
either saline (n=16 male; 8 female) or CJL-1-87 in saline (n=8 male; 4 female) in wild 
type mice. (A) Male dose response of food intake in first 8 hours as appear in primary 
manuscript (appears here for comparison.) (B) Female dose response of food intake in first 
8 hours. Data is not significant. (C)  Male dose response of food intake between 24-72 
hours. Data is not significant. (D) Female dose response of food intake between 24-72 
hours. The 24 hr time point is significant (p<0.05). Data is shown as mean ± SEM. Data 
was analyzed using the PRISM program (v4.0; GraphPad Inc.) by a one-way ANOVA 
followed by a Bonferroni post test in order to compare individual doses to saline 
administration. *p<0.05, ** p<0.01. This figure has been adapted with permission from 
Lensing, C.J. et al, J. Med. Chem. 2016, 59, 3112-3128.25 Copyright (2016) American 
Chemical Society.
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  HPLC k' HPLC k' Mass Mass Purity 
Comp. Structure (Syst. 1) (Syst. 2) (calcd.) (obs.) % 
CJL-1-14 Ac-His-DPhe-Arg-Trp-NH2 3.2 5.5 685.34 685.39 >99% 
CJL-5-35-4 Ac-His-DPhe-Arg-Trp-(PEDG20)-NH2 4.6 8.3 1003.52 1003.70 >95% 
CJL-1-116 (PEDG20)-His-DPhe-Arg-Trp-NH2 4.0 6.4 961.51 961.57 >96% 
CJL-5-35-1 Ac-His-DPhe-Arg-Trp-(Pro-Gly)6-NH2 4.3 8.5 1609.79 1610.00 >97% 
CJL-1-41 (Pro-Gly)6-His-DPhe-Arg-Trp-NH2 3.6 6.2 1567.78 1568.28 >95% 
CJL-1-31 Ac-His-DPhe-Arg-Trp-(Pro-Gly)6-His-DPhe-Arg-Trp-NH2 4.9 7.4 2237.10 2237.18 >99% 
CJL-1-87 Ac-His-DPhe-Arg-Trp-(PEDG20)-His-DPhe-Arg-Trp-NH2 4.0 7.9 1629.83 1629.80 >99% 
CJL-5-72 Ac-His-DPhe-Arg-Trp-(PEDG20)-(PEDG20)-His-DPhe-Arg-Trp-NH2 5.2 9.5 1949.01 1949.00 >95% 
CJL-1-80 Ac-His-DNal(2')-Arg-Trp-NH2 4.3 7.5 735.36 735.30 >98% 
CJL-5-35-5 Ac-His-DNal(2')-Arg-Trp-(PEDG20)-NH2 4.7 8.6 1053.54 1053.70 >95% 
CJL-1-132 (PEDG20)-His-DNal(2')-Arg-Trp-NH2 5.2 8.3 1011.53 1011.59 >98% 
CJL-1-140 Ac-His-DNal(2’)-Arg-Trp-(PEDG20)-His-DNal(2')-Arg-Trp-NH2 6.4 10.9 1729.86 1730.03 >95% 
CJL-1-20 Ac-His-DPhe(p-I)-Arg-Trp-NH2 3.4 6.1 811.2 811.4 >99% 
CJL-5-35-6 Ac-His-DPhe(p-I)-Arg-Trp-(PEDG20)-NH2 4.7 8.7 1129.4 1129.6 >96% 
CJL-5-009 (PEDG20)-His-DPhe(p-I)-Arg-Trp-NH2 4.5 8.0 1087.4 1087.3 >98% 
CJL-5-64 Ac-His-DPhe(p-I)-Arg-Trp-(PEDG20)-His-DPhe(p-I)-Arg-Trp-NH2 6.0 10.5 1881.6 1881.6 >97% 
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Table 3.1. Analytical data for peptides synthesized in this Chapter 3. HPLC k' = (peptide 
retention time - solvent retention time) / solvent retention time. System 1 is a 10% to 90% 
gradient of acetonitrile in water containing 0.1% trifluoroacetic acid over 35 minutes at a 
flow rate of 1.5 mL/min, and system 2 is the same gradient with methanol replacing 
acetonitrile. Product purity was determined by integrating the area under the curves of the 
chromatograms collected at 214 nm. The solvent system that resulted in the lowest purity 
was used for the purity % in the table above. Mass observed was calculated from the M+1 
or (M+2)/2 peak. This table has been adapted with permission from Lensing, C.J. et al, J. 
Med. Chem. 2016, 59, 3112-3128.25 Copyright (2016) American Chemical Society.
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mMC1R mMC3R mMC4R Selectivity  
IC50 (nM) IC50 (nM) IC50 (nM) Ratios 
Compound 
Number 
Mean ± 
SEM 
n Fold 
Diff
 
Mean ± SEM n Fold 
Diff.
 
Mean ±  
SEM 
n Fold 
Diff
 
1R:3R:4R 
NDP-MSH 0.31±0.08 6 
 
4.18±0.61 14 
 
1.09±0.12 19 
 
1:13:4 
CJL-1-14 388±52 2 1 60% @100 µM 2 1a 214±55 6 1 1:374:1 
CJL-5-35-4 178±4 2 2 13400±5100 2 6 83±14 4 3 2:162:1 
CJL-1-116 705±6 2 0.6 78% @100 µM 3 ND 292±67 4 0.7 2:ND:1 
CJL-5-35-1 225±63 2 2 85% @100 µM 2 ND 841±290 2 0.3 1:ND:4 
CJL-1-41 1090±110 3 0.4 8430±230 2 9 258±27 2 0.8 4:33:1 
CJL-1-31 27.5±2.2 2 14 3250±760 2 25 33±5.1 3 6 1:119:1 
CJL-1-87 68.6±5.3 3 6 3470±510 2 23 9.9±2.9 4 22 7:351:1 
CJL-5-72 131±18 2 3 10200±1300 2 8 54±10 2 4 2:190:1 
CJL-1-80 1630±120 2 1 1430±190 2 1 26.0±3.4 2 1 63:55:1 
CJL-5-35-5 997±190 2 2 1310±120 2 1 10.7±0.6 2 2 94:123:1 
CJL-1-132 1870±220 4 1 999±290 2 1 21.8±1.9 3 1 85:46:1 
CJL-1-140 430±40 3 4 350±80 5 4 10.4±0.03 2 2 41:34:1 
CJL-1-20 190±10 2 1 780±90 2 1 6.0±1.2 2 1 31:130:1 
CJL-5-35-6 130±10 2 1 550±10 2 1 2.7±0.4 2 2 48:203:1 
CJL-5-009 460±170 3 0.4 230±70 2 3 13.5±5.0 3 0.4 34:17:1 
CJL-5-64 NS   NS   NS    
Table 3.2. Summary of competitive binding experiments for compounds evaluated at the 
mouse melanocortin receptors. The experimental compounds were used to displace 125I-
NDP-MSH in a dose-response manner to calculate the IC50 values. % represent the amount 
of 125I-NDP-MSH signal reduction at 100 µM. The “n” column represents the number of 
independent experiments performed. The reported errors are the standard error of the mean 
(SEM). ND means not determined. a Fold difference for mMC3R was calculated based on 
an estimated IC50 of 80,000 nM for CJL-1-14.  Compound CJL-5-64 was not soluble (NS) 
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in bioassay solvents. This table has been adapted with permission from Lensing, C.J. et al, 
J. Med. Chem. 2016, 59, 3112-3128.25 Copyright (2016) American Chemical Society. 
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mMC1R mMC3R mMC4R mMC5R Selectivity 
Compound Agonist EC50 (nM) Agonist EC50 (nM) Agonist EC50 (nM) Agonist EC50 (nM) Ratios  
Mean±SEM Fold 
Diff. 
Mean±SEM Fold 
Diff. 
Mean±SEM Fold 
Diff. 
Mean±SEM Fold 
Diff. 
1R:3R:4R:5R 
NDP-MSH 0.03±0.01a 
 
0.24±0.01a 
 
0.46±0.04a 
 
0.31±0.03a 
 
1:9:18:12 
α-MSH 0.15±0.05 
 
0.76±0.05 
 
4.0±0.9 
 
0.59±0.03 
 
1:5:28:4 
ɣ-MSH 1090±300 
 
34.6±4.0 
 
869±66 
 
35.1±18.7 
 
31:1:25:1 
CJL-1-14 14.1±2.6a 1 55.5±12.2a 1 13.7±1.9a 1 9.8±2.7a 1 1:4:1:1 
CJL-5-35-4 26.2±9.9 0.5 47.4±12.7 1 5.7±2.9 2 2.1±0.3 5 13:23:3:1 
CJL-1-116 24.9±5.9a 0.6 30.9±7.5a 2 18.5±2.9a 0.7 3.9±1.3a 2 6:8:5:1 
CJL-5-35-1 5.7±.7 2 107±66 0.5 74.1±14.1 0.2 52.4±10.3 0.2 1:19:13:9 
CJL-1-41 16.4±4.7a 0.9 27.2±5.2a 2 14.5±2.7a 0.9 4.9±1.2a 2 3:6:3:1 
CJL-1-31 4.4±0.6a 3 20.2±4.0a 3 9.2±1.0a 1 3.8±0.9a 2 1:5:2:1 
CJL-1-87 6.4±1.5a 2 10.1±2.5a 5 3.6±0.5a 4 3.1±0.6a 3 1:3:1:1 
CJL-5-72 12.6±3.8 1 22.7±3.7 2 7.3±2.1 2 4.0±0.2 2 3:6:2:1 
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Table 3.3 Summary of functional experiments for His-DPhe-Arg-Trp-based compounds 
evaluated at the mouse melanocortin receptors. AlphaScreen® assays were performed to 
determine relative potency of compounds to induce cAMP signaling. The reported errors 
are the standard error of the mean (SEM) determined from at least three independent 
experiments. Changes less than 3-fold were considered to be within the inherent 
experimental assay error. a denotes six or more independent experiments. This table has 
been adapted with permission from Lensing, C.J. et al, J. Med. Chem. 2016, 59, 3112-
3128.25 Copyright (2016) American Chemical Society.
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mMC1R mMC3R mMC4R mMC5R  
Agonist EC50  
(nM) 
Agonist EC50  
(nM) 
Antagonist 
(pA₂) 
Agonist EC50  
(nM) 
Antagonist 
(pA₂) 
Agonist EC50 
(nM) 
Compound Mean±SEM Fold 
Diff. 
Mean±SEM Mean±SEM Mean±SEM Mean±SEM Mean±SEM 
CJL-1-80 98.4±32.2a 1 45% at 100 µM 6.04±0.09 40% at 100 µM 8.09±0.04 75% at 100 µM 
CJL-5-35-5 112±19 0.9 40% at 100 µMa 6.14±0.06 20% at 100 µMa 8.39±0.08 PA, 70% at 100 µM 
CJL-1-132 139±17a 0.7 PA, 50% at 100 µMa 6.07±0.18 40% at 100 µMa 7.97±0.29 PA, 65% at 100 µMa 
CJL-1-140 563±142a 0.2 80% at 100 µMa 6.08±0.11 85% at 100 µMa 7.68±0.37 786±185a 
CJL-1-20 12±2 1 55% at 100 µMa 6.79±0.08 50% at 100 µM 8.57±0.08 2.75±1.15 
CJL-5-35-6 9.5±1.7 1 PA, 60% at 100 µM 7.30±0.07 PA, 45% at 100 µM 8.67±0.05 28±12 
CJL-5-009 30±6 0.4 PA, 60% at 100 µM 7.01±0.22 PA, 45% at 100 µM 8.49±0.24 4.5±1.6 
CJL-5-64 NS  NS NS NS NS NS 
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Table 3.4 Summary of functional experiments for His-DNal(2')-Arg-Trp and the His-
DPhe(p-I)-Arg-Trp based compounds evaluated at the mouse melanocortin receptors. 
AlphaScreen® assays were performed to determine relative potency of compounds to 
induce cAMP signaling. The reported errors are the standard error of the mean (SEM) of 
at least three independent experiments. Antagonist activity was evaluated at only the 
mMC3R and mMC4R with all compounds based on the His-DNal(2')-Arg-Trp and the His-
DPhe(p-I)-Arg-Trp pharmacophores. The pA₂ values were calculated by a Schild analysis 
in which NDP-MSH was in a standard dose response (10-12 to 10-6) and three doses of 
antagonist were used to shift the agonist dose response. PA indicates partial agonist activity 
was observed. Percentage (%) indicate the amount of activity relative to maximal NDP-
MSH response was observed at 100 µM. a denotes six or more independent experiments. 
A bar graph representation of the partial functional responses and the associated error can 
be seen in the supplemental information. Compound CJL-5-64 was not soluble (NS) in 
bioassay solvents. This table has been adapted with permission from Lensing, C.J. et al, J. 
Med. Chem. 2016, 59, 3112-3128.25 Copyright (2016) American Chemical Society.  
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Group 1 Group 2  
Day 1 Saline CJL-1-87 (5 nmol) 
Day 2 CJL-1-87 (5 nmol) Saline 
Day 3 Saline CJL-1-87 (2.5 nmol) 
Day 4 CJL-1-87 (2.5 nmol) Saline 
Table 3.5 Latin-square (Cross-over) paradigm used for in vivo feeding experiments in 
Chapter 3. All animals received both compound and saline in this order. The same animals 
were used throughout the experiment. There was at a least 6 day washout period between 
injections. This table has been adapted with permission from Lensing, C.J. et al, J. Med. 
Chem. 2016, 59, 3112-3128.25 Copyright (2016) American Chemical Society. 
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Chapter 4: A Direct In Vivo Comparison of The Melanocortin Monovalent Agonist 
Ac-His-DPhe-Arg-Trp-NH2 versus The Bivalent Agonist Ac-His-DPhe-Arg-Trp-
PEDG20-His-DPhe-Arg-Trp-NH2: A Bivalent Advantage 
Portions of the studies presented in this chapter have previously been published and 
are currently being reproduced with permission from: Lensing, C. J.; Adank, D. N.; Wilber, 
S. L.; Freeman, K. T.; Schnell, S. M.; Speth, R. C.; Zarth, A. T.; Haskell-Luevano, C. A 
Direct In Vivo Comparison of The Melanocortin Monovalent Agonist Ac-His-DPhe-Arg-
Trp-NH2 versus The Bivalent Agonist Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-Arg-
Trp-NH2: A Bivalent Advantage. ACS Chem. Neurosci. 2017.132 Copyright (2017) 
American Chemical Society. All animal studies were performed by Cody Lensing, Danielle 
Adank, and Stacey Wilber. Competitive binding assays were performed by Cody Lensing, 
Katie Freeman, and Sathya Schnell. BRET assays were performed by Katie Freeman with 
Cody Lensing contributing to the design of the experiments. AlphaScreen assays were 
performed by Cody Lensing. Radiolabeled compounds were prepared by Robert Speth. All 
experimental compounds were synthesized and prepared by Cody Lensing. Serum stability 
studies were performed by Cody Lensing and Adam Zarth. 
4.1 Chapter Overview:  
As discussed in Chapter 1 and Chapter 3,1, 25 bivalent ligands targeting putative 
melanocortin receptor dimers have been developed and characterized in vitro, however 
studies of their functional in vivo effects have been limited. This chapter compares the 
effects of homobivalent ligand CJL-1-87, Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-
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Arg-Trp-NH2, to monovalent ligand CJL-1-14, Ac-His-DPhe-Arg-Trp-NH2 on energy 
homeostasis in mice after administration into the lateral ventricle of the brain, based on the 
initial in vivo results presented in Chapter 3. Bivalent ligand CJL-1-87 had noteworthy 
advantages as an anti-obesity probe over CJL-1-14 in a fasting-refeeding in vivo paradigm. 
Treatment with CJL-1-87 significantly decreased food intake compared to CJL-1-14 or 
saline (50% less intake 2 to 8 hours after treatment). Furthermore, CJL-1-87 treatment 
decreased the respiratory exchange ratio (RER) without changing the energy expenditure 
indicating that fats were being burned as the primary fuel source. Additionally, CJL-1-87 
treatment significantly lowered body fat mass percentage 6 hours after administration (p < 
0.05) without changing the lean mass percentage. The bivalent ligand significantly 
decreased insulin, C-peptide, leptin, GIP, and resistin plasma levels compared to levels 
after CJL-1-14 or saline treatments. Alternatively, ghrelin plasma levels were significantly 
increased. Serum stability of CJL-1-87 and CJL-1-14 (T1/2 = 6.0 h and 16.8 h, 
respectively) was sufficient to permit physiological effects.  
The differences in binding affinity of CJL-1-14 compared to CJL-1-87 are 
speculated as a possible mechanism for the bivalent ligand’s unique effects. We also 
provide in vitro evidence for the formation of a MC3R-MC4R heterodimer complex, for 
the first time to our knowledge, that may be an unexploited neuronal molecular target. 
Regardless of the exact mechanism, the advantageous ability of CJL-1-87 compared to 
CJL-1-14 to increase in vitro binding affinity, increase the duration of action in spite of 
decreased serum stability, decrease in vivo food intake, decrease mice’s body fat percent, 
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and differentially affect mouse hormone levels demonstrates the distinct characteristics 
achieved from the current melanocortin agonist bivalent design strategy. 
4.2 Introduction 
As discussed in Chapter 1,1 bivalent ligand design strategies have been utilized to 
develop novel ligands for various GPCR systems including the opioids,5-12 gonadotropin-
releasing hormone receptor,13, 14 adenosine,15 cannabinoid,16, 17 serotonin,18-20 dopamine,21, 
22 chemokine,10, 23 oxytocin,24 and melanocortin receptor systems.25-40 There has been 
increasing evidence that heterobivalent ligands featuring pharmacophores for two different 
receptors can be an efficacious targeting strategy for heterodimers and results in unique 
properties in vivo.10, 11, 46, 225 Reports of homobivalent ligands containing two 
pharmacophores for the same receptor have shown them to possess distinct characteristics 
in vitro compared to monovalent ligands. Reports of homobivalent ligands’ in vivo 
functions compared to their monovalent counterparts are sparser.24, 25, 132, 236, 237 Because 
bivalent ligands can have unique functional characteristics compared to monovalent 
ligands that are not easily assayed in vitro (i.e. alterations of receptor trafficking42-44 or 
tissue selectivity5, 10), it is important to establish their in vivo functional significance. This 
in vivo data can be used to guide future bivalent drug design strategies and identify 
molecular probes for in vivo mechanism of action hypothesis driven research. A recent 
report demonstrated that homobivalent ligands targeting the oxytocin receptor system 
exhibited 40- and 100-fold greater potency in zebrafish and mice, respectively, establishing 
that a homobivalent design strategy can have noteworthy advantages in vivo.24  
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There have been several reports of bivalent ligands targeting the melanocortin 
receptor system.25-40 Many of these studies focus on the development of bivalent ligands 
for their use as high affinity imaging tools or targeting agents for melanoma.28-40 Given 
that chemical probes for the five melanocortin receptor subtypes (MC1-5R) have been 
utilized to study several diseases and disorders including Alzheimer’s disease, 60-62 sexual 
function disorders, 51, 66 social disorders, 67, 68 cachexia, 69-73, 189 and obesity; 25, 56, 76 it is of 
interest to study the biological functions of bivalent ligands targeting these receptors. The 
limited reports of the in vitro functional effects of melanocortin homobivalent ligands have 
all shown increased functional potency (up to 16-fold).25, 26, 28 Although melanocortin 
bivalent ligands have been used in vivo as imaging tools;38-40 to our knowledge no other 
laboratories beside us have reported on the functional effects of melanocortin homobivalent 
ligands in vivo to date.25, 132 
As reported in Chapter 3, our melanocortin homobivalent ligands possessed 
increased binding affinity of 14- to 25-fold, and increased in vitro functional potency of 3- 
to 5-fold depending on the individual melanocortin receptor subtype compared to 
monovalent control counterparts.25 Specifically, compound CJL-1-87, Ac-His-DPhe-Arg-
Trp-PEDG20-His-DPhe-Arg-Trp-NH2, was the most potent bivalent ligand at the 
melanocortin 3 receptor (MC3R) and melanocortin 4 receptor (MC4R). This compound 
consists of two monovalent agonist His-DPhe-Arg-Trp tetrapeptide scaffolds connected 
through a 20-atom polyethylene diamine diglycolyic acid linker (PEDG20). It had an 
increased binding affinity of 23- and 22- fold, and an increased functional potency of 5- 
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and 4-fold compared to its monovalent counterpart CJL-1-14, Ac-His-DPhe-Arg-Trp-
NH2, at the MC3R and MC4R, respectively. As predicted, administering CJL-1-87 directly 
into the brain dose-dependently decreased food intake demonstrating its in vivo efficacy at 
the MC3R and/or MC4R (as seen in Chapter 3).25  
The MC3R and MC4R are centrally located and are implicated in the melanocortin 
system’s role in energy homeostasis.57, 76, 107 Agonist stimulation of the MC3R and MC4R 
decreases food intake and increases energy expenditure. Therefore, agonist ligands may be 
potential therapeutics for the treatment of obesity.57, 76, 107, 112 It is hypothesized that the 
distinct pharmacological profile of agonist homobivalent ligand CJL-1-87 may be 
advantageous in vivo compared to monovalent agonist ligands by enhancing desirable 
effects such as decreasing food intake and weight loss while hopefully minimizing 
undesirable side effects. However, given the lack of studies directly comparing the effects 
of melanocortin monovalent and bivalent ligands in vivo; exploratory in vivo studies are 
necessary to characterize the physiological profile of homobivalent ligands, assess their 
side effect profiles, and guide future design and in vitro SAR studies. Direct comparison 
of bivalent ligand CJL-1-87 to monovalent ligand CJL-1-14 may provide insight into the 
advantages and disadvantages of a melanocortin bivalent ligand design strategy in the 
development of anti-obesity therapeutics. These studies may also help further elucidate the 
complex melanocortin pharmacology within the brain and particularly the role of the MC3-
MC4 receptor homo- and heterodimerization. Furthermore, understanding the in vivo 
pharmacology of homobivalent ligands is of utmost importance when attempting to 
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decipher the effects of more complex bivalent ligands such as the MUmBLs presented in 
Chapter 5.  
Previously published literature pertinent to comparing CJL-1-87 to its monovalent 
counterpart was inconclusive as to whether there is any significant advantages or 
disadvantages of the bivalent ligand CJL-1-87 over the monovalent ligand CJL-1-14 in 
vivo. 25, 76 Thus it is necessary to perform direct head to head comparison studies in different 
experimental paradigms to draw definitive conclusions.25, 76 In the current chapter, 
evidence is provided that the melanocortin bivalent agonist ligand CJL-1-87 possesses 
distinct advantages in a mouse fasting-refeeding paradigm compared to its monovalent 
counterpart CJL-1-14 including: decreased in vivo food intake, reduced in vivo body fat 
percentage, and differentially effected mouse hormone levels. These data have led us to 
postulate two possible mechanisms to explain the differences in the in vivo pharmacology 
between CJL-1-14 and CJL-1-87. The first possible mechanism is that CJL-1-87 can 
compete more effectively with endogenous antagonist agouti-related peptide (AGRP) in 
the fasting state due to its increased binding affinity compared to CJL-1-14. The other 
possible mechanism is that CJL-1-87 is targeting melanocortin dimers. To test this 
hypothesis, bioluminescence resonance energy transfer (BRET) studies were performed 
and support MC3R-MC4R heterodimer formation in vitro. This heterodimer may be a 
novel neuronal target for treating metabolic disorders, but its physiological relevancy 
remains to be determined. Although the exact molecular mechanism accounting for the 
differences observed in vivo remains unclear, the studies presented in the current chapter 
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provide direct evidence that the ICV administration of bivalent ligand CJL-1-87 and 
monovalent control CJL-1-14 result in different effects on energy homeostasis in mice in 
the fasting-refeeding experimental paradigm.  
4.3 Results and Discussion: 
4.3.1 In Vitro Mouse Serum Stability Assays 
In order to assess the metabolic stability of the peptides, in vitro mouse serum 
stability assays were performed as described in Chapter 2 (Figure 4.1). As reported 
previously, α-MSH was rapidly degraded with less than 1% intact peptide remaining 
following a 6 h incubation (Figure 4.1).74, 94, 238 It had a half-life of 0.9 h which is 
comparable with previous literature reports in rat serum.74 Compound CJL-1-14, Ac-His-
DPhe-Arg-Trp-NH2, was the most stable peptide in mouse serum and had a half-life of 
16.8 h. After incubation in mouse serum for 72 hours 12% of the Ac-His-DPhe-Arg-Trp-
NH2 peptide remained intact. The next most stable peptides were the linker control peptides 
CJL-5-35-4 and CJL-1-116 that have a PEDG20 linker added to the N-terminus or C-
terminus to Ac-His-DPhe-Arg-Trp-NH2. They possessed half-lives of 12.5 h and 10.6 h, 
respectively. This supports the hypothesis that the PEDG20 linker is not rapidly degraded 
in mouse serum. The PEDG20-based bivalent ligand CJL-1-87 had similar stability to 
NDP-MSH, the enzymatically stable analog of α-MSH.94, 238 Compound CJL-1-87 and 
NDP-MSH had half-lives of 6.0 and 5.1 h, respectively. Considering NDP-MSH is 
currently approved for clinical use in the European Union,117 the similar half-lives of CJL-
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1-87 and NDP-MSH suggest that CJL-1-87 would have a reasonable metabolic stability 
for in vivo applications. 
The current results demonstrate that the bivalent ligand CJL-1-87 is metabolized 
faster by the serum proteases present in the mouse serum than its monovalent counterpart 
CJL-1-14. This implies that the bivalent ligand CJL-1-87 would be at a disadvantage to 
the monovalent ligand CJL-1-14 if in vivo metabolic stability is desired. In order to 
interpret the data completely, it must be noted that it would be necessary to metabolically 
inactivate both pharmacophores of CJL-1-87 before it was rendered completely 
pharmacologically inactive. For example, if the N-terminal His-DPhe-Arg-Trp was 
cleaved by serum proteases, the C-terminal His-DPhe-Arg-Trp would retain activity at the 
melanocortin receptors similar to that of CJL-1-116 (cAMP signaling EC50 = 31 nM and 
19 nM at the mMC3R and mMC4R, respectively) until the C-terminal His-DPhe-Arg-Trp 
was metabolized.25 In the current thesis, only the loss of fully intact peptide was monitored 
to give an indication of metabolic stability. Further studies into the rate of functional 
inactivation of the peptides will be necessary to determine how fast pharmacological 
activity is lost, but is outside the scope of the current study. 
The previously reported bivalent ligands that were synthesized using a (Pro-Gly)6 
linker were included in the current study for comparison of the linker design for future in 
vivo applications.25 The linker control ligands with the tetrapeptide and the (Pro-Gly)6, 
CJL-5-35-1 and CJL-1-41, and the bivalent ligand CJL-1-31 were rapidly degraded 
(Figure 4.1). There was ≤ 2% intact peptide of CJL-1-41, CJL-1-31, and CJL-5-35-1 
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remaining after 0.5 h (Figure 4.1). It is unclear currently whether the loss of intact peptide 
results in loss of functional melanocortin activity or if the linker is merely being degraded 
rapidly while the active His-DPhe-Arg-Trp pharmacophore remains intact. Nevertheless, 
the current results validate the previous hypothesis that although a Pro-Gly based linker 
may be useful for determining in vitro pharmacology,25 its use is limited for in vivo 
applications to study bivalent design strategies unless rapid degradation is desired. It should 
also be noted that if a Pro-Gly linker system is used for in vitro applications in any bivalent 
design strategy for any receptor system, the supplementation of assay buffer with serums 
[i.e. fetal bovine serum (FBS), newborn calf serum (NCS)] may result in rapid degradation 
of the linker system. 
Beyond the useful data obtained about the bivalent design strategy and metabolic 
stability, the current data demonstrates for the first time that the Ac-His-DPhe-Arg-Trp-
NH2 is more stable in mouse serum than NDP-MSH (Figure 4.1). This suggests that Ac-
His-DPhe-Arg-Trp-NH2 is less susceptible to common proteases found in mouse serum 
and supports further research into the tetrapeptide scaffold.  
4.3.2 The Effect of ICV Administration of CJL-1-14 versus CJL-1-87 on Mouse 
Energy Homeostasis 
A direct head to head in vivo crossover experimental paradigm (Figure 2.3A) was 
designed to compare 5 nmol monovalent CJL-1-14 to 5 nmol bivalent CJL-1-87 utilizing 
the TSE Phenotypic metabolic cages configured to measure food intake, water intake, 
changes in CO2 and O2, and beam break activity. In a nocturnal satiated paradigm in which 
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compound was administered ICV two hours before lights out and food is available ad 
libitum, no significant differences were observed in food intake, water intake, energy 
expenditure, respiratory exchange ratio (RER) values, or activity between CJL-1-14 and 
CJL-1-87 (Figure 4.2). The observation of approximately equal food intake in this 
paradigm was consistent with the previous reports of food intake after CJL-1-14 and CJL-
1-87 treatment in the literature, and no further experiments utilizing this experimental 
paradigm were performed.25, 76 However, significant differences between bivalent ligand 
CJL-1-87 and monovalent ligand CJL-1-14 were observed on food intake and RER values 
when utilizing a fasting-refeeding paradigm (Figure 4.3).  
In the fasting-refeeding paradigm, food was removed from mice immediately 
before the lights out cycle on the previous day. Treatment occurred two hours prior to lights 
out and food was reintroduced (Figure 2.3B). Due to the fast, a hyperphagic response 
occurs during refeeding and this robust response can aid in the detection of effects. 
However, fasting can also mask subtle effects due to the strong desire to eat.218 During 
fasting many hormone levels change to promote feeding. Of important relevance to the 
melanocortin system, the endogenous MC3R/MC4R antagonist agouti-related peptide 
(AGRP) is upregulated in the hypothalamic regions that are also innervated by 
proopiomelanocortin (POMC) neurons.113, 239-241 AGRP blocks the agonism of endogenous 
melanocortin agonist peptides (e.g. α-MSH, β-MSH, γ-MSH, ACTH) and is also known to 
function as an inverse agonist at the MC4R to increase feeding and lower energy 
expenditure.76, 113, 242 In addition, fasting upregulates several other hormones including 
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ghrelin, corticosterone, and neuropeptide Y (NPY) while several hormones are also 
downregulated including insulin, leptin, and resistin (for a review see Jensen, 2013.243) 
These changes in hormonal expression levels are hypothesized to drive the hyperphagic 
response. Although the maximal signal and, therefore, signal to noise is increased in a 
fasting-refeeding paradigm compared to a nocturnal feeding paradigm due to the increased 
baseline or control food intake, achieving a measurable decrease in food intake can 
sometimes be challenging. This is because the experimental compounds need to overcome 
these robust hormone changes to have observable activity.  
 In the current fasting-refeeding experiments, food intake after 5 nmol CJL-1-87 
compared to saline administration was significantly reduced between 2 to 16 hours after 
ICV administration as expected for a melanocortin receptor agonist (Figure 4.3B). 
Approximately 50% less food was consumed compared to saline and 5 nmol CJL-1-14 at 
the 2-8 hour time points. Notably, there was no significant difference in food intake after 
fasting between CJL-1-14 and saline groups. Compared to CJL-1-14 food intake after 
CJL-1-87 treatment was significantly reduced at every time point from 2 to 24 hours after 
compound administration (Figure 4.3B). It is worth noting that the current experiments 
were performed in a crossover design paradigm, such that all 11 age matched male mice 
included in the study were administered saline, 5 nmol CJL-1-14 and 5 nmol CJL-1-87 
on different days with a washout period of one week in between administrations and no 
mice were excluded. 
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The RER was determined by dividing the volume of CO2 produced by the volume 
of O2 consumed by an animal.189, 244, 245 Because the oxidation of carbohydrates or fatty 
acids produces different amounts of CO2 for each O2 molecule utilized, the RER indicates 
whether mice are using carbohydrates or fats as the primary fuel source. RER values of 
about 1.0 indicate that carbohydrates are the primary fuel source being utilized, whereas 
values of approximately 0.7 indicate that fats are primarily being utilized. 189, 244, 245 The 
RER in the current experiment was indirectly calculated by measuring the amount of CO2 
and O2 entering and exiting the sealed metabolic cages as previously described.132, 189, 244, 
245  
During the fast, RER values for all groups dropped to slightly above 0.7 indicating 
that fats are primarily being used as a source of energy (Figure 4.3C). This is expected due 
to the lack of carbohydrates available from food during the fast that results in a reliance of 
fat storage for energy, an effect previously described.246, 247 At the 0 h time point, the 
compound or saline is administered and food is reintroduced to the cage. A rapid increase 
in the RER is observed in the saline treatment group until the fuel source is primarily 
carbohydrates during the initial dark cycle as anticipated. Treatment with both CJL-1-87 
and CJL-1-14 resulted in a more gradual increase in RER (Figure 4.3C). Significant 
reduction of RER values was observed 2-9 and 11 hours after CJL-1-87 treatment 
compared to after saline treatment during the first dark cycle. Significant reduction in RER 
values were observed 5-9 and 11-15 hours after CJL-1-87 treatment compared to CJL-1-
14 treatment. The compound-specific reduction in RER suggests that the mice are using 
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more fats after CJL-1-87 administration compared to either saline or CJL-1-14. No 
significant differences in energy expenditure (kcal/kg/h) was observed between any 
treatment groups (Figure 4.3D). The energy expenditure taken together with the RER data 
indicates that the mice are burning approximately the same amount of calories upon 
different treatments, however the CJL-1-87 treated mice appear to be utilizing more fats 
for their energy in lieu of carbohydrates (Figure 4.3C-D). 
 During the following light cycle (t = 14-26 h), the RER decreased for all groups 
most likely due to decreased feeding and decreased activity that is expected with nocturnal 
feeders like mice. The RER increases again preceding and during the second dark cycle (t 
= 26-38 h). Although no clear trend was observed in food intake beyond 24 hours, the RER 
was still significantly lower after CJL-1-87 treatment compared to saline or CJL-1-14 at 
time points 27-34 h (Figure 4.3C). This second time period of significantly decreased RER 
in the absence of decreased food intake suggests that compound CJL-1-87 has long-lasting 
effects on energy homeostasis that do not appear to directly correlate to food intake. This 
is not observed with the monovalent ligand CJL-1-14.  
 The length of time that CJL-1-87 affected energy homeostasis was unexpected 
since the initial nocturnal paradigm studies presented in Chapter 3 showed no significant 
effects on food intake past 8 hours with this compound,25 and less than 3% of the CJL-1-
87 remained intact after 24 hours in the in vitro serum stability assays (Figure 4.1). 
However, the serum stability studies give only an indication of the metabolic stability of 
CJL-1-87 in the brain as the proteases present in the cerebrospinal fluid (CSF) may be 
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different than those in the serum. Another factor in the interpretation of the long lasting 
effects on RER of CJL-1-87 is the rate of clearance from the ventricular system of the 
brain into the peripheral. Although the rate of clearance is currently unknown for CJL-1-
87 and CJL-1-14, it has previously been reported that CSF empting time and compound 
clearance from the CSF is rapid after ICV administration. 248-250 These data suggest the 
long-lasting response was the result of a pharmacological effect due to receptor binding, 
and not due to the drug being present in the cerebrospinal fluid (CSF) for an extended 
period of time. It could be that once CJL-1-87 is bound to a receptor, it avoids degradation 
and clearance from the brain while promoting long lasting effects, or that the binding of 
CJL-1-87 to melanocortin receptors may cause unique downstream signaling cascades not 
observed with its monovalent counterpart. Either way, the increased duration of action on 
RER with increased utilization of fat stores for energy is a distinct characteristic of the 
bivalent ligand that is not observed with the monovalent ligand. Further studies into the 
CSF clearance rate of CJL-1-87 and CJL-1-14 as well as studies thoroughly characterizing 
the absorption, distribution, metabolism, and excretion of these ligands will be necessary 
to draw clear conclusions about the long-lasting (>24 h) effects. 
 Whenever an experiment’s measurements are based on loss of function, it can raise 
questions about assay artifacts. In this particular assay paradigm, it may be questioned 
whether the reduction in food intake and RER are a consequence of an adverse reaction or 
toxicity to CJL-1-87. In order to address this concern, mice were monitored visually for at 
least 2 hours post treatment and no adverse reactions in any of the three treatment groups 
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were observed. Additionally, no significant effect was observed between saline, CJL-1-87 
or CJL-1-14 on locomotor activity (beam breaks), water intake (mL), or energy 
expenditure (kcal/h/kg) (Figure 4.3D-F). If sick-like behavior or toxicity were suspect for 
the observed decrease in food intake and RER, it would be expected that these other 
parameters would be lowered as well. In particular, locomotor activity, as quantified by 
infrared beam breaks along the side of the cages (X-axis), would be negatively affected 
because a sick mouse wound typically be hunched and inactive in the corner of the cage 
(Figure 4.3E). The lack of effect observed on activity between all treatment groups 
supports that visceral illness or other adverse reactions were not likely to be contributing 
factors to the significant effects observed.  
4.3.3 The Effect of ICV Administration of CJL-1-14 and CJL-1-87 on Body 
Composition 
To study the effect of CJL-1-87 and CJL-1-14 on body composition and 
metabolically active hormone levels in the blood plasma of mice, a new cohort of 32 male 
age matched mice (saline, n=10; CJL-1-14, n=11; CJL-1-87, n=11) underwent 
cannulation surgery and placement validation as previously discussed in Chapter 2. The 
animals were administered a single treatment of saline vehicle control, 5 nmol CJL-1-14, 
or 5 nmol CJL-1-87 and sacrificed 6 h post-treatment in the fasting-refeeding paradigm 
described above but in conventional cages (Figure 2.3B). Once again, CJL-1-87 treatment 
decreased food intake as compared to CJL-1-14 and saline (Figure 4.3B, Figure 4.4A). 
As expected the decreased food intake was accompanied by a significant reduction in the 
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amount of weight gained after the food was reintroduced with CJL-1-87 treatment 
compared to CJL-1-14 for the first 6 h post-treatment (Figure 4.4B). Mice treated with 
CJL-1-87 gained back 55% less weight than saline and CJL-1-14 treated mice 6 h post 
fast. The CJL-1-87 treated mice also gained significantly less weight than saline treated 
mice 4 and 6 h post-fast (Figure 4.4B).  
 The amount of lean mass and fat mass was measured pre-fast, immediately before 
compound administration, and 6 h post-administration just before sacrificing the animals 
using an EchoMRI-100H system. There were no significant differences between the saline, 
CJL-1-14, and CJL-1-87 treatment in their effect on body percentage of lean mass before 
the fast, at compound administration, or 6 h after compound administration (Figure 4.4C). 
There were no significant differences in body fat mass percentage before the fast, or 
immediately before treatment between saline, CJL-1-14, and CJL-1-87 as expected. The 
body fat percentage was significantly lower in mice that received CJL-1-87 treatment 
compared to saline treatment 6 h post-administration (Figure 4.4D). Mice treated with 
CJL-1-87 gained back 45% less fat mass 6 h after the fast compared to saline treated mice. 
Mice treated with CJL-1-14 gained back 15% less fat mass compared to saline treated 
mice, however there were no significant differences in body fat percentage between CJL-
1-14 compared to saline or CJL-1-87. The decreased body fat percentage after CJL-1-87 
treatment is consistent with the lowered RER values in the metabolic cage studies 
supporting the hypothesis that fat, and not carbohydrates, is the primary fuel source after 
CJL-1-87 treatment (Figure 4.3C).  
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4.3.4 The Effect of ICV Administration of CJL-1-14 and CJL-1-87 on Hormone 
Levels 
The same 32 mice from the body composition studies were sacrificed and trunk 
blood was collected 6 h post ICV treatment with saline, 5 nmol CJL-1-14, or 5 nmol CJL-
1-87. The plasma was analyzed using a multiplex Luminex Milliplex system to assess six 
hormones and one cytokine: insulin, C-peptide, leptin, ghrelin, glucose-dependent 
insulinotropic polypeptide (GIP), resistin, and interleukin 6 (IL-6) (Figure 4.4 E-K). Mice 
treated with CJL-1-87 had significantly lower levels of insulin, C-peptide, leptin, GIP and 
resistin compared to mice receiving either saline or CJL-1-14 (Figure 4.4E-H and K). 
Also CJL-1-87 treated mice had significantly lower levels of IL-6 compared to saline, but 
there was no significant difference between CJL-1-14 and CJL-1-87 treatment (Figure 
4.4J). Mice receiving CJL-1-87 had significantly increased ghrelin levels compared to 
mice receiving saline or CJL-1-14 (Figure 4.4I). Mice receiving CJL-1-14 had 
significantly reduced C-peptide, leptin, GIP, and IL-6 compared to mice receiving saline 
(Figure 4.4F-H and J). 
The differences in metabolic hormone levels observed between all three treatment 
groups demonstrate unique effects of the melanocortin bivalent agonist ligand design. The 
unique effects were evident in the significant differences in the levels of insulin, C-peptide, 
leptin, GIP, ghrelin, and resistin between CJL-1-14 treatment and CJL-1-87 treatment 
(Figure 4.4E-I and K). It should be noted that although the same molar amount of peptide 
(5 nmols) was administered, the bivalent ligand CJL-1-87 contains twice as many 
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pharmacophores. It could, therefore, be hypothesized that differences between CJL-1-14 
and CJL-1-87 on C-peptide, leptin, and GIP were due to a “dose-dependent” effect of the 
pharmacophores (Figure 4.4F, H, and I). However, this is an intricate argument, since a 
similar “dose-dependent” effect was not observed with insulin, ghrelin, IL-6, or resistin. 
Doubling of the pharmacophores could be a contributing factor, but the complexity of the 
in vivo pharmacology suggests that the effects are due to characteristics of CJL-1-87 that 
are distinct from CJL-1-14. The unique characteristics may originate from the bivalent 
design strategy, differences in receptor selectivity (e.g.MC3R vs MC4R as discussed in 
Chapter 3), different receptors being responsible for the different responses (e.g. hormone 
release vs food intake), or the different distribution of CJL-1-87 and CJL-1-14 after ICV 
delivery. Further experimentation will be necessary to determine the exact neuronal 
mechanism of action of the observed in vivo response differences. However, it is clear that 
in the current fasting-refeeding in vivo experimental paradigm that CJL-1-87 behaviors 
differently than its monovalent counterpart. Possible in vitro molecular mechanisms 
focused on how the bivalent ligand CJL-1-87 may be interacting with melanocortin dimers 
will be discussed below.  
 The effects of the melanocortin ligands on the hormone plasma levels are consistent 
with previous literature reports (Table 4.1). 251-263 For example, it has previously been 
reported that melanocortin agonists decreased insulin serum and plasma levels, regardless 
of food intake.251-253 This is consistent with the decreased insulin levels observed herein 
with CJL-1-87 treatment, albeit no effect was observed with CJL-1-14 treatment (Figure 
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4.4E). As would be anticipated, C-peptide was also decreased by melanocortin agonism 
(Figure 4.4F), because insulin and C-peptide are produced in equimolar amounts from the 
cleavage of proinsulin.254, 255 Similarly, decreased leptin levels in the serum or plasma have 
been reported following administration of melanocortin agonists as observed herein 
(Figure 4.4G).252, 253 There is also evidence that melanocortin agonist administration 
decreases GIP, similar to the current results (Figure 4.4H).256 At least two studies have 
reported that the melanocortin agonist MTII has no effect on resistin serum levels although 
one study found that resistin mRNA expression was upregulated after MTII treatment. 257, 
258 Also, the MC3R and MC4R antagonist SHU9119 was reported to increase resistin 
serum levels making interpretation of the data inconclusive.257, 258  The significant decrease 
in resistin levels after CJL-1-87 treatment appears to be a unique effect of the bivalent 
ligand compared to the monovalent ligand CJL-1-14 and the previous studies (Figure 
4.4K).257, 258  Previous studies reported melanocortin agonists decreasing IL-6 gene 
expression and secretion after administration in mice which is also consistent with the 
current results (Figure 4.4J).259-261 However, this effect is confounded by conflicting data 
indicating that α-MSH increases IL-6 expression.262 Although ghrelin is usually thought of 
as an upstream regulator of the melanocortin pathway, there is some evidence that α-MSH 
can directly affect the release of ghrelin (Figure 4.4I).263 It is therefore unclear if the 
current increase in ghrelin after CJL-1-87 treatment is a direct pharmacological effect or 
an effect of the decreased food intake.  
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Although the above literature provides evidence that some of the changes in 
hormone levels may be from activation of melanocortin receptors, it is possible that some 
of the changes in hormones are due to lowered refeeding of CJL-1-87 treated mice. During 
the fasting state prior to compound administration, the lack of food intake is likely to cause 
a decrease in the serum concentration of insulin, C-peptide, leptin, resistin, and GIP. 243, 
256, 264-266 Inversely, ghrelin is normally elevated during fasting and decreased after food 
intake (Table 4.1).243, 267 IL-6 is also thought to be increased during fasting.268 While it is 
possible that direct pharmacological agonism causes the changes in the plasma hormone 
levels after compound administration, the decrease in food intake resulting from CJL-1-
87 administration may slow the rate of change in hormones levels from the fasting state. 
However, such slowing cannot explain the significantly reduced plasma levels of C-
peptide, leptin, GIP and IL-6 observed with CJL-1-14 treated mice compared to saline 
treated mice that had the same food intake. This indicates that these hormone changes are 
a direct effect of agonizing the melanocortin receptors with CJL-1-14. The effects of CJL-
1-87 on hormone levels may be attributed to pharmacological agonism of the melanocortin 
receptors, decreased food intake, or some combination of both. Regardless, it appears that 
CJL-1-87 has physiological effects that significantly reduce food intake after fasting in 
spite of the increased levels of the orexigenic peptide ghrelin and the decreased levels of 
the anorexigenic peptides leptin and insulin.  
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4.3.5 125I-AGRP Competitive Binding Studies 
Although the bivalent ligand CJL-1-87 is advantageous in reducing food intake, 
body weight, and fat mass gained when utilizing a fasting-refeeding paradigm compared 
to CJL-1-14, the exact molecular mechanism is unclear. Two major hypotheses can be 
envisioned based on the bivalent design concept: 1) The c.a 20-fold increased binding 
affinity of CJL-1-87 compared CJL-1-14 discussed in Chapter 3 helps it compete more 
effectively with endogenous AGRP that is upregulated in the fasting state. 2) The bivalent 
ligands are interacting with melanocortin homodimers or heterodimers in a unique fashion 
that is different than the monovalent counterpart. In order to investigate how effectively 
CJL-1-87 can displace AGRP, competitive radioligand binding assays using 125I-
AGRP(87-132) were performed (Table 4.2). Results from Chapter 3 for CJL-1-14 and 
CJL-1-87 competition against 125I-NDP-MSH and results from antagonist monovalent 
tetrapeptide Ac-His-DNal(2')-Arg-Trp-NH2 and antagonist homobivalent ligand CJL-1-
140, Ac-His-DNal(2’)-Arg-Trp-(PEDG20)-His-DNal(2')-Arg-Trp-NH2, are provided for 
easier comparison (Table 4.2).25 
At the mMC4R, the IC50 values obtained by competing experimental ligands 
against 125I-AGRP(87-132) are within experimental error (less than 3-fold change) of those 
obtained by competing against 125I-NDP-MSH in Chapter 3.25 Bivalent ligand CJL-1-87 
had a 17-fold higher binding affinity when competing against 125I-AGRP(87-132) 
compared to its monovalent counterpart CJL-1-14 at the mMC4R. At the mMC3R, the 
experimental agonist ligands tended to be better at displacing 125I-AGRP(87-132) 
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compared to 125I-NDP-MSH. In fact, compound CJL-1-14 and CJL-1-87 had 
approximately a 10-fold shift in the IC50 values obtained when displacing 125I-AGRP(87-
132) compared to 125I-NDP-MSH at the mMC3R. Unlabeled NDP-MSH and antagonist 
ligand Ac-His-DNal(2’)-Arg-Trp-NH2 had less than 3-fold changes in IC50 values to 
compete 125I-NDP-MSH and 125I-AGRP(87-132). Homobivalent antagonist CJL-1-140 
had nearly a 3-fold shift in its IC50 value when competing against 125I-AGRP(87-132) 
compared to the value obtained when competing against 125I-NDP-MSH in Chapter 3. The 
homobivalent agonist ligand CJL-1-87 had an 18-fold higher binding affinity compared to 
its monovalent counterpart CJL-1-14 when both are competing against 125I-AGRP(87-
132) at the mMC3R (Table 4.2). This increase in binding affinity of the agonist ligands 
when competing against 125I-AGRP(87-132) compared to 125I-NDP-MSH at the mMC3R 
and not the mMC4R may implicate that the mMC3R has increased regulation in reducing 
refeeding from the fasting state. This observation is consistent with a previous report that 
MC3R knockout mice have lowered food intake after fasting compared to wild type 
mice.240  
During fasting, the expression of endogenous MC3R and MC4R antagonist/ inverse 
agonist AGRP is upregulated and promotes a state of hunger that drives refeeding. 113, 239-
241 This may allow melanocortin agonists to have two functional effects by both activating 
the melanocortin receptors, and functionally antagonizing AGRP’s orexigenic effects by 
blocking the endogenous AGRP from binding the melanocortin receptors. This dual action 
may be able to explain a mechanism of how bivalent ligand CJL-1-87 has more significant 
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effects in the fasting-refeeding paradigm than the monovalent ligand CJL-1-14, but not in 
the nocturnal paradigm. Although CJL-1-87 was previously reported in Chapter 3 to 
possess only about 3- to 5-fold increased agonist potency to stimulate cAMP signaling 
compared to CJL-1-14,25 the increased in vitro binding affinity of 17- to 18-fold may 
increase CJL-1-87’s ability to compete effectively with AGRP in vivo. In the nocturnal 
paradigm in which there would be lower amounts of AGRP present, the increase in binding 
affinity would be less of a driving force in decreasing feeding and, therefore, CJL-1-14 
and CJL-1-87 would have more similar in vivo effects based on the closer functional 
cAMP potencies.25, 76 However, in the fasting state there would be a higher concentration 
of AGRP and the ability of CJL-1-87 to compete with and antagonize AGRP’s orexigenic 
effects would become increasingly important. Monovalent ligand CJL-1-14 may not have 
a strong enough binding affinity to effectively compete with AGRP and antagonize its 
orexgenic effects, whereas CJL-1-87 with a 17- to 21-fold increased binding affinity at 
both the mMC3R and mMC4R would block the orexigenic effects of AGRP in vivo 
resulting in significantly decreased refeeding. 
It should be noted that although the hypothesized binding affinity mechanism may 
explain the current observation of bivalent ligand CJL-1-87’s advantages in the fasting 
paradigm over the monovalent ligand CJL-1-14, this proposed mechanism does not 
exclude the possibility that melanocortin receptor dimerization is also responsible. In fact, 
the increased binding affinity of CJL-1-87 is hypothesized to be a result of synergistic 
bivalent binding at melanocortin dimers.25 It is possible that the dimerization of 
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melanocortin receptors may play a functional role beyond synergistic bivalent binding in 
the pharmacology of CJL-1-87 which will be discussed further below. Regardless of the 
exact mechanism, it does appear that the bivalent design strategy is responsible either by 
synergistic binding, or by targeting melanocortin dimers for the ability of the bivalent 
ligand, and not the monovalent ligand, to decrease feeding in the fasting-refeeding 
paradigm. 
4.3.6 Bioluminescence Resonance Energy Transfer (BRET) Supports mMC3R-
mMC4R Heterodimerization 
The second hypothesis for the significant differences between CJL-1-14 and CJL-
1-87 in the fasting-refeeding paradigm could be the interaction of the compounds with 
melanocortin receptor dimers. Portoghese and coworkers have demonstrated that bivalent 
ligands can be designed to selectively target opioid heterodimers.5-11 It has previously been 
supported that the melanocortin receptors can form homodimers, heterodimers, or higher-
order oligomers utilizing various techniques to demonstrate proximity and association.125, 
127, 129-131, 204-209 Furthermore, it has recently been demonstrated that coexpression of the 
MC1R and MC5R can create ligand-dependent signal modulation providing evidence that 
melanocortin heterodimerization can have functional consequences.209 Considering that 
the bivalent ligands were designed to interact with melanocortin receptor dimers, it is 
possible that the unique in vivo effects of CJL-1-87 versus CJL-1-14 could be from 
bivalent binding specifically to homodimers or heterodimers. In order to explore whether 
these effects could be mediated through a MC3R-MC4R heterodimer, bioluminescence 
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resonance energy transfer (BRET) studies were undertaken to show association of the two 
receptors. Additionally, cAMP-based AlphaScreen experiments were performed on cells 
coexpressing both the mMC3R and mMC4R to begin elucidating the possible functional 
significance of a mMC3R-mMC4R heterodimer. 
  BRET is a biophysical technique that can be used to demonstrate the association 
of two proteins. It has previously been utilized to show that the mMC3R and mMC4R are 
in close proximity suggesting that they form homodimers or higher-order oligomers.130, 204, 
205 It has also been shown that the hMC1R closely associates with the hMC3R by BRET 
suggesting heterodimerization.204 To our knowledge, the MC3R and MC4R have never 
been studied by BRET for heterodimerization prior to this thesis work.132 In rats, mRNA 
of both the MC3R and MC4R have been detected in select regions of the brain such as the 
anteroventral periventricular (AVPV), ventral premammillary (PMV), and posterior 
hypothalamic nuclei suggesting possible in vivo coexpression.81, 211, 212 Also in vitro 
coexpression of the MC3R and MC4R in neuronal cells colocalize on the cell membrane 
suggesting heterodimerization is possible.211 This hypothesized heterodimer may explain 
some of the ambiguous pharmacology of the melanocortin system such as the mechanism 
of the synergistic effects observed in the MC3R-MC4R double knockout mice as discussed 
in the Chapter 1.1, 58, 210 Furthermore, due to the differential expression profile of the 
mMC3R and mMC4R, ligands that would target a mMC3R-mMC4R heterodimer could be 
developed to be tissue selective acting only in the distinct regions within the brain that 
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coexpress the receptors. Further studies will be needed to demonstrate whether individual 
neurons do in fact coexpress the MC3R and MC4R.  
 BRET studies were performed on HEK293 cells expressing only the mMC3R, only 
the mMC4R, or coexpressing the mMC3R and mMC4R (Figure 4.5). The Promega 
NanoBRET™ Protein:Protein interaction system was utilized with limited modifications 
to develop mMC3R and mMC4R fused to both the NanoLuc® fusion protein and the 
HaloTag® fusion protein. HEK293 cells expressing the mMC3R-NanoLuc® and the 
mMC3R-HaloTag® resulted in a BRET ratio of 90 ± 5 mBU, supporting mMC3R 
homodimerization. This data is similar to a previous result observed with a slightly 
different BRET system that showed a BRET ratio of 350 mBU with the hMC3R. The 
decrease in signal currently observed might be explained by differences in assay paradigms 
including using Cos-7 cells, the human receptors, or DeepBlueC substrate.204 HEK293 
cells expressing the mMC4R-NanoLuc® and the mMC4R-HaloTag® resulted in a high 
BRET ratio of 100 ± 10 mBU. This is in good agreement with previous results reported by 
two independent laboratories using different BRET conditions (e.g. using Cos-7 cells 
versus HEK293 cells) that reported BRET ratios of 75 mBU and 110 mBU with the 
hMC4R.130, 205 
  HEK293 cells that were transfected to coexpress mMC4R-NanoLuc® and the 
mMC3R-HaloTag® gave a high BRET ratio of 150 ± 10 mBU (Figure 4.5). As a negative 
control, a plate of cells was transiently transfected with the mMC4R-NanoLuc® and a 
separate plate was transfected with mMC3R-HaloTag®. These cells were mixed in equal 
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amounts and assayed together which resulted in minimal BRET signal (1.6 ± 0.5 mBU). 
This suggested that BRET signal was indeed from specific mMC3R-mMC4R interactions 
on the same cell membrane, and not from non-specific interactions of the receptors being 
assayed at the same time. As a further negative control, unrelated mouse double minute 2 
(MDM2)-NanoLuc® and the mMC3R-HaloTag® were coexpressed as well as mMC4R-
NanoLuc® and the p53-HaloTag® that resulted in minimal signal (7.7 ± 4.0 mBU and 3.4 
± 0.3 mBU, respectively). 
The increased signal from mMC4R-NanoLuc® and mMC3R-HaloTag® 
coexpression compared to singly expressed mMC3R or mMC4R suggests that the mMC3R 
and the mMC4R form heterodimers in addition to homodimers. The ratio of homodimers 
to heterodimers is yet to be determined. It also should be noted that the relative BRET 
signal could be affected by the expression levels of the transiently transfected receptors 
which was not quantified in this study. It is also possible that higher-order oligomers are 
responsible for the high BRET signal of both homodimers and heterodimers as it is possible 
that the receptors could form tetramers (or even higher-order oligomers) that are 
“heterodimers” of the homodimer species. This would cause strong BRET signal of both 
homo- and heterodimers as observed herein. 
4.3.7 Coexpression of mMC3R and mMC4R effects on Functional Potency 
Based upon the BRET data indicating mMC3R-mMC4R heterodimerization, 
cAMP AlphaScreen assays were performed on cells coexpressing both the mMC3R and 
mMC4R to elucidate any functional significance. In these experiments, HEK293 cells 
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stably expressing one receptor subtype were transiently transfected with the second 
receptor subtype to achieve dual expressing cells (Figure 4.6). To determine if the effects 
were due to the receptors being expressed on the same cell membrane (Figure 4.6 C, and 
D) versus the receptors being assayed together; an equal mixture of both individual stable 
cells lines was assayed as a control (Figure 4.6 E). Five cell categories (i.e. stable mMC3R 
cells, stable mMC4R cells, stable mMC3R cells transiently expressing the mMC4R, stable 
mMC4R cells transiently expressing the mMC3R, and an equal mixture of stable mMC3R 
cells and stable mMC4R cells) were screened in parallel at the same time to control for 
inherent day to day assay variability (Figure 4.6, Table 4.3). Only cells that coexpressed 
the mMC3R and mMC4R could possibly contain mMC3R-mMC4R heterodimers (Figure 
4.6 C and D), whereas the mixture of mMC3R stable cells with mMC4R stable cells would 
contain no heterodimers even though both cell types are assayed together (Figure 4.6 E). 
At least three independent experiments were performed on separate days. The EC50 values 
for ligands NDP-MSH, α-MSH, MTII, CJL-1-87, and CJL-1-14 at the singly expressed 
mMC3R and mMC4R were consistent with the field.25, 269, 270  
The EC50 values for the four monovalent ligands (i.e. NDP-MSH, α-MSH, MTII, 
and CJL-1-14) were within the inherent experimental error (<3-fold difference) when 
comparing the coexpressing cells (with possible heterodimers) to the mixed stable cell 
category (with no possible heterodimers) (Table 4.3). The values obtained for coexpressed 
cell lines corresponded well with the most potent EC50 value at the individually expressed 
cells lines (i.e. stable mMC3R or stable mMC4R cells) as expected based on the principle 
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of the harmonic mean.271 This indicates that there is no observable effect on the potency of 
these monovalent compounds (in our hands) of the mMC3R and mMC4R being 
coexpressed in the same cells compared to on different cells. Although it should be noted 
that the monovalent ligand CJL-1-14 was observed to trend towards increased potency 
(2.5 fold increase) when the mMC4R stable cells were transiently transfected with the 
mMC3R plasmid, but this is within the inherent 3-fold experimental error associated with 
these assays in our laboratory.  
Bivalent ligand CJL-1-87 possessed subnanomolar potency that was over 3-fold 
more potent compared to results achieved with the stable cell mixture when the mMC3R 
was transiently transfected into the stable mMC4R cell line (Table 4.3). These results may 
suggest that the bivalent ligand induced a synergistic effect during coexpression of the 
mMC3R and mMC4R presumably through a mMC3R-mMC4R heterodimer. However, the 
increase observed was slight (3-fold) especially considering the monovalent CJL-1-14 
resulted in a trending increase as well (2.5-fold). Also the opposite transfection order in 
which stable mMC3R cells were transiently transfected with the mMC4R did not result in 
a difference (see Section 4.3.8 for further discussion). Therefore, these results are currently 
inconclusive, but warrant further studies to establish the functional effects of melanocortin 
coexpression, and whether the mMC3R-mMC4R heterodimer may be a future neuronal 
molecular drug target.  
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4.3.8 Coexpression of mMC3R and mMC4R Effects on Functional Potency and 
Discussion of Expression Levels 
One noteworthy trend observed in the cAMP functional coexpression experiments 
is that for all compounds coexpression of the mMC3R transiently in mMC4R stable cells 
resulted in slightly more potent EC50 values than the opposite transfection order in which 
stable mMC3R cells were transiently transfected with the mMC4R plasmid (Table 4.3). 
This was especially true with dosing of CJL-1-14 and CJL-1-87 that both resulted in about 
2-fold differences in EC50 values. Although this is within experimental error of 3-fold, 
these changes are still worth discussing as they are consistent and may indicate that further 
study will be necessary. 
These differences likely have to do with the ratio of the amount of mMC3R and 
mMC4R expressed on the cell surface. It is dogma in the field that transient transfection 
results in a greater expression of receptors on the cell membrane than selected stable 
receptor populations of cells. Therefore, when the mMC3R is transiently transfected into 
the stable mMC4R cells, it is anticipated that more mMC3R than mMC4R would be 
expressed on the cell surface. If heterodimers do exist on the cell surface, the relative 
concentration of each receptor would be hypothesized to affect the equilibrium of the ratios 
of mMC3R monomers, mMC4R monomers, mMC3R homodimers, mMC4R homodimers, 
and mMC3R-mMC4R heterodimers (or how they compose higher-order oligomers). 
Considering CJL-1-87 has 45- to -350 fold higher binding affinity (depending on the 
radioligand used) at the mMC4R compared to the mMC3R, these shifts in equilibrium 
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between dimer species would affect how much of the dosed CJL-1-87 is binding mMC4R 
homodimers, mMC3R homodimers, or mMC3R-mMC4R heterodimers. To our 
knowledge, there is no technology feasibly capable of distinguishing how much of a ligand 
is binding to each of the different dimer states at this time. However, the increased potency 
in the coexpression system suggests that the heterodimerization of the mMC3R-mMC4R 
could play a role in the altered in vivo effects of CJL-1-87 compared to CJL-1-14, and 
that the mMC3R-mMC4R heterodimer may be a future neuronal molecular drug target.  
4.4 Conclusions 
The studies in the current chapter demonstrate that the homobivalent ligand CJL-
1-87 has a distinct pharmacological in vivo profile compared to the monovalent control 
ligand CJL-1-14. The findings reported here, along with Chapter 3,25, 132 provide new 
knowledge of molecular probes for future anti-obesity drug design and in vivo mechanism 
of action studies. The bivalent ligand CJL-1-87 had an increased ability to reduce food 
intake, promote fat utilization, modulate metabolic hormones, and decrease percent body 
fat when utilized in a mouse fasting-refeeding experimental paradigm as compared to the 
monovalent control ligand CJL-1-14. This extended the results in Chapter 3 that CJL-1-
87 has c.a. 20-fold increased binding affinity and moderately increased functional activity 
in vitro.25 However, in vivo paradigm-specific effects of CJL-1-87 could not have been 
predicted by in vitro assays from Chapter 3. Compound CJL-1-87 appears to be effective 
at reducing food intake in spite of peripheral hormone signals that stimulate hunger and 
refeeding including elevated ghrelin levels and depressed insulin and leptin levels.  
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It is postulated that the current in vivo differences reported herein, between CJL-
1-87 and CJL-1-14, are due to the bivalent ligand design strategy. Two possible 
mechanisms to explain the distinct pharmacology of CJL-1-87 compared to CJL-1-14 
based on the homobivalent ligand design have been presented. In the first proposed 
mechanism, the lowered entropy of the bivalent ligand binding allows CJL-1-87 to 
compete more effectively at displacing the endogenous MC3R/MC4R antagonist AGRP 
(that is upregulated in the fasting state) resulting in both agonism of the melanocortin 
receptors and antagonism of the orexigenic effects of AGRP. The monovalent ligand CJL-
1-14 has a lower binding affinity and is speculated to not compete as effectively with 
endogenous AGRP. In the second proposed mechanism, it is postulated that CJL-1-87 
interacts with melanocortin receptor homo- and/or heterodimers in a distinct molecular 
mechanism as compared to the monovalent counterpart CJL-1-14. The unique 
pharmacology observed in vivo may be a result of interacting with MC3R homodimers, 
MC4R homodimers, or MC3R-MC4R heterodimers that were all identified to form during 
in vitro BRET studies. It is possible that both of these postulated mechanisms play a 
synergistic role in the present in vivo observations. However, additional experimental 
studies are necessary to validate the postulated physiological significance of melanocortin 
dimers in vivo.  
The result presented herein provides “proof-of-concept” and a foundation that 
homobivalent ligands can achieve unique in vivo effects that are discrete from their 
monovalent counterparts. These results validate melanocortin homobivalent ligands as a 
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design strategy for therapeutically relevant compounds towards the treatment of energy 
homeostasis disorders such as obesity or cachexia. The advantage of CJL-1-87 compared 
to CJL-1-14 is increased in vitro binding affinity, increased in vivo functional potency, 
increased duration of action, decreased food intake after fasting, decreased body fat 
percentage, and differentially altered metabolic hormone levels. These findings justified 
further study of the SAR of melanocortin homobivalent ligands as presented in Chapter 
6. This chapter also allows for better understanding for the of the in vivo pharmacology of 
the MUmBLs that will be presented in Chapter 5.  
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Figure 4.1. In vitro serum stability of bivalent ligands and control ligands. Ligands (10 
µM) were incubated in mouse serum and monitored for degradation of the parent molecule 
by LC-ESI+-MS/MS. The PEDG20 based compounds were relatively metabolically stable, 
whereas (Pro-Gly)6 based compounds were rapidly degraded. Half-lives were calculated 
from two technical replicates of the in vitro serum stability assays. This figure has been 
adapted with permission from Lensing, C. J. et. al, ACS Chem. Neurosci. 2017, in press.132 
Copyright (2017) American Chemical Society. 
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Figure 4.2. Investigation of 5 nmol bivalent ligand CJL-1-87 ( ) compared to 5 nmol 
monovalent ligand CJL-1-14 ( ) (A) on energy homeostasis in TSE metabolic cages 
following a cross-over nocturnal feeding paradigm (Figure 2.3A). Treatment was given 
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ICV at time 0 h, and food was available ad libitum throughout the entire experiment. No 
significant effects were observed on any parameters. Grey boxes represent lights off. 
Because no significant differences were observed, no further experiments with this 
paradigm were performed.  
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Figure 4.3. Investigation of 5 nmol bivalent ligand CJL-1-87 ( ) compared to 5 nmol 
monovalent ligand CJL-1-14 ( ) (A) and saline ( ) on energy homeostasis in TSE 
metabolic cages following a cross-over paradigm (Figure 2.3A). Male mice were fasted 
starting at the previous light cycle (t=-22 h) until 2 h prior to the light cycle (t=0 h). 
Treatment was given ICV at time 0 h and food was returned immediately thereafter (Figure 
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2.3B). Cumulative food intake (B) was significantly reduced by CJL-1-87 compared to 
saline and CJL-1-14. The RER (C) was significantly reduced after CJL-1-87 treatment 
compared to saline and CJL-1-14. No significant effects were observed between saline, 
CJL-1-14, and CJL-1-87 on energy expenditure (D), ambulatory activity (E), or water 
intake (F). No significant effects were observed on any parameters past 24 h other than 
RER and, therefore, data is not shown. Grey boxes represent lights off. *p<0.05; **p<0.01, 
***p<0.001 for CJL-1-87 compared to saline. +p<0.05; ++ p<0.01, +++p<0.001 CJL-1-
87 for compared to CJL-1-14. This figure has been reproduced with permission from 
Lensing, C. J. et. al, ACS Chem. Neurosci. 2017, in press.132 Copyright (2017) American 
Chemical Society. 
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Figure 4.4. A new cohort of male mice received a single treatment of saline vehicle control 
( , n=10), 5 nmol CJL-1-14 ( , n=11), or 5 nmol CJL-1-87 ( , n=11) in the 
fasting paradigm used above (Figure 2.3B). CJL-1-87 treatment resulted in lowered 
refeeding food intake (A) corresponding to slower regain of body weight (B) measured 
manually. Measurements using an EchoMRI-100H system showed no change in lean body 
mass percentage (C), but a significant decrease in body fat mass percentage was observed 
6 h after treatment with CJL-1-87. (D). Mice were sacrificed 6 h post-treatment and their 
trunk blood was analyzed using an Luminex Milliplex systems to examine insulin (E), C-
peptide (F), leptin (G), GIP (H), ghrelin (I), IL-6 (J), and resistin (K). Hormone and 
cytokine levels are reported as pg per mL of plasma. Time 0 h was defined as the time of 
treatment. *p<0.05; **p<0.01; ***p<0.001 for CJL-1-87 compared to saline. +p<0.05; ++ 
p<0.01; +++p<0.001 for CJL-1-87 compared to CJL-1-14. % p<0.05; %% p<0.01; %%% 
p<0.001 for CJL-1-14 compared to saline. This figure has been reproduced with 
permission from Lensing, C. J. et. al, ACS Chem. Neurosci. 2017, in press.132 Copyright 
(2017) American Chemical Society. 
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Figure 4.5. Bioluminescence resonance energy transfer (BRET) of the mMC3R and 
mMC4R. As previously shown in similar systems, coexpression of the mMC3R-
NanoLuc® and the mMC3R-HaloTag® result in high BRET signal supporting 
homodimerization. Similar results were achieved when the mMC4R-NanoLuc® and the 
mMC4R-HaloTag® were coexpressed. When the mMC4R-NanoLuc® and the mMC3R-
HaloTag® are coexpressed an even higher BRET signal is observed suggesting 
heterodimerization. Cells expressing mMC4R-NanoLuc® were mixed with cells 
expressing the mMC3R-HaloTag® in equal amounts and produced minimal signal. As a 
negative control, unrelated mouse double minute 2 (MDM2)-NanoLuc® and the mMC3R-
HaloTag® are coexpressed as well as mMC4R-NanoLuc® and the p53-HaloTag®. Both 
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resulted in minimal signal. Receptors were expressed at a 1:4 donor NanoLuc® plasmid to 
acceptor HaloTag® plasmid. Data are the mean ± standard error of the mean (SEM) 
determined from three independent experiments, except for the mMC4R-NanoLuc® and 
the mMC3R-HaloTag® coexpression which was performed in six independent 
experiments. This figure has been reproduced with permission from Lensing, C. J. et. al, 
ACS Chem. Neurosci. 2017, in press.132 Copyright (2017) American Chemical Society.  
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Figure 4.6. Cell categories for cAMP AlphaScreen® functional assays during 
coexpression experiments (Table 4.3). (A) Cells stably expressing mMC3R. (B) Cells 
stably expressing the mMC4R. (C) Cells stably expressing the mMC3R that were then 
transiently transfected with mMC4R plasmid. (D) Cells stably expressing the mMC4R that 
were then transiently transfected with mMC3R plasmid. (E) Cells stably expressing the 
mMC3R were mixed 1:1 with cells stably expressing the mMC4R. This mixture cannot 
contain MC3R-MC4R heterodimers.  This figure has been reproduced with permission 
from Lensing, C. J. et. al, ACS Chem. Neurosci. 2017, in press.132 Copyright (2017) 
American Chemical Society.
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Hormone Fasting from Lit. 
Fasting 
Citations 
MC 
Agonism 
from Lit. 
MC 
Agonism 
Citations 
CJL-1-14 
(Current Study) 
CJL-1-87 
(Current Study) 
Insulin ↓ 243, 265 ↓ 251-253 ↔ ↓↓↓ 
C-Peptide ↓ 
243, 254, 
255, 265 
↓ 251-255 ↓↓ ↓↓↓ 
Leptin ↓ 243, 265 ↓ 252, 253 ↓↓ ↓↓↓ 
GIP ↓ 256, 266 ↓ 256 ↓↓ ↓↓↓ 
Ghrelin ↑ 243, 267 ? ↑ 263 ↔ ↑↑↑ 
IL-6 ↑ 268 ? ↓ 259-262 ↓↓↓ ↓↓↓ 
Resistin ↓ 243, 264 ? 257, 258 ↔ ↓↓ 
Table 4.1. Summary of the effects of fasting and melanocortin (MC) receptor agonism on hormone and cytokine levels from the 
literature (Lit.) and the current study. Results from fasting and melanocortin (MC) agonism are from the literature with citations 
referenced directly to their right. A question mark (?) indicates conflicting results. Results from 5 nmol CJL-1-14 and CJL-1-87 
treatments are summarized from the current study. In the current studies, the significance of treatment compared to saline treatment is 
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indicated such that one arrow is p<0.05, two arrows are p<0.01, and three arrows are p<0.001. This table has been adapted with 
permission from Lensing, C. J. et. al, ACS Chem. Neurosci. 2017, in press.132 Copyright (2017) American Chemical Society.
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Table 4.2: The experimental compounds were used to displace either 125I-NDP-MSH or 125I-AGRP in a dose-response manner to 
calculate the IC50 values. The % represents the amount of 125I-NDP-MSH signal reduction at 100 µM. The reported errors are the 
standard error of the mean (SEM) determined from at least two independent experiments. aThe IC50 values obtained by competition with 
125I-NDP-MSH were reported previously in Chapter 3, but are included herein for easier comparison.21 This table has been adapted 
with permission from Lensing, C. J. et. al, ACS Chem. Neurosci. 2017, in press.132 Copyright (2017) American Chemical Society.
  125I-NDP-MSH IC50 (nM)a 125I-AGRP IC50 (nM) 
Compound Structure mMC3R mMC4R mMC3R mMC4R 
  Mean±SEM Mean±SEM Mean±SEM Mean±SEM 
NDP-MSH  4.2±0.6 1.1±0.1 3.3±0.08 2.6±0.09 
CJL1-14 Ac-His-DPhe-Arg-Trp-NH2 60% @100 µM 210±60 6200±1700 130±20 
CJL1-87 Ac-His-DPhe-Arg-Trp-(PEDG20)-His-DPhe-Arg-Trp-NH2 3500±500 9.9±3 330±40 7.5±2 
CJL1-80 Ac-His-DNal(2')-Arg-Trp-NH2 1400±200 26±3 660±20 12±4 
CJL1-140 Ac-His-DNal(2’)-Arg-Trp-(PEDG20)-His-DNal(2')-Arg-Trp-NH2 350±80 10±0.03 120±10 11±2 
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 Agonist cAMP Based Alpha Screen Results EC50 (nM) 
Compound mMC3R mMC4R mMC3R 
Trans 
mMC4R 
mMC4R 
Trans 
mMC3R 
mMC3R Mixed 
with mMC4R 
 Mean±SEM Mean±SEM Mean±SEM Mean±SEM Mean±SEM 
NDP-MSH 0.13±0.02 0.46±0.07 0.19±0.03 0.12±0.01 0.13±0.02 
α-MSH 0.21±0.02 3.1±0.7 0.27±0.05 0.20±0.03 0.19±0.03 
MTII 0.10±0.02 0.11±0.03 0.09±0.02 0.06±0.01 0.08±0.02 
CJL1-14 23±3 8.5±1 7.7±1 4.0±0.5 9.9±2 
CJL1-87 2.6±0.4 1.2±0.3 1.4±0.3 0.63±0.1 2.0±0.4 
Table 4.3: Functional cAMP AlphaScreen® assays were performed to determine in vitro 
potency of compounds to induce cAMP signaling in five cell categories (Figure 4.6): (A) 
stable mMC3R cells, (B) stable mMC4R cells, (C) stable mMC3R cells transiently 
transfected with mMC4R, (D) stable mMC4R cells transiently transfected with mMC3R, 
and (E) an equal mixture of stable mMC3R cells and mMC4R cells. All assays and cell 
categories were run in parallel. The reported standard error of the mean (SEM) was 
determined from at least three independent experiments. This table has been adapted with 
permission from Lensing, C. J. et. al, ACS Chem. Neurosci. 2017, in press.132 Copyright 
(2017) American Chemical Society. 
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Chapter 5: Developing Biased Unmatched Bivalent Ligands (BUmBLs) to Target 
Asymmetrically Signaling Melanocortin-4 Receptor Homodimers 
All peptides were designed, synthesized, purified, and analytically characterized by 
Cody Lensing under the supervision of Carrie Haskell-Luevano. The in vitro pharmacology 
studies were performed by Cody Lensing, Katie Freeman, and Sathya Schnell, all members 
of the Haskell-Luevano lab group. Radiolabeled 125I-NDP-MSH was prepared by Robert 
Speth. All animal studies were performed by Cody Lensing, Danielle Adank, and Stacey 
Wilber. BRET assays were performed by Katie Freeman with Cody Lensing contributing 
to the design of the experiments. Serum stability studies were performed by Cody Lensing 
and Adam Zarth.  
5.1 Chapter Overview 
A major limitation in understanding the functional relevance of homodimerization 
of G protein-coupled receptors (GPCRs) has been the limited number of molecular tools to 
assess asymmetric signaling within dimer pairs comprised of the same receptor type. In the 
chapter, we present melanocortin unmatched bivalent ligands (MUmBLs) as tools for 
studying asymmetric function of melanocortin receptor homodimers. MUmBLs contain 
one agonist pharmacophore and one antagonist pharmacophore designed to target a 
melanocortin homodimer pair such that one protomer is occupied by an agonist and other 
one by an antagonist pharmacophore. Utilizing this design strategy to target the 
melanocortin-4 receptor (MC4R), first in class biased unmatched bivalent ligands 
(BUmBLs) were discovered. The BUmBLs displayed biased agonism in which they 
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potently stimulated cAMP signaling, but resulted in minimal activation of the β-arrestin 
recruitment pathway. After in vitro characterization, the lead BUmBL (CJL-5-58) was 
evaluated in vivo for its effect on energy homeostasis in mice utilizing TSE Phenotypic 
metabolic cages. These studies indicate a unique pharmacology purportedly due to the 
BUmBL design strategy employed demonstrating in vivo that the agonist pharmacophore 
overrides the antagonist pharmacophore in the regulation of food intake behavior. To the 
best of our knowledge, we report the first single compound design strategy to 
pharmacologically target melanocortin receptor allosteric signaling that occurs between 
putative GPCR homodimers that can be applied easily both in vitro and in vivo to other 
GPCR systems. 
5.2 Introduction 
G protein-coupled receptors (GPCRs) are highly sought after drug targets in the 
pharmaceutical industry with approximately 30-40% of drugs targeting them.2, 3 
Classically, medicinal chemists targeted GPCRs as monomeric units; however increasing 
evidence has shown GPCRs form dimers with themselves (homodimers) and with other 
GPCRs (heterodimers).4, 272 Targeting GPCR homodimers’ and heterodimers’ distinct and 
exploitable functions may yield a revolution in GPCR targeting therapeutics. Although 
ligands targeting heterodimers have shown much promise in both in vitro and in vivo 
preclinical studies,10, 11, 44, 46, 48 there has been limited development of ligands targeting the 
allosterism that can occur within homodimers.  
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Pharmacologically targeting homodimers possess a unique conundrum: How do 
you target and detect a homodimer when the two receptors comprising it are structurally 
similar, usually respond to the same ligands, and appear to have the same propensity to 
signal in standard cell culture assays? Various groups have devised clever strategies around 
these problems to demonstrate the functional consequences of asymmetric homodimers.207, 
231, 273-287 Some of these groups focus on demonstrating subtle changes in pharmacology 
utilizing strategically designed in vitro experiments and other groups exploited receptor 
mutation strategies in order to differentiate between the two protomers making up the 
dimer. 207, 231, 273-287  For example, Han and coworkers in 2009 combined different receptor-
G protein fusions and various mutant receptors to demonstrate allosteric modulation within 
a dopamine homodimer.231 They reported that the D2 dopamine receptor homodimers are 
maximally activated upon a single agonist binding a single protomer in the dimer pair. 
When a second agonist binds the second protomer, it blunts the signal. If an inverse agonist 
binds the second protomer, it actually enhances the signal beyond agonist alone.231 In a 
different strategy, Teitler and coworkers developed pseudo-irreversible inactivators and 
reactivators that can be used to block only one of the protomers within the dimer pair in 
order to demonstrate the crosstalk within wild type serotonin homodimers.274 This 
approach can and has been used to demonstrate the allosteric regulation within homodimers 
in native tissue samples, however application of this technique in vivo would be difficult 
given the multiple dosing regimen necessary and, therefore, would have very limited 
therapeutic applications.274 Although these reports provide critical proof of the relevancy 
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and functional significance of asymmetric signaling homodimers, the techniques employed 
are limited by their use of receptor mutations or subtle pharmacological differences that 
make adaption of the approaches to in vivo applications difficult and therapeutic 
applications inexecutable. Ideally, a pharmacological approach is needed to target and 
exploit allosteric communication between homodimers with a single chemical entity that 
could be used to examine the in vivo effects of native asymmetric GPCR homodimers in 
order to study their potential as therapeutic targets. 
 As discussed in Chapter 1, one approach to pharmacologically targeting GPCR 
dimers is utilizing bivalent ligands. This approach was pioneered Portoghese and 
coworkers targeting the opioid receptors.7, 12 Heterobivalent ligands featuring 
pharmacophores for two different receptor types have been utilized to exploit allosteric 
interactions within heterodimers to develop ligands with novel pharmacological profiles, 
tissue selectivity, and different functional effects.10, 11, 44-47 However, to our knowledge, no 
one has exploited the allosteric communication that may occur between homodimers with 
bivalent ligands to produce novel pharmacologies. In the current report, we exploit the 
allosteric communication between melanocortin-4 receptor (MC4R) homodimers with 
melanocortin unmatched bivalent ligands (MUmBLs) to produce biased agonists. 
Unmatched bivalent ligands (UmBLs) have an agonist pharmacophore on one side of the 
bivalent ligand connected to an antagonist pharmacophore through an inert linker. We use 
the term UmBLs to separate this class of ligands from heterobivalent ligands that also have 
different pharmacophores on each side of the bivalent ligand, but are usually used to target 
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different receptor types. This type of ligand design has been proposed and reported 
previously, however, to our knowledge they have not been used to successfully exploit 
asymmetric signaling of GPCR homodimers.22, 30, 288 One of the best examples of the 
UmBL strategy was reported by Kühhorn and coworkers. They reported UmBLs targeting 
the dopamine D2 receptors that had some agonist efficacy (13% maximal) and did not 
induce receptor internalization suggesting biased agonism may be possible with this design 
strategy, although they conclude “ligand bias” was not accomplished.22  
 In Chapter 3 and Chapter 4, both agonist and antagonist homobivalent ligands 
targeting the melanocortin receptor system were described.25, 132 It is hypothesized that 
ligands that target melanocortin homodimers may have unique effects from the current 
monovalent approaches, and may, therefore circumvent some side effects. In these chapter, 
we show that an agonist homobivalent ligand produces a distinct in vivo pharmacological 
profile compared to monovalent counterpart suggesting that targeting melanocortin dimers 
may have therapeutic relevancy.132 Furthermore, biased ligands would be valuable 
pharmacological probes to elucidate which signaling pathway is responsible for the various 
melanocortin dependent effects (i.e. lowered food intake vs increased blood pressure). In 
this chapter, we report the design and synthesis of MUmBLs to target asymmetrically 
signaling melanocortin homodimers. We study the in vitro effects of these ligands in 
competitive binding assays, functional cAMP assays, and β-arrestin recruitment assays. A 
biased agonist for cAMP pathway over the β-arrestin pathway was discovered which has 
not been reported in the literature for the melanocortin receptors to date. Lead ligand CJL-
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5-58 was studied in vivo using mice housed in TSE Phenotypic metabolic cages to 
demonstrate unique effects on energy homeostasis presumably due to the bivalent ligand 
design. The current study provides novel molecular probes for the melanocortin receptors 
as well as an in vitro and in vivo proof-of-concept of using the BUmBL design strategy to 
target asymmetrically signaling homodimers. This innovative design strategy that could be 
applied to various GPCR systems for the creation of biased ligands.  
5.3. Results and Discussion 
5.3.1 Design and Synthesis 
As discussed in Chapter 3, homobivalent ligands targeting melanocortin receptors 
have previously resulted in increased binding affinity (~14 to 25-fold) consistent with a 
synergistic binding mode resulting from receptor dimer binding.25, 26, 28-31, 33-37, 132 In spite 
of an increased binding affinity, we have observed much smaller fold increases in cAMP 
based functional activity (3 to 5-fold).25 Hruby and coworkers noted similar effects with 
melanocortin bivalent ligands in which cAMP accumulation was not as dramatically 
increased with synergistic multivalent binding.28 One possibility for the incongruity 
between binding affinity increases and functional signaling increases with bivalent ligands 
may be due to allosterism between the melanocortin receptors within homodimers.25  
A new paradigm can be hypothesized that one receptor within the melanocortin 
homodimer might be responsible for cAMP signaling and the other receptor might be 
responsible for signaling through a different cellular pathway (e.g. β-arrestin recruitment 
pathway) (Figure 5.1A-B). It would then follow that the increased binding would not 
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necessarily result in an increase in functional agonist activity observed in a cAMP assay, 
since the effect of the second binding event is not detected by this cellular assay paradigm. 
Furthermore, there has been reports of asymmetry within melanocortin homodimers in both 
binding experiments and functional assays.205-207, 219 In order to the exploit this possibility 
of asymmetric homodimers, we designed and synthesized MUmBLs that contained the 
known agonist melanocortin moiety His-DPhe-Arg-Trp on one side of the molecule,96, 98 
and the known MC3R and MC4R antagonist moiety His-DNal(2’)-Arg-Trp 97, 289 
connected by three different linker systems previously validated in Chapter 3 (Table 
5.1).25, 30, 31, 168 We also synthesized and biologically evaluated MUmBLs that contained 
the His-DPhe(p-I)-Arg-Trp moiety on one side of the molecule. Due to the discrepancies 
with the tetrapeptide Ac-His-DPhe(p-I)-Arg-Trp-NH2 between the cAMP AlphaScreen 
assay and CRE/β-galactosidase reporter gene assay described thoroughly in Chapter 3 
Section 3.4.1, the biological results of these His-DPhe(p-I)-Arg-Trp containing MUmBLs 
are difficult to interpret. Therefore, these peptides will not be discussed further, but their 
characterization and functional assessment can be found the appendix.    
Because bivalent ligands presumably occupy both orthosteric binding sites in a 
receptor dimer due to synergistic binding, a MUmBL is postulated to occupy one receptor 
within a homodimer pair with an agonist pharmacophore and the other receptor within the 
same homodimer with an antagonist pharmacophore (Figure 5.1C). This assumes 
approximately equal binding affinities of the pharmacophores, and low enough 
concentrations of ligand so that intermolecular competition does not occur. The MUmBLs 
160 
 
should favor a bivalent binding mode supported in Chapter 3 pushing the equilibrium 
towards occupation of one receptor with agonist and the other receptor with antagonist in 
the homodimer, but other binding states probably exist in equilibrium (Figure 5.2). It 
should also be noted, that we are currently assuming that only orthosteric binding is 
occurring, because allosteric binding has never been reported with either the His-DPhe-
Arg-Trp or the His-DNal(2’)-Arg-Trp pharmacophores even though they both have been 
extensively studied as tetrapeptides and in standard control ligands NDP-MSH and 
SHU9119.94-97 Both of these tetrapeptides are also direct competitors of 125I-NDP-MSH 
and 125I-AGRP(87-132) that further validates an orthosteric binding mode.1, 25, 132  
Ligands CJL-1-124, CJL-5-74, and CJL-1-63 feature the His-DPhe-Arg-Trp 
scaffold on the C-terminus and the His-DNal(2’)-Arg-Trp scaffold on the N-terminus 
(Table 5.1). Since the molecules are not symmetric, the opposite composition of CJL-1-
124 was designed and synthesized with the His-DNal(2’)-Arg-Trp scaffold on the C-
terminus and His-DPhe-Arg-Trp scaffold on the N-terminus in compound CJL-5-58. In 
particular, the construction of CJL-5-58 with the PEDG20 linker system was selected 
because this linker system was previously shown to be optimal in homobivalent ligands 
compared to the PEDG20-PEDG20 or Pro-Gly linker systems at the mMC4R.25, 30 Also in 
Chapter 4, the PEDG20 linker was shown to be more metabolically stable than the Pro-
Gly linker system and would allow in vivo applications.132 In an in vitro mouse serum 
stability assay, CJL-5-58 had similar serum stability (half-life = 6.9 h) as the previously 
reported CJL-1-87 confirming the PEDG20 linker selection (Figure 5.3).132  
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Bivalent melanocortin ligands featuring agonist and antagonist pharmacophores 
were synthesized previously and were reported to possess increased binding affinity.30 
These ligands provide evidence that UmBLs can bind hMC4R homodimers, but no 
functional activity was evaluated.30, 290 Therefore, the effects of functional asymmetric 
homodimers could not be detected. In the current study, all compounds were synthesized 
using standard Fmoc chemistry utilizing solid-phase synthesis methodology.191, 228, 291 A 
split resin approach for control ligands and bivalent ligands was performed as described in 
Chapter 2.25 The ligands were purified to >95% by semi-preparative RP-HPLC and their 
mass was confirmed by ESI-MS (Table 5.2). The inclusion of compound from Chapter 3 
and Chapter 4 are provided for easier comparison currently.  
5.3.2 Biased Signaling at the hMC4R 
Upon agonist stimulation, melanocortin receptors are known to signal through a 
Gαs-protein mediated signaling pathway that results in intracellular cAMP accumulation. 
Agonist stimulation of the melanocortin receptors also results in β-arrestin recruitment and 
receptor desensitization. 199-201 In order to evaluate the ligands efficacy and potency to 
stimulate cAMP signaling, the ALPHAScreen™ cAMP Assay Technology was utilized to 
assess live HEK293 cells stably expressing human (h)MC4R.292, 293 All ligands that 
contained the His-DPhe-Arg-Trp pharmacophore, including the MUmBLs, were single-
digit or sub-nanomolar agonists in the cAMP assay (Table 5.1, Figure 5.4A). The most 
potent ligand (besides control ligand NDP-MSH) was the bivalent ligand CJL-1-87 that 
had an EC50 of 570 pM and was 3-fold more potent than its monovalent counterpart CJL-
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1-14. This result was similar to that previously observed in Chapter 3 with CJL-1-87 at 
the mouse (m)MC4R.25  The ligands that only contained the His-DNal(2’)-Arg-Trp 
antagonist scaffold were not able to elicit a full response when tested up to 10 µM. 
Homobivalent ligand CJL-1-140 with two His-DNal(2’)-Arg-Trp resulted in 70% cAMP 
accumulation of that seen with NDP-MSH at 10 µM which is also consistent with previous 
reports at the mouse receptors in Chapter 3.25 These results suggest that there is minimal 
species variation within the monovalent and homobivalent ligands currently tested.   
The MUmBLs (i.e. CJL-1-63, CJL-5-58, CJL-1-124, and CJL-5-74) were all 
single digit nanomolar potent agonists at the hMC4R. For comparison with the MUmBLs, 
as a control an equal mixture of tetrapeptides CJL-1-14 + CJL-1-80 was assayed and 
resulted in an agonist dose response curve with an EC50 of 1.9±0.2 nM.  In order to give 
the best comparison to the MUmBLs, 1 nM of the tetrapeptide mixture contained 1 nM 
CJL-1-14 and 1 nM CJL-1-80 (for a final concentration of 2 nM total peptide) was tested. 
This would be directly comparable to 1 nM of a MUmBL when looking at final 
pharmacophore concertation. From this data, it appears that antagonist scaffold His-
DNal(2’)-Arg-Trp is not capable of effecting the cAMP agonist pharmacology of His-
DPhe-Arg-Trp agonist scaffold when mixed in equal portions.  
Theoretically, if both the agonist scaffold and antagonist scaffolds compete equally 
for binding, then at 100% receptor occupancy 50% of the receptors would be occupied by 
agonist tetrapeptide scaffold and 50% would be occupied by the antagonist tetrapeptide 
scaffold (Figure 5.2 A-B, E-J). Based on this assumption, the MUmBLs full cAMP agonist 
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pharmacology would be achieved by only 50% receptor occupancy by the agonist scaffold 
at the receptors, since the antagonist scaffold would be occupying approximately 50% of 
the receptors. This is consistent with both the spare receptor theory,294, 295 and the 
hypothesis presented above for asymmetric signaling homodimers in which ~50% of the 
receptors are responsible for β-arrestin recruitment and 50% are responsible for cAMP 
signaling (Figure 5.1). In practice, the MUmBLs may be binding to the melanocortin 
receptor monomers, dimers, and/or higher-order oligomers and may not be binding in 
exactly equal amounts of agonist and antagonist due to intermolecular competition. 
(Figure 5.2)  
It was, therefore, hypothesized that the second binding event within the GPCR 
dimer may be responsible for a different functional response. It has previously been 
observed that β-arrestin recruitment of one protomer within the AT1 angiotensin receptor 
homodimer can be allosterically regulated by selective stimulation of the other protomer.282 
In order to examine if β-arrestin recruitment to the hMC4R was regulated differently by 
MUmBLs versus agonist or antagonist homobivalent ligands, we utilized the PRESTO-
Tango assay developed by Roth and colleagues.202, 203 The PRESTO-Tango technology is 
an open-source resource that has been utilized to identify ligands for orphan receptors 
based on β-arrestin recruitment. This assay has previously been validated at the hMC4R 
that agonist stimulation results in β-arrestin recruitment.202 In agreement with these results, 
classic monovalent agonist ligands result in the recruitment of β-arrestin and high signal 
(Table 5.1, Figure 5.4B-C). The classical melanocortin control agonists NDP-MSH, MTII 
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and the tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 all resulted in maximal β-arrestin 
recruitment with MTII being the most potent ligand. The linker control and homobivalent 
ligands that featured only the His-DPhe-Arg-Trp pharmacophore all resulted in maximal 
β-arrestin recruitment relative to NDP-MSH control. Among the linker controls, compound 
CJL-5-35-4 with the PEDG20 linker on the C-terminus resulted in a 5-fold increase in β-
arrestin recruitment compared to the tetrapeptide CJL-1-14. This ligand also resulted in a 
3-fold increase in the cAMP signaling assay. The other PEDG20 linker compound CJL-1-
116 resulted in less than a 3-fold increase in β-arrestin recruitment compared to CJL-1-14. 
The His-DPhe-Arg-Trp that utilized the Pro-Gly linker system did result in a decrease in 
the potency for β-arrestin recruitment in spite them retaining their full cAMP pathway 
functional activity.   
The ligands containing only the antagonist His-DNal(2’)-Arg-Trp pharmacophore 
resulted in minimal β-arrestin recruitment consistent with a classical antagonist 
pharmacology. The tetrapeptide Ac-His-DNal(2’)-Arg-Trp-NH2 resulted in 30% response 
at 10 µM compared to the maximal efficacy of NDP-MSH. The other linker control ligands 
and the bivalent ligand CJL-1-140 resulted in equal or lower β-arrestin recruitment. This 
result was not surprising given the antagonist nature of these compounds and that 
antagonists have previously been reported to result in minimal β-arrestin recruitment and 
receptor internalization.199-201 
Interestingly, the MUmBLs resulted in minimal β-arrestin recruitment. The most 
potent MUmBL was CJL-1-63 that resulted in 55% maximal efficacy at 10 µM compared 
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to NDP-MSH. All other MUmBLs resulted in less β-arrestin recruitment. Because these 
ligands still potently stimulate cAMP signaling but result in minimal β-arrestin recruitment, 
it supports the current hypothesis that one pharmacophore is responsible for the activation 
of the cAMP pathway, but the other pharmacophore is responsible for the β-arrestin 
recruitment. When a bivalent ligand is comprised of an agonist pharmacophore and an 
antagonist pharmacophore, it should bind to a GPCR dimer in equal portions. The agonist 
pharmacophore would then signal effectively through the cAMP pathway, but the 
antagonist pharmacophore would block the β-arrestin recruitment pathway (Figure 5.1). 
The current results are not consistent with the current dogma in the field, however, these 
results may be explained by the asymmetric allosteric signaling within GPCR homodimers. 
Although there have been reports of biased agonists at different melanocortin 
pathways including cAMP, calcium mobilization, and receptor internalization,296-298  to the 
best of our knowledge the MUmBLs are the first melanocortin biased agonists for the 
cAMP pathway over the β-arrestin recruitment pathway. Biased ligands for GPCRs have 
been of interest for future drug development due their distinct pharmacology and functional 
selectivity.299, 300 In particular, it is hypothesized that biased ligands stabilize a specific 
conformation of the receptor that favors one signaling pathway over another. 299, 300 We 
currently hypothesize similarly that the MUmBLs stabilize specific dimer conformational 
states (as opposed to monomeric receptor conformational states) that results in the cAMP-
signaling biased agonism. 
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An explanation of the biased agonism is through a model for allosterically 
interacting receptor dimers (Figure 5.5).301, 302 In this model, one receptor within a dimer 
can allosterically stabilize the other receptor within the dimer to different conformations. 
These different conformations are thought to be dynamic in that the receptors oscillate 
between the different states even with no ligand present.301 However, it is postulated that 
with no ligand bound both receptors are conformationally open to cAMP signaling upon 
agonist stimulation (Figure 5.5A). After the first agonist binding event, a conformational 
change occurs which induces cAMP signaling pathway (Figure 5.5B) and this 
conformational change allosterically modifies the second receptor to have a propensity to 
signal through the β-arrestin pathway (Figure 5.5E). For this reason, monovalent agonist 
ligands, homobivalent agonist ligands, and the MUmBLs all produce full agonist cAMP 
induction, since the first agonist binding event is similar. After the first agonist binding 
event, the second receptor in the dimer is hypothesized to have structural bias for β-arrestin 
recruitment upon agonist binding. Therefore, the second agonist binding event results in β-
arrestin recruitment (Figure 5.5F). This is the same for monovalent and homobivalent 
agonist ligands since both result in a second agonist binding event and this is observed in 
full β-arrestin recruitment results (Figure 5.4). However, the MUmBLs result in an 
antagonist binding the second receptor instead of another agonist. The MUmBL’s 
antagonist pharmacophore prevents β-arrestin recruitment that results in minimal signal in 
the PRESTO-Tango assay (Figure 5.5G-I).  
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There is an assumption above that the agonist tetrapeptide scaffold of the MUmBLs 
binds first before the antagonist tetrapeptide scaffold, but in practice the order of binding 
is not determined (Figure 5.5J-L). However, antagonist scaffolds restrict the GPCR from 
accessing conformational states that result in GPCR signaling (i.e. G-protein or β-arrestin). 
Therefore, even if the antagonist does bind first to the receptor dimer pair (Figure 5.5K), 
it is would not induce G-protein signaling. Instead it would still require the first agonist 
binding event to the second receptor in the dimer pair to occur that would result in cAMP 
signaling (Figure 5.4A), and allosteric modulation to the β-arrestin ready state. However, 
the antagonist scaffold would already be bond to the dimer, and would block β-arrestin 
recruitment resulting in minimal PRESTO-Tango signal (Figure 5.4B).  
This interpretation of the data is based on the model for allosteric interaction in 
receptor dimers that has previously been reported.301, 302 However, to add further 
complexity to the current model, it has been supported that GPCRs oscillate between 
monomeric, dimeric, and high-order oligomeric states and models that include these states 
have also been purposed (Figure 5.2).301, 302 206, 207, 214 Also the MUmBLs may bind in 
various different ways such that antagonist scaffold displaces the agonist scaffolds or vice 
versa resulting in more agonist scaffolds bound than antagonist scaffolds. These different 
confrontational states may help explain the β-arrestin recruitment observed at higher 
concentrations of the MUmBLs. It is predicted that similar states are present in various 
GPCR systems, and that a biased unmatched bivalent ligand (BUmBL) design strategy 
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could be applied to any asymmetric GPCR homodimer system for the creation of biased 
ligands. 
This model may help explain a variety of observations in the field related to 
melanocortin dimerization and oligomerization. For example, Piechowski and coworkers 
reported in 2013 that disruption of hMC4R homodimerization leads to increased cAMP 
signaling capacity (or efficacy) although receptor expression was unchanged.206 This can 
be explained by the current model of asymmetric homodimers (Figure 5.1), since 
disruption of the dimer to monomers would increase the amount of receptors capable of 
accessing the cAMP signaling states (Figure 5.5 B). In other words, with more monomers 
there would be less receptors being allosterically modulated to signal through β-arrestin 
recruitment since the asymmetric signaling could not occur. Therefore, more receptors 
would signal through the cAMP signaling pathway upon agonist binding increasing 
signaling capacity. To experimentally establish this hypothesis further, a concerted effort 
of pharmacological intervention, receptor mutagenesis and other techniques would be 
necessary. For this thesis, we are delighted that using the hypothesis of asymmetrically 
signaling melanocortin homodimers allowed for the creation of first-in-class biased 
agonists for the cAMP signaling over the β-arrestin recruitment, even if the hypothesis still 
needs further validation. 
5.3.3 Characterization of cAMP Signaling at the Mouse Melanocortin Receptors  
Initial in vivo evaluations are often performed in mouse models, therefore, we 
evaluated the MUmBLs ability to promote cAMP signaling in HEK293 cells stably 
169 
 
expressing the mouse (m)MC1R, mMC3R, mMC4R, and mMC5R. The MC2R was 
excluded from the study as it has been reported to only be stimulated by ACTH.49 The 
mouse receptor pharmacology for control ligands (except CJL-5-35-2) and homobivalent 
ligands were previously discussed in Chapter 3,25 but are also included for complete 
comparison in Table 5.3 and Table 5.4 and Table 5.5. In order to compare the 
pharmacology of the MUmBLs, a tetrapeptide mixture of CJL-1-14 and CJL1-80 in equal 
proportions was assayed as controls as discussed above. 
Similar to the hMC4R, the MUmBLs displayed some agonist activity at all four 
receptors subtypes (Table 5.3, Figure 5.6). At the mMC1R, both the Ac-His-DPhe-Arg-
Trp-NH2 and Ac-His-DNal(2’)-Arg-Trp-NH2 function as agonists (EC50 = 14 nM and 98 
nM, respectively). Functional data from the mixture of CJL-1-14 and CJL-1-80 were 
equipotent as the most potent agonist monovalent ligand CJL-1-14. Changes <3-fold were 
considered to be within the intrinsic error of the assay (in our hands). Similar potency was 
observed with MUmBL compounds CJL-1-63, CJL-5-58, and CJL-1-124 at the mMC1R 
(Figure 5.6A). Compounds CJL-1-14, CJL-5-58, and CJL-1-124 were more than 3-fold 
potent compared to CJL-5-74. In Chapter 3, we observed that the 40 atom PEDG20-
PEDG20 linker was not optimal for bivalent binding most likely due to linker being too 
long,25 and the non-optimal linker may be responsible for the decreased potency of CJL-
5-74. At the mMC5R, all MUmBL compounds were comparable to the mixture of CJL-1-
14 and CJL-1-80 in their cAMP potency (Figure 5.6D). 
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 At the mMC3R, the mixture of CJL-1-14 and CJL-1-80 seemed to match the 
functional activity of CJL-1-14 from 10-11 to 10-7 M, but began plateauing at 75% max 
efficacy of NDP-MSH at 10 µM. (Table 5.3, Figure 5.6B). This loss of max efficacy is 
postulated to be due to the antagonism of the CJL-1-80 (pA2=6.04, Ki= 912 nM) in the 
mixture which is known to possess a more potent binding affinity than CJL-1-14 at the 
mMC3R (Table 5.3).25 Unlike the control mixture, all MUmBLs resulted in full nanomolar 
cAMP agonist activity (EC50 = 15-30 nM) at the mMC3R. Compounds CJL-1-63 and 
CJL-1-124 were >3-fold more potent than the tetrapeptide CJL-1-14 alone, and CJL-5-
58 and CJL-5-74 trended towards increased potency. This suggests the MUmBL design at 
the mMC3R favors CJL-1-14 tetrapeptide’s agonism overiding CJL-1-80 tetrapeptide’s 
antagonist properties which is consistent with the hypothesized asymmetry of melanocortin 
homodimers (Figure 5.1).  
At the mMC4R, the mixture of CJL-1-14 and CJL-1-80 resulted in partial agonism 
with a max efficacy of 50% at 10 µM. (Table 5.3, Figure 5.6C). This decrease in max 
efficacy likely resulted due to the competition between the strong full agonism of CJL-1-
14 (EC50 = 14 nM) with the strong antagonism of CJL-1-80 (pA2 = 8.09, Ki = 8.1 nM) at 
the mMC4R. Interestingly, unlike the mMC3R, two MUmBLs, CJL-1-124 and CJL-5-74, 
have similar pharamacologies as the tetrapeptide mixture both resulting in partial agonism. 
However, MUmBLs CJL-5-58 and CJL-1-63 were both potent agonist with EC50 values 
of about 13 nM. The partial agonist properties observed with both the mixture of CJL-1-
14 and CJL-1-80 and the MUmBLs CJL-1-124 and CJL-5-74 demonstrates a species 
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difference between the mouse and human MC4R. This demonstrates the importance of 
performing in vitro pharmacology on species specific receptors for in vivo interpretation. 
The partial agonism of bifunctional ligands possessing agonist pharmacophores and 
antagonist pharmacophores were predicted by simulation data by Zhu in 2005.303 However, 
the full agonism observed with CJL-5-58 and CJL-1-63 was unexpected. The 
pharmacology differences between CJL-5-58 and CJL-1-63 compared to CJL-1-124 and 
CJL-5-74 were also unexpected considering these differences were not observed at the 
other four receptor types assayed (i.e. mMC1R, mMC3R, mMC5R, and hMC4R). Both of 
these pharmacologies have much interest as pharmacology probes. Especially considering 
this design strategy should be applicable to various GPCR systems.  
In contemplating the usefulness of intentionally designing partial agonists such as 
CJL-1-124 and CJL-5-74, we thought about their possible ability to increase a therapeutic 
window. This design of partial agonist GPCR UmBLs may offer an approach to increase 
the therapeutic window of GPCR ligands, since these compounds resulted in 50% receptor 
activation for a wider dose response window compared to standard agonist compounds 
(Figure 5.7). This may happen in cases were full functional activation may result in side 
effects or characteristics that lead to abuse (e.g. euphoria), however partial functional 
activation is therapeutic. Partial agonisms may therefore allow the drug to remain in the 
therapeutic window for much longer without side effects and result in easier dosing. 
In contrast to this partial agonism, CJL-5-58 and CJL-1-63 were observed to be 
full nanomolar potent agonists with similar pharmacologies to monovalent ligand CJL-1-
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14 (EC50 = 14 nM). The full agonism observed at the mMC3R with all MUmBLs and at 
the mMC4R with CJL-5-58 and CJL-1-63 is consistent with the hypothesis that only one 
receptor in a dimer pair needs agonist activation for full cAMP signal transduction, but not 
the second receptor in the putative GPCR dimer. In an idealized bivalent binding mode, 
each dimer is occupied by one bivalent ligand assuming equal binding affinity of both 
pharmacophores. In the case of MUmBLs, each mMC3R or mMC4R homodimer is 
hypothesized to have one receptor occupied by the His-DPhe-Arg-Trp agonist 
pharmacophore or His-DNal(2’)-Arg-Trp antagonist pharmacophore. This results in full 
cAMP signaling from the His-DPhe-Arg-Trp agonist pharmacophore, but the His-
DNal(2’)-Arg-Trp antagonist pharmacophore results in minimal β-arrestin recruitment 
(Figure 5.1C). Furthermore, given the consistent pharmacology with the human and mouse 
receptor isoforms and the better metabolic stability of the PEDG20 linker (Figure 5.3), 
CJL-5-58 stands out as a lead ligand for in vivo characterization.  
The most interesting part of the MUmBL SAR is the comparison of CJL-5-58 and 
CJL-1-124 at the mMC4R that possess the same linker system, but CJL-5-58 resulted in 
a full agonist response curve in cAMP signaling (EC50 = 14±6 nM) and CJL-1-124 resulted 
in a partial agonist (55% activation at 10 µM). The difference between the two ligands is 
that the His-DNal(2’)-Arg-Trp antagonist is on the N-terminus of CJL-1-124 but on the 
C-terminus of CJL-5-58; and the His-DPhe-Arg-Trp pharmacophore is present C-terminus 
in CJL-5-58 and the N-terminus of CJL-1-124. Since the current ligands are not 
symmetrical, this suggest the three-dimensional orientation of the pharmacophores effects 
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the in vitro receptor pharmacology at the mMC4R but not at any of the other melanocortin 
receptors examined in this study.  
For the sake of comparison based on the site of attachment of the linker to the 
pharmacophore (N- versus C-terminus), compound CJL-5-58 can be thought to be 
comprised of CJL5-35-4 and CJL-1-132. Compound CJL-1-124 can be considered to be 
comprised of CJL5-35-2 and CJL-1-116. The His-DPhe-Arg-Trp based compound CJL-
5-35-4 (EC50= 5.7±2.9) with the PEDG20 linker on the C-terminus as seen in CJL-5-58 
was 3-fold more potent at the mMC4R than CJL-1-116 (EC50= 18.5±2.9) with the 
PEDG20 linker on the N-terminus as seen in CJL-1-124. The His-DNal(2’)-Arg-Trp based 
compound CJL-1-132 (pA2=7.97±0.29) with the PEDG20 linker on the N-terminus as 
seen in CJL-5-58 resulted in 15% maximal agonist activation at 10 µM at the mMC4R 
compared to the 10% observed with CJL-5-35-5 (pA2=8.38±0.08) with the PEDG20 linker 
at the C-terminus as seen in CJL-1-124 (Table 5.4). The components that comprise CJL-
5-58 do appear to have more propensity for agonism, however, these small differences are 
postulated not to be the driving force between the large pharmacological differences 
observed at the mMC4R. In order to examine the pharmacology of these compound in more 
detail, competitive displacement binding assays were performed.  
5.3.4 125I-NDP-MSH Competitive Binding Assays.  
Competitive radioligand binding assays were utilized to further understand the in 
vitro molecular pharmacology of the MUmBL design strategy at the mMC3R and mMC4R 
(Table 5.3, Figure 5.8, Figure 5.9). Although ligand development towards the mMC1R 
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was not the focus of the current study, the binding data was included since the MC1R has 
been identified as a drug target and a potential melanoma diagnostic target (Figure 5.9).117, 
158 It has previously been shown that bivalent ligands can dramatically increase the binding 
affinity compared to monovalent ligands due to a synergistic binding event and lowered 
entropic cost of binding.7, 25  
At the mMC1R, the MUmBLs resulted in increased binding affinity even compared 
to the tightest binding tetrapeptide scaffold CJL-1-14. Compound CJL-1-63 with the (Pro-
Gly)6 linker resulted in a 7-fold decreased IC50 value which was the highest binding affinity 
for the mMC1R among the MUmBLs (Table 5.3, Figure 5.9). This was consistent with 
previous results that the mMC1R preferred the (Pro-Gly)6 linker over the PEDG20 and 
PEDG20-PEDG20 linker systems in homobivalent ligands (Table 5.5).25 It should be 
noted that the binding affinities of the tetrapeptide scaffolds CJL-1-14 and CJL-1-80 that 
make up the MUmBLs are different by more than 4-fold at all the receptor subtypes 
examined in this study. In theory, this difference in binding affinity of the tetrapeptide 
scaffolds results in the higher affinity scaffold on one side of the MUmBL acting as a 
“targeting” region to bring the lower affinity scaffold to the second binding site in the 
homodimer assuming all binding is orthosteric. The entropic gains from a bivalent binding 
mode for the lower affinity tetrapeptide scaffold (i.e. His-DNal(2’)-Arg-Trp at the 
mMC1R, or His-DPhe-Arg-Trp at the mMC3R and mMC4R) would be much greater than 
the gains for the tighter binding tetrapeptide scaffold (i.e. His-DPhe-Arg-Trp at the 
mMC1R, or His-DNal(2’)-Arg-Trp at the mMC3R and mMC4R). This is observed in 
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compound CJL-1-63 at the mMC1R that has a 28-fold increase in binding affinity 
compared to CJL-1-80, but only a 7-fold increase in binding affinity compared to CJL-1-
14. Regardless, the increased binding affinity of the MUmBLs are consistent to that 
observed from synergistic bivalent binding modes. 1, 7, 25, 132, 230 
At the mMC3R, the MUmBL’s also resulted in an increased binding affinity 
compared to the monovalent ligand CJL-1-14 with IC50 values that are 130 to 480-fold 
lower (Table 5.3, Figure 5.8A). When comparing the MUmBL’s to the higher affinity 
tetrapeptide scaffold CJL-1-80 at the mMC3R, the MUmBL’s ligands had lower fold 
increases ranging from 3 to 8-fold. This supports the hypothesis that His-DNal(2’)-Arg-
Trp scaffold is functioning as a targeting moiety to bring the His-DPhe-Arg-Trp scaffold 
to the putative homodimer. Further evidence of the MUmBLs’ synergistic binding can be 
observed by comparing the mixture of CJL-1-14 and CJL-1-80 that represent the same 
amount of tetrapeptide scaffold as the MUmBL’s without being linked together. All the 
MUmBLs resulted in greater than 10-fold increased binding affinity as compared to the 
tetrapeptide monomeric CJL-1-14 and CJL-1-80 mixture. The tightest binding MUmBL, 
CJL-1-63, possessed a 40-fold increased binding affinity compared to the mixture of CJL-
1-14 and CJL-1-80 which supports the hypothesis of synergistic binding due to bivalent 
ligand design (Table 5.3, Figure 5.8A). 
At the mMC4R, the MUmBLs resulted in a 14- to 30-fold increased binding affinity 
compared to monovalent ligand CJL-1-14 (Table 5.3, Figure 5.8B). This supports that the 
His-DNal(2’)-Arg-Trp scaffold is acting as a “targeting” moiety to deliver the agonist 
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scaffold His-DPhe-Arg-Trp to the putative melanocortin homodimer. When the MUmBLs 
are compared to CJL-1-80, only ligand CJL-1-124 had an increase in binding affinity 
above the 3-fold inherent error of the assay. The reason why a substantial increase in 
binding affinity might not have been observed when compared to the Ac-His-DNal(2’)-
Arg-Trp-NH2 tetrapeptide is because CJL-1-80 is already a strong nanomolar binder and 
may mask further increases in binding affinity. This has been described by others utilizing 
high affinity scaffolds in bivalent and multivalent ligands.27, 122, 223 This type of masking 
was explained in more detail in Chapter 3 Section 3.3.3.2 as it was observed with a 
homobivalent ligand CJL-1-140 in which increased binding affinity was observed at the 
mMC1R and mMC3R, but not at the mMC4R.25  
Analysis of the binding data helps interpret the functional cAMP assay data at the 
mMC4R. Comparison of CJL-5-58 and CJL-1-124 in which the only difference is that the 
orientation of the tetrapeptide scaffolds are switched, but one is a full agonist and the other 
is a partial agonist in cAMP signaling in spite of similar binding affinities. In order to 
understand the difference between these two ligands, the effect of the site of attachment of 
the linker on the two different tetrapeptide scaffolds must be considered. Compound CJL-
5-58 can be thought of being comprised of CJL-5-35-4 with the linker attached to the C-
terminus of the His-DPhe-Arg-Trp scaffold and CJL-1-132 with linker attached to the N-
terminus of the His-DNal(2’)-Arg-Trp scaffold. Conversely, CJL-1-124 can be thought of 
as being comprised of CJL-1-116 and CJL-5-35-5 with the contrasting attachments of the 
linker to each scaffold (See structures in Table 5.1). 
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The linker control ligands, CJL-5-35-4 and CJL-1-132, for CJL-5-58 have 
comparable binding affinities to each other at the mMC4R (Figure 5.8C, Table 5.5). 
Compound CJL-1-132 possessed 4-fold increased binding affinity compared to CJL-5-
35-4. In comparison, the linker control ligands, CJL-1-116 and CJL-5-35-5, for CJL-1-
124 have notable differences in binding affinities. The IC50 value for CJL-5-35-5 is 27-
fold lower than the IC50 value for CJL-1-116 at the mMC4R (Figure 5.8D, Table 5.5). 
This suggests that CJL-5-35-5 is a tighter binder than CJL-1-116. It could be postulated 
that the differences in the balance (i.e. 4-fold difference compared to 27-fold difference) 
of the linker control ligands’ binding affinities within the bivalent ligands are responsible 
to the difference in the functional cAMP dose response curves. At higher concentrations of 
CJL-1-124, the compound may start competing against itself for receptor occupancy, such 
that the higher affinity side of the ligand [i.e. Ac-His-DNal(2’)-Arg-Trp-(PEDG20)] would 
be displacing the lower affinity side for binding (Figure 5.2D). This may result in a lack 
of binding of the agonist pharmacophore to the receptors and may cause the partial agonism 
to occur since more than 50% of the total receptors (the level necessary for full receptor 
cAMP signaling based on asymmetric homodimer hypothesis) will be bound by His-
DNal(2’)-Arg-Trp instead of by agonist. In contrast, compound CJL-5-58 has a much more 
balanced binding profile of the two sides (i.e. 4-fold difference in control ligands), and 
competition of the pharmacophores should not as readily favor one over the other. 
Therefore, it can be postulated that approximately equal binding of both tetrapeptides 
would occur, and that at 100% receptor occupancy approximately 50% of the receptors 
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would be occupied by the His-DPhe-Arg-Trp scaffold and 50% would be occupied by the 
His-DNal(2’)-Arg-Trp scaffold (Figure 5.2E-H). Then based on these assumptions and 
the hypothesis of asymmetric MC4R homodimer, no plateau would arise because 50% of 
the receptors would be occupied by the agonist His-DPhe-Arg-Trp scaffold which is all 
that is necessary to achieve full cAMP signaling (Figure 5.1C, Figure 5.5I and Figure 
5.5L).  
5.3.5 Ligand Dependent Modulation of BRET Signal  
Bioluminescence resonance energy transfer (BRET) has been routinely used to 
assess GPCR dimerization.304 Specifically, the MC3R and MC4R have been reported to 
result in high basal BRET signal supporting the formation of homodimers as discussed in 
Chapter 4.130, 132, 204, 205  Furthermore, BRET has been utilized to support the existence of 
hMC1R-hMC3R and mMC3R-mMC4R heterodimers. 132, 204 It has also been suggested 
that ligand treatment can increase or decrease GPCR dimerization which should be 
detectable with changes in BRET signal. 18, 213, 214, 305-308  However, these reports vary 
depending on the receptor system and ligands used.305 For example, agonist treatment at 
the somatostatin receptor 2 has been reported to cause the homodimers to dissociate into 
monomers.306 Whereas at the vasopressin V1a, agonist ligand had no observable effect on 
dimerization ratio.307 There are also several examples of bivalent ligand treatment resulting 
in increased BRET signal suggesting they are inducing or increasing dimerization. 18, 213, 
214, 308 In previous reports focused on melanocortin receptors, no significant effect of 
agonist or antagonist ligand was reported for the hMC1R, hMC3R, or hMC4R 
179 
 
homodimerization.130, 204  However, in the BRET study involving the hMC4R, there does 
appear to be a trend towards decreasing BRET signal after agonist dosing, albeit not 
significant. After dosing α-MSH at 1 µM the mean BRET signal decreased by 
approximately 20% compared to basal BRET signal of the hMC4R.130 Because of the 
potential of our compounds to be modulating the dimer or oligomer state or changing the 
dimer conformational state (Figure 5.5), we investigated the response of BRET signal from 
mMC4R homodimers in response to ligand treatment.  
Ligands α-MSH, CJL-1-14, and CJL-1-87, that have full agonist activity in both 
the cAMP signaling assay and the β-arrestin recruitment assay, resulted in a dose dependent 
decrease in BRET signal (Figure 5.10). Dosing these ligands at 10 µM resulted in a 
significant 15% reduction in BRET signal compared to basal signal. In contrast, ligands 
CJL-1-80 and CJL-1-140 contain only the antagonist tetrapeptide scaffold and have 
minimal functional agonist activity in both the cAMP signaling assay and the β-arrestin 
recruitment assay. These antagonist-based ligands resulted in no significant changes in 
BRET signal from basal levels. In addition, the equal mixture of agonist CJL-1-14 and 
antagonist CJL-1-80 resulted in no significant changes from basal signal.  The MUmBLs, 
CJL-1-124 and CJL-5-58, resulted in a significant effect in which dosing at 10 µM 
resulted in approximately an 8% reduction in BRET signal compared to basal signal 
(Figure 5.10). 
The reduction of BRET signal observed with agonist containing ligands could be 
the result of two different mechanisms: 1) The dimerization or oligomerization is being 
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disrupted and moving towards a lower oligomer state (e.g. dimers to monomers). 2) A 
conformational change is occurring within the intact dimer or higher-order oligomer in 
which the NanoLuc®-donor and the HaloTag®-acceptor are being orientated such that the 
BRET signal is being reduced (e.g. moving further away or dipole orientation is 
incorrect.)309 It is currently difficult to determine which of these two possibilities are the 
driving force for the BRET signal reduction observed in our studies. Regardless, it is 
apparent that some sort of conformational change is occurring that effects the BRET signal 
which relates with a ligand’s agonist activity both for cAMP and for β-arrestin recruitment. 
These changes match the proposed asymmetric signaling of MC4R homodimers (Figure 
5.1, Figure 5.5). It follows from the proposed model that at basal levels in which only 
assay buffer is added (Figure 5.5A), no conformational changes have occurred. With the 
addition of agonist ligand and the first binding event, cAMP signaling pathways are 
activated and a conformational change occurs that effects BRET signal (c.a. 7-8% change) 
(Figure 5.5B or E). This is observed with all ligands that contain an agonist scaffold 
including α-MSH, CJL-1-14, CJL-1-87, CJL-1-124, and CJL-5-58 (Figure 5.10). The 
second agonist binding event is hypothesized to result in an additional conformational 
change at the second receptor in the homodimer, and this is postulated to be responsible 
for the maximal observed decrease in BRET signal (c.a. 15%) (Figure 5.5F). This is 
observed with ligands α-MSH, CJL-1-14, and CJL-1-87 because they result in the second 
conformational change with in the homodimer due to a second agonist binding event on 
the second receptor. However, the second receptor in the homodimer pair is postulated to 
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be bound by an antagonist scaffold with ligands CJL-5-58 and CJL-1-124 (Figure 5.1C) 
and, therefore, the full conformational change to the homodimer does not occur (Figure 
3I) resulting in the lack of β-arrestin recruitment (Figure 2B-C) and the only 50% maximal 
change in BRET signal (i.e. 7-8% change instead of 15%) (Figure 5.10). 
Although further experimental work will be necessary to determine the exact dimer 
conformational changes that are occurring, the current studies support the hypothesis that 
the bias agonism observed currently with CJL-5-58 is the results of a conformational 
change of the dimeric state as correlate with the changes observed in the BRET signal. 
These conformational changes could be changes in the oligomeric number (e.g. dimers to 
monomers), orientation of the receptors within a dimer pair (e.g. which transmembrane 
helixes are interacting), or changes in the cellular location of the receptors (e.g. receptor 
internalization).10, 206, 207 Further elucidation of these mechanisms will be necessary. 
5.3.6 MUmBLs Effects on Energy Homeostasis in Mice 
The novel in vitro pharmacological profile of the MUmBLs warranted further 
evaluation in vivo to study their effects on energy homeostasis and physiological 
consequences. In particular, compound CJL-5-58 was selected due to its biased agonism 
at the hMC4R, consistent pharmacology in cAMP accumulation assays between the mouse 
and human isoforms, and the increased serum stability of a PEDG20 linker compared to a 
Pro-Gly linker (Figure 5.3).132 We selected to administer the compound 
intracerebroventricularly (ICV) directly into the lateral ventricle of the brain in order to 
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avoid the confounding effects of metabolism and brain delivery and to be consistent with 
previous work in the field.1, 25, 76, 107, 132, 189 
5.3.6.1 Preliminary Food Intake Studies of CJL-5-58 in Mice 
The initial dose response studies were performed in “conventional” standard mouse 
cages in which all measurements were taken manually. Compound CJL-5-58 resulted in 
no signs of adverse effects at doses of 2.5 nmols and 5.0 nmols in the conventional cage 
experiments. Compound CJL-5-58 resulted in a dose dependent decrease in food intake 
when refeeding was measured after a 22 hour fast. Significant decreases in food intake 
were observed at 2, 4, 6, and 8 hours after compound administration in male mice (Figure 
5.11A), and 2 and 4 hours in female mice (Figure 5.11B). Consistent with the decreased 
food intake, male mice receiving CJL-5-58 in the fasting refeeding paradigm did not return 
to their pre-fasting weights as quickly as the saline controls. A significant difference was 
observed in the change in weight of the male mice after compound administration at time 
points 2, 4, 6, 8, and 24 hours after compound administration (Figure 5.12A). Only the 2 
hour time point was significant in female mice (Figure 5.12B). 
Interestingly, no statistically significant effect on either food intake or body weight 
was observed with CJL-5-58 at a 5.0 nmol dose in a nocturnal free-feeding paradigm 
(Figure 5.13 and Figure 5.14). In the nocturnal feeding paradigm, mice have free access 
to food the entire course of the experiments, and compound is administered 2 hours before 
lights out.25, 132, 189 Since mice consume approximately 70% of their food during the dark 
cycle with their biggest meal being soon after lights out, this paradigm should measure the 
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effect on food intake with minimal disruption of homeostasis.218 However, in the fasting-
refeeding paradigm, mice are fasted from the start of the previous dark cycle until 2 hours 
before lights out. At which point mice were administered the compound and food was 
returned. This disrupts the normal homeostasis of the mice by putting them in a fasting 
state, but the fast creates a robust re-feeding response that can help to detect significant 
effects.132, 218 Specific to the melanocortin system, expression of endogenous antagonist 
AGRP is upregulated upon fasting.113, 239, 241  
In Chapter 4, we observed that agonist homobivalent ligand CJL-1-87 has a 
significantly greater effect in a fasting-refeeding paradigm than monovalent agonist CJL-
1-14, even though they have similar effects in a nocturnal feeding paradigm.132 This was 
hypothesized to be the result of either increased binding affinity of CJL-1-87 or due to 
specific interactions in vivo with melanocortin homo- or heterodimers, but the exact 
mechanism remains unclear.132 It can be hypothesized that the differences between 
paradigms observed is due to similar mechanisms as that proposed previously for CJL-1-
87. For example, CJL-5-58’s potent binding affinity (IC50 = 14 nM) may allow it to 
compete more effectively against endogenous ligands for binding. In the fasting paradigm, 
compound CJL-5-58 is directly competing with agouti-related peptide (AGRP) which is 
an endogenous MC3R/MC4R antagonist whose expression levels are upregulated during 
fasting.113, 239, 241  It, therefore, may be hypothesized that CJL-5-58 achieves its effects in 
the fasting state by blocking the orexigenic effects of AGRP, and not from melanocortin 
agonist action. Indeed, food intake after CJL-5-58 is consistent between the nocturnal 
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paradigm and the fasting paradigm suggesting that it maintains consistent feeding patterns 
regardless of endogenous homeostasis regulation. 
5.3.6.2 Effects of CJL-5-58 In Vivo 
In order to better characterize the effects of CJL-5-58 on energy homeostasis, it 
was decided to perform compound administration in TSE Phenotypic metabolic cages that 
are configured to automatically measure water intake, food intake, changes in the CO2 and 
O2 levels within the cages, and beam break activity. A new cohort of littermate age match 
male mice was cannulated and acclimated to the TSE metabolic cages for one week. 
Consistent with the conventional cage data, the administration of 5 nmols of CJL-5-58 
resulted in a decrease in food intake up to 12 hours after administration in the fasting 
paradigm (Figure 5.15A). Because no consistent long term effects (>24 hours) were 
observed at any parameters measured, the discussion will be focused on the first 24 hours, 
with the majority of effects observed within the first 12 hours. (For full time course, see 
Figure 5.16). A decrease in water intake was observed with 5 nmols of CJL-5-58 at time 
points 4, 6, 8, 10, and 12 hours after compound administration in the fasting paradigm 
(Figure 5.15C). This was not surprising since water intake correlates directly to food intake 
and is known to decline during fasting paradigms.218 It is, therefore, difficult in the current 
study to know if the decrease in water intake is a consequence of decreased food intake 
after CJL-5-58 administration or a direct pharmacological effect. As observed in the 
conventional cages, no significant effect was observed with the administration of CJL-5-
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58 in the nocturnal feeding paradigm (Figure 5.17A, Figure 5.18A). Also no difference in 
water intake was observed in the nocturnal paradigm (Figure 5.17C).  
As discussed in Chapter 4, melanocortin ligands have previously been reported to 
effect the respiratory exchange ratio (RER), with agonist compounds decreasing the RER, 
and antagonist compounds increasing the RER.112, 216, 242, 310 The RER can be measured 
indirectly utilizing TSE metabolic cage system by measuring the amount of CO2 and O2 
entering and exiting the sealed cages. A RER value of c.a. 0.7 gives an indication that fats 
are the primary fuel source that the animal is utilizing. 35,118,127,128 A RER value of c.a. 1.0 
gives an indication that carbohydrates are the primary fuel source the animal is utilizing.132, 
189, 244, 245 As expected, during the fast a baseline RER value of slightly above 0.7 was 
observed (Figure 5.15B, Figure 5.16B). This value has been reported previously in the 
literature,132, 246, 247  and is purportedly due to the lack of carbohydrates available for energy 
during a fast that results in a reliance of fat storage as the primary energy source. After 
saline treatment and the return of food, the RER value increases rapidly towards 1.0 as the 
mice consume food and the consumed carbohydrates become the primary fuel source 
through the first dark cycle. Administration of CJL-5-58 resulted in more gradual increase 
in RER from the 0.7 baseline value to 1.0. A significantly lower RER was observed for the 
first 9 hours and at 17 hours after compound CJL-5-58 administration compared to saline 
(Figure 5.16B). The lowered RER values support a hypothesis that in addition to eating 
less, the mice were burning more fats instead of carbohydrates. In the nocturnal feeding 
paradigm, compound administration resulted in significantly lowered RER values only 
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until 2 hours after administration supporting a hypothesis that the pharmacological effect 
of CJL-5-58 is amplified by fasting (Figure 5.17B, Figure 5.18B).  
Melanocortin ligands have been reported to effect the energy expenditure such that 
agonists increase the amount of calories burned as seen in Chapter 4, and antagonist 
decrease the amount of calories burned. 112, 216, 242, 310 In the fasting paradigm, the energy 
expenditure decreases rapidly during fasting which is consistent with the mice conserving 
energy (Figure 5.15D). The baseline energy expenditure is c.a. 12 kcal/h/kg prior to 
treatment. Following saline treatment and the reintroduction of food, energy expenditure 
increases rapidly in rate up to c.a. 17-19 kcal/h/kg. After the administration of the 5 nmol 
dose of CJL-5-58, energy expenditure also increases to c.a. 17-19 kcal/h/kg, however, the 
increase is more gradual and the energy expenditure remains significantly lower for the 
first 3 hours post-treatment. The mice’s rate of energy expenditure eventually recovered 
and an increased energy expenditure is observed 15, 17, and 21 hours after compound 
administration compared to saline (Figure 5.15D).  This is interesting, because all other 
parameters are consistent with CJL-5-58 functioning as an agonist in vivo, but CJL-5-58 
effects on energy expenditure is consistent with it functioning as an antagonist. The 
decrease in energy expenditure may be due to the robust decrease in food intake that keeps 
the mice in an energy conservative state.  
Another hypothesis for the lowered energy expenditure may be the biased signaling 
of CJL-5-58 for the cAMP signaling pathway over the β-arrestin recruitment pathway. It 
could be hypothesized that the β-arrestin pathway is responsible for classic agonist effect 
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to increase energy expenditure. Therefore, CJL-5-58, with minimal β-arrestin recruitment, 
results in a more gradual change in energy expenditure from baseline. However, further 
experimentation is necessary before hypothesis could be validated. In the nocturnal 
paradigm, an increase in energy expenditure was observed 5, 13, 15, and 16 hours after 
treatment which is consistent with agonist function (Figure 5.17D, Figure 5.18D).   
Of note some adverse reactions were observed during the TSE cage experiments 
that were not observed during the conventional cage experiments (Table 5.6). These 
adverse reactions began with the individual mouse putting its tail upright in the air then 
increased sporadic activity about 15-30 minutes post-compound administration. Then the 
mouse went through 10-15 second bouts of “barrel roll” type behavior. This behavior was 
repeated 2-3 times with approximately 4-5 minutes between bouts. At which point the 
mouse either died, or completely recovered. All mice were completely recovered within 
two hours (unless there was death). 
During the fasting paradigm, four adverse reactions were observed within 30 
minutes of injection, and one mouse died about 2 hours post-injection. During the nocturnal 
paradigm there was a total of 2 adverse reactions and one mouse died 30 minutes post-
administration. Mice experiencing adverse reactions recovered rapidly (<1 hr). Due to the 
lack of significant effects observed in the nocturnal paradigm group as well as in the 
ambulatory activity measurements in both paradigms (Figure 5.16, Figure 5.18), the 
adverse reactions observed do not seem to be having a significant effect on the parameters 
measured during the experiments. If the effects of the compound were due to toxicity, it 
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would be expected that the mice receiving compound in the nocturnal paradigm would be 
adversely effected as well, and decreases in food intake, RER, energy expenditure, and 
water intake would be observed after compound administration.  Furthermore, visceral 
illness and toxicity is usually accompanied by decreased activity, however no significant 
differences were observed in activity between saline and CJL-5-58 in the fasting paradigm 
in the TSE cages. In the nocturnal paradigm, an increase in activity was observed during 
the first 5 hours after administration which is inconsistent with toxic effects associated with 
a compound.  
5.3.6.3 Effects of Co-administration of CJL-1-14 and CJL-1-80 In Vivo 
 In order to help elucidate if the in vivo effects were due to the MUmBL design or 
were due to the co-treatment of an agonist and antagonist, co-administration experiments 
were performed in the same mice as the CJL-5-58 experiment with 5 nmols of CJL-1-14, 
Ac-His-DPhe-Arg-Trp-NH2, and 5 nmols of CJL-1-80, Ac-His-DNal(2’)-Arg-Trp-NH2, 
that would reconstitute the 10 nmols of tetrapeptide scaffolds administered with CJL-5-58 
at the 5 nmol dose. In the fasting paradigm and the nocturnal paradigm, no statistically 
significant effect on food intake or water intake were observed compared to saline within 
24 hours of administration expect for in the 2 hours timepoint in the nocturnal paradigm 
(Figure 5.15A and C, Figure 5.17A and C). There was a significant decrease in food intake 
2 hours post-administration compared to saline in the nocturnal paradigm, but no other 
time points were significant. These data are consistent with the hypothesis in the field that 
co-administration of an antagonist with an agonist cancels out the effects on food intake.56 
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No significant effect was observed in energy expenditure between saline and co-
administration of CJL-1-80 and CJL-1-14 in the fasting paradigm (Figure 5.15D, Figure 
5.16D). In the nocturnal paradigm, there was a significant effect on energy expenditure 
observed 19 hours after administration, but no other time point was significant (Figure 
5.17D, Figure 5.18).  The RER was significantly lower than saline in the fasting paradigm 
at the 1 hour and 4 hour time points (Figure 5.15B). The RER was also lower in the 
nocturnal paradigm at 1-4 hour time points (Figure 5.17B). 
 A direct comparison of CJL-5-58 to the co-administration of CJL-1-14 and CJL-
1-80 reveals some differences. There was significant differences in the food intake at 2 and 
4 hour time point in the fasting paradigm comparing CJL-5-58 to the tetrapeptide 
combination. There was significant differences in RER at the 2, 3, 6, and 7 hour time points 
in the fasting paradigm. Energy expenditure was also significantly higher for CJL-5-58 at 
the 13 and 17 hour time points in the fasting paradigm. In the nocturnal paradigm, no 
significant differences were observed for any parameter between the co-administration of 
the tetrapeptide combination and CJL-5-58.  
 The combination of CJL-1-14 and CJL-1-80 resulted more adverse observations 
than CJL-5-58. In the fasting paradigm, three mice died after compound administration. 
In the nocturnal paradigm, one mouse died. As with CJL-5-58, in the energy homeostasis 
parameters measured compound toxicity was not observed. If compound toxicity was 
suspect for the in vivo effects on energy homeostasis, it would be expected that decreases 
in food intake and water intake would be observed in both the fasting paradigm and the 
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nocturnal paradigm. Furthermore, ambulatory activity resulted in very little significant 
changes compared to saline. The only significant changes observed in ambulatory activity 
were at hours 18 and 19 post-administration. It would be expected in the case of compound 
toxicity, a more significant effect on activity would be observed. 
5.3.6.4 CJL-5-58 Administration into Melanocortin Knockout Mice 
 In order to more clearly understand the effects of the biased agonism at the MC4R, 
the effects of administration of CJL-5-58 was explored in MC3R knockout (KO) mice and 
MC4RKO mice. In male MC3RKO mice, a significant decrease in food intake was 
observed in the nocturnal feeding paradigm (Figure 5.19). Food intake was decreased at 
time points 2-12 hours after compound ICV administration at the 5 nmol. Furthermore, 
RER was significantly decreased at time points 1-5, 8 and 12 hours after compound 
administration. Also significant increased RER was observed 18, 19, and 24 hours after 2.5 
nmol compound administration. Finally, energy expenditure was significantly reduced at 
time points 1-3 hrs after 5 nmol administration compared to saline. After 2.5 nmol CJL-5-
58 administration, energy expenditure was significant reduced 1-8 and 13 hours post-
treatment. It must be taken into account that adverse reactions were also observed at the 
2.5 and 5 nmol concentrations which may be a confounding factor in interpretation of this 
data (Table 5.6). Adverse reactions included two mice dying after the 5 nmol dose. It 
should also be noted that although no significant reductions in activity were observed, the 
activity for CJL-5-58 at 5 nmols trended towards being lowered (p=0.069) and the error 
with the activity at 2.5 nmols is high. The large error in activity may serve as an indication 
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of toxicity. It is currently difficult to decipher whether the adverse reactions observed are 
due to paradigm effects, genotype difference, or compound toxicity. No adverse reactions 
were observed at the 1 nmol dose in the nocturnal paradigm, however, no significant effects 
were observed at the 1 nmol dose.  
The effects of CJL-5-58 on male MC3RKO mice in a fasting-refeeding paradigm 
were evaluated for comparison with wild type mice. However due to the adverse reactions 
observed with higher dosing in the nocturnal paradigm, the effects were only evaluated at 
0.5 and 1 nmols (Figure 5.20). Significant reduction in food intake was observed at 2 and 
4 hour time points after the 1.0 nmol CJL-5-58. Significant reductions in energy 
expenditure were observed in the fasting paradigm at time points 1 and 2 hours at the 1 
nmol dose. RER was significantly reduced at 2 and 3 hours after the 1 nmol administration 
of CJL-5-58. The only significant effect observed at 0.5 nmol dosing was a significant 
increase in RER at time point 24 hours. No other parameters were significantly affected by 
administration of 0.5 nmols of CJL-5-58. It should be noted that some minor signs of 
adverse reactions (such as tail going upright without barrel rolls) were observed with 
administration of CJL-5-58 at 1 nmol in the fasting paradigm that could confound these 
results (Table 5.6). 
In male MC4RKO mice, CJL-5-58 was administered at 5 nmols in both a nocturnal 
paradigm and a fasting-refeeding paradigm in standard conventional cages (Figure 5.21). 
The dose was well handled in the nocturnal paradigm, but minimal effect was observed. 
There was an immediate reduction in food intake 2 hours after compound administration. 
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There was also a significant increase in body weight 6 hours after compound 
administration. In the fasting-refeeding paradigm, administration of CJL-5-58 at 5 nmols 
resulted in decreased food intake at 2, 4, 6, 8 and 24 hours after compound administration 
with no effect on mouse body weight. Mice looked healthy in the nocturnal paradigm, 
however some signs of adverse reactions (such as tail going upright without barrel rolls) 
were observed in the fasting-refeeding paradigm (Table 5.6).  
Due to the observed adverse physiological effects that were observed in the 
different housing and different genotypes (Table 5.6), the exact in vivo pharmacology for 
MUmBL CJL-5-58 will need further elucidation. However, there are some key 
conclusions that may be drawn. First the adverse reactions seem to be acute and short-term 
(<1 h), suggesting that longer effects are due to the ligands on-target pharmacology. 
Second, the observed adverse reactions were increased during the fasting-refeeding 
paradigm, suggesting the adverse reactions are paradigm related and probably has a very 
specific pharmacological cause that remains to be identified. Third, the adverse behaviors 
appeared to be more notable in the MC3RKO mice, followed by the wild type mice, and 
minimal in the MC4RKO mice. This may suggest the melanocortin pathway may play a 
role, but experimental evidence would be necessary. 
 In Chapter 4, homobivalent ligand CJL-1-87, which differs from CJL-5-58 by 
substitution of one the DNal(2’) to DPhe, had no observable adverse reactions in similar 
mouse studies.31,32 Compound CJL-1-87 also had similar cAMP functional activity and 
binding affinity as CJL-5-58 (Table 5.3), and therefore,25, 132 it may be hypothesize that 
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the lack β-arrestin recruitment may be associated with the adverse reactions observed with 
CJL-5-58. It may be hypothesized that biased agonism of the cAMP pathway over the β-
arrestin recruitment results in amplification of toxicity known to melanocortin ligands such 
as their effects on the cardiovascular system.52 Experimental evidence of the cardiovascular 
effects and molecular probes which favor the β-arrestin over the cAMP pathway will be 
necessary to confirm this hypothesis, but are lacking in the field to date.  Although the 
current adverse effects are less than ideal in future drug design, they have been reported 
for full disclosure and good scientific practice. Further study in the effect of CJL-5-58 in 
vitro as well as methods of targeting homodimers will be necessary to determine how to 
properly exploit these the asymmetric signaling of homodimers to reduce side effects.  
5.3.6.5 Administration of CJL-1-124 to WT, MC3RKO, and MC4RKO Mice in 
Metabolic Cages 
 In order to study the effects of the orientation of the tetrapeptide scaffolds at the N-
terminus and the C-terminus in vivo, CJL-1-124 was administered to wild type, MC3RKO, 
and MC4RKO mice and parameters about their energy homeostasis was recorded using 
TSE phenotypic metabolic cages. In preliminary conventional cages experiments, strong 
adverse effects as described above were observed after compound administration in the 
fasting paradigm, therefore only the nocturnal paradigm was performed. No significant 
effect on male wild type mice was observed in the nocturnal paradigm at either the 2.5 
nmol or 5 nmol dose of CJL-1-124 compared to saline on food intake, water intake, or 
activity (Figure 5.22). Compound CJL-1-124 did appear to cause a dose dependent 
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decrease in RER at the first 2 hours after compound administration. Energy expenditure 
appeared to be lowered by both the 2.5 nmol and the 5 nmol dose of CJL-1-124 for the 
first 3 hours after administration compared to saline. Furthermore, it was observed that the 
2.5 nmol dose of CJL-1-124 significantly increased the energy expenditure 15, 18, 20, and 
24 hours post compound administration compared to saline. There were some signs of 
adverse reactions observed at higher 5 nmol dose in the wild type nocturnal paradigm. 
 The administration of 2.5 nmols or 5.0 nmols CJL-1-124 to male MC3RKO mice 
resulted in no significant changes in food intake or water intake (Figure 5.23). Energy 
expenditure was significantly reduced 1-6 hours after administration of 5.0 nmols of CJL-
1-124. A significant increase in energy expenditure was observed 15 hours after compound 
administration. A significant reduction in energy expenditure was observed 1 and 2 hours 
after administration of 2.5 nmols of CJL-1-124, and a significant increase at 19 hours after 
compound administration. The RER was significantly increased from 15-21 and 24 hours 
after administration of 5 nmols of CJL-1-124. The RER of was significantly increased 
from 16-17, 19, 22, and 24 hours after administration of 2.5 nmols of CJL-1-124. The 
activity was significantly increased at 15 hours after 5 nmols of CJL-1-124, otherwise no 
significant changes were observed in the male MC3RKO mice. The administration of CJL-
1-124 to MC4RKO mice resulted in minimal significant change in food intake or body 
weight. The only significant change was the increase in food intake observed 2 hours after 
administration of 2.5 nmol CJL-1-124 (Figure 5.24). It should again be noted that some 
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signs of toxicity were observed in the MC3RKO and the MC4RKO mice including animal 
death after administration 
5.4 Conclusions 
There is a growing amount of evidence that GPCR homodimers are functionally 
relevant and are possible pharmaceutical targets. A broadly applicable drug design strategy 
that targets homodimers, as opposed to monomeric receptors, would theoretically double 
the amount GPCR drug targets. Although various labs have presented different techniques 
and proof of concepts for methods to target asymmetrically signaling GPCR 
homodimers,231, 273-286 these techniques would be difficult to adapt to therapeutic design 
and in vivo applications. The current report presents a design strategy that targets 
asymmetric homodimers that should be easily amendable to various GPCR systems and in 
vivo targeting applications.  
In the current report, we designed bivalent ligands that contained an agonist 
tetrapeptide scaffold and antagonist tetrapeptide scaffold for the MC4R. The MUmBL 
design strategy aims at occupying each of the two receptors within the homodimer with a 
different pharmacophore such that an agonist pharmacophore and an antagonist 
pharmacophore each occupy one of the two receptors within each homodimer. This design 
strategy produced biased ligands at the hMC4R in which the cAMP signaling pathway was 
robustly activated at nanomolar concentrations (EC50 ~ 2 to 6 nM) but the β-arrestin 
pathway was only partially activated at a concentration of 10 µM. To our knowledge, these 
are the first melanocortin biased ligands favoring cAMP signaling over β-arrestin 
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recruitment and will be valuable chemical probes to study melanocortin signaling in the 
disease states and disorders in which the melanocortin receptors are implicated including: 
cancer,6, 28, 63, 156, 158 skin pigmentation disorders,117 social disorders,67, 68 sexual function 
disorders,66, 114, 116 Alzheimer’s disease,61, 62 cachexia69, 70, 72, 73, and obesity.25, 56, 76, 107  
We then functionally characterize the MUmBLs at the mouse melanocortin 
receptors. Two of the compounds showed species difference in which a partial agonist dose 
response curve was observed at the mMC4R. Furthermore, the partial agonist curve was 
present when assaying an equal mixture of the individual tetrapeptide pharmacophore 
scaffolds, and therefore, is not a result of the BUmBL design strategy. This identified CJL-
5-58 as the lead ligand for in vivo evaluation due to its biased agonism at the hMC4R, 
consistent pharmacology in cAMP signaling assays between the mouse and human 
receptors, and the increased serum stability of a PEDG20 linker compared to a Pro-Gly 
linker.132 
The evaluation of CJL-5-58 in mice identified that it decreased food intake, water 
intake, and RER values in a fasting paradigm which is consistent with it functioning as an 
agonist in the cAMP signaling in vitro assays. However, the ligand did result in a decreased 
energy expenditure which is more consistent with it functioning as an antagonist like that 
seen in its β-arrestin recruitment assay results. There were significant differences observed 
between the administration of bivalent CJL-5-58 compared with the administration of an 
equal mixture of the tetrapeptide pharmacophores ligands, CJL-1-14 and CJL-1-80, 
suggesting that the bivalent design strategy is at least partially responsible for the in vivo 
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effects. This suggests we are indeed targeting asymmetric homodimers in vivo, although 
further experimental evidence would be necessary to confirm these results. 
Some adverse reactions were observed in the current mouse studies with the 
administration of both CJL-5-58 and the co-administration of CJL-1-14 and CJL-1-80. 
Although these adverse reactions did not appear to effect the parameters measured (i.e. 
activity, food intake, water intake, RER, and energy expenditure), the adverse reactions 
cannot be ignored and have been reported for full disclosure and good scientific practices. 
Historically, one of the most detrimental side effects of melanocortin agonist ligands is 
their ability to increase blood pressure and heart rate that is thought to be mediated through 
MC4R neuronal pathways.52, 311 It could be conceived that by reducing β-arrestin 
dependent desensitization, we are increasing the MC4R acute cardiovascular effects 
resulting in short-term (<60 minutes) adverse effects, but with minimal effects on our 
longer parameter measurements (≥60 minutes). This might be an indication that the 
opposite type of biased ligand in which the β-arrestin recruitment pathway is selectively 
activated over the cAMP pathway would be preferable. Further elucidation in the 
pharmacology of biased melanocortin ligands will be necessary, but the current report 
provides the field with the first-in-class biased ligand that favors the cAMP pathway over 
the β-arrestin pathway.  
Furthermore, the UmBL methodology presented currently should be applicable to 
various other GPCRs and can easily accommodate the plethora of well-studied and 
developed selective agonists and antagonists for various GPCR systems. This bivalent 
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ligand targeting method should allow for biased ligands or unique pharmacologies at 
various receptors by combining known agonists and antagonists with an effective linker. 
Considering the wide array of GPCRs that are already reported to exist as allosterically 
modulated or asymmetric homodimers (including the vasopressin,287 dopamine,231 
adenosine,286 metabotropic glutamate,279 and serotonin receptors273) this strategy should be 
broadly applicable. In order to effectively synthesize UmBLs for other receptor systems, it 
will be necessary to perform some standard medicinal chemistry to optimize the connection 
points of the linker to the pharmacophores, optimize the linker properties, and optimize the 
orientation of the pharmacophores. In the current study, it was important to have a balance 
in the binding affinity of the agonist side of the UmBL and the antagonist side of the 
UmBL. The unbalance ligand, CJL-1-124, did not appear to give a significant difference 
as compared to unlinked pharmacophores most likely due to competition of the stronger 
binding side of the UmBL.  
The exact pharmacology achieved through the UmBLs design strategy will be as 
diverse as the allosteric mechanisms between different GPCR homodimers. For example, 
based on the results of Han and coworkers it can be hypothesized that UmBLs targeting 
the dopamine D2 receptor would result in increased receptor activation beyond just 
monovalent agonist alone. This is because allosteric cross-talk of a second agonist 
protomer was shown to blunt activation, so the occupation of the second protomer with an 
antagonist instead of an agonist should increase signal activation.231 In contrast if the 
UmBL approach was applied to the metabotropic glutamate receptor, it would be 
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hypothesized to result in lower than full receptor activation of agonist alone as Kniazeff 
and coworkers observed that one agonist can partially activate a dimeric unit but two 
agonists are required for full activation.279 Finally, it has been reported that the vasopressin 
V1b receptor signals through both the Gq/11-inositol phosphate (IP) and the cAMP 
pathways.287 It was hypothesized by Orcel and coworkers in 2009 that “the IP pathway 
could be activated by the binding of either one or two AVP molecules to a single receptor 
dimer… By contrast, cAMP production could only be turned on upon the binding of two 
ligands to a dimer.” Their observations and hypothesis is consistent with asymmetric 
homodimers such that the IP pathway is activated by the first agonist binding event and the 
cAMP pathway is activated second agonist binding event (similar to Figure 5.1).287 
Therefore, if the UmBL design strategy was applied to ligands targeting the vasopressin 
V1b receptor, it would be predicted to result in biased ligands in which the agonist 
pharmacophore would activate the IP pathway, and the antagonist pharmacophore would 
block the cAMP pathway activation within the homodimer. The UmBL design approach 
could also be applied to GPCR systems in which asymmetry between homodimers has not 
been identified, or even systems in which homodimerization has not yet been observed. In 
these situations, designed UmBLs could be evaluated for their ability to induce signaling 
in multiple signaling pathways (e.g. cAMP, Ca+, kinase signaling, β-arrestin signaling, 
ect.), in order to identify asymmetrically signaling GPCR homodimers.  
In conclusion, the UmBL design approach reported herein has been used to progress 
the melanocortin field by suppling the first known biased ligands for cAMP pathway over 
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β-arrestin recruitment pathway. This chapter also provided functional pharmacological 
evidence of asymmetric homodimerization that complements previous BRET studies 
supporting homodimerization,132, 204 radioligand binding studies suggesting asymmetry of 
melanocortin homodimers propensity to bind ligands,205, 219 and functional reports 
demonstrating the significance of melanocortin oligiomerization.206, 207 In a much broader 
sense, the UmBL approach provides a medicinal chemistry design strategy for the future 
advancement of GPCR pharmacology that can be applied to various receptor systems.  
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Figure 5.1. Hypothesized interaction of ligands with asymmetrically signaling 
melanocortin homodimers. A) Monovalent agonist ligands (blue circle) could occupy both 
receptors and result in both cAMP signaling and β-arrestin recruitment. B) Agonist 
homobivalent ligands (blue circle connected with black linker) could result in similar 
functional cAMP assays as monomeric ligands in spite of increased binding affinities due 
to asymmetric signaling. C) Working paradigm herein in which biased unmatched bivalent 
ligands (BUmBLs) containing an agonist pharmacophore (blue circle) and antagonist 
pharmacophore (red octagon) are postulated to result in biased signaling by agonizing one 
signaling pathway while antagonizing the other pathway when bound to the asymmetrical 
homodimer.  
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Figure 5.2. Different possible binding states of a MUmBL. The MUmBL can bind to a 
monomer with either the agonist scaffold (A) or the antagonist scaffold (B). The MUmBL 
can bind to a dimer in a monomeric fashion (C-F) or a bivalent fashion (G-H). Finally 
higher-order oligomers may exist in which the MUmBLs can bind in a bivalent fashion (I), 
a monomeric fashion (J), or some combination of both. It is postulated that some 
combination of all these states exist, however, bivalent binding to dimers or higher-order 
oligomers should be favored due to the synergist binding mode of bivalent ligands that was 
supported in Chapter 3.25  
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Figure 5.3. In vitro mouse serum stability assay to aid in the design of the MUmBLs. 
Ligands (10 μM) were incubated in mouse serum and monitored for degradation of the 
parent molecule by LC-ESI+-MS/ MS. Results from α-MSH, CJL-1-87, and CJL-1-14 
were within error of previously reported results in Chapter 4.132 MUmBL/BUmBL CJL-
5-58 had a similar metabolic stability in two technical replicates as CJL-1-87 suggesting 
adequate metabolic stability for in vivo evaluation. The signal intensity at time point 0 h 
was arbitrarily set as 100% and the percent of intact peptide at each time point was used to 
calculare the relative amount intact. For full methods see Chapter 2.132  
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Figure 5.4. Illustrations of the in vitro functional pharmacology at the hMC4R of 
MUmBLs, A) The cAMP signaling potency was determined by AlphaScreen® assays. B 
and C) The β-arrestin recruitment potency was determined by PRESTO-Tango assays.202 
The * symbol represents the two monovalent tetrapeptides Ac-His-DPhe-Arg-Trp-NH2 and 
Ac-His-DNal(2’)-Arg-Trp-NH2 assayed together each at the indicated M concentration 
such that pharmacophore concentration is the same as the bivalent pharmacophore 
concentration. Functional cAMP data was normalized as discussed in experimental section 
to show tradition dose response curve with increasing response at increasing agonist 
concentration.  
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Figure 5.5. Illustrations of a previously reported model for allosteric interactions in GPCR 
dimers. (Durroux 2005, Casdao 2007).301, 302 In this model, GPCRs oscillate through 
different conformational states. Different conformations have different propensity to signal 
through cAMP or through β-arrestin. Signaling is represented by green arrows (B, C, E, F, 
H, I, L). Conformational changes are represented based on receptor highlighting (B, C, D, 
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E, F, H, I, L). The binding of an agonist pharmacophore to one receptor that signals 
through cAMP stabilizes the second receptor’s conformation to increases its propensity to 
signal through the β-arrestin recruitment pathway (State E). Therefore, the second agonist 
binding event results in β-arrestin recruitment (State F). The BUmBL design strategy can 
be used to block the β-arrestin recruitment by increasing the likelihood of an antagonist 
pharmacophore binding the second receptor in the homodimer (States G-I). Even in if the 
opposite binding order occurs, the antagonist blocks β-arrestin recruitment since it is 
already bound to the receptor after the agonist induces a conformational change (States J-
L). This models assumes that the receptors are in GPCR dimers, but they are likely in an 
equilibrium as monomers and higher order oligomers.214, 301, 302 This models also assumes 
that the bivalent synergistic binding mode is favored with MUmBLs due to the decreased 
entropic cost of binding of the second pharmacophore.25 It is possible that MUmBLs 
compete in monovalent fashion (Figure 5.2), but then the increased binding affinity 
observed below would not be expected. 
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Figure 5.6. Illustrations of the in vitro functional pharmacology of the MUmBLs at the 
mMC1R, mMC3R, mMC4R, and mMC5R expressed in HEK293 cells. The cAMP 
signaling potency was determined by AlphaScreen® assays. The reported errors are the 
standard error of the mean (SEM) determined from at least three independent experiments. 
Functional cAMP data was normalized as discussed in experimental section to show 
tradition dose response curve with increasing response at increasing agonist concentration. 
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Figure 5.7. The functional dose response curve of CJL-1-124 ( ) may increase the 
therapeutic window versus traditional dose response curves ( ). For example, if the ligand 
is effective at 40% receptor activation, but has side effects above 60 % receptor activation, 
the ligand with the traditional curve can only be given at doses between ~10 nM to 25 nM 
to be active without side effects. Ligand CJL-1-124 can be given at doses between ~50 
nM to 5,000 nM to be active without side effects. However, this is speculative and would 
need to be confirmed experimentally. 
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Figure 5.8: Illustrations of the competitive binding experiments against 125I-NDP-MSH at 
the mMC3R and mMC4R. Top panels: MUmBL ligands compared to monovalent 
tetrapeptide ligands separately and in a mixture at the mMC3R (A) and mMC4R (B). 
Bottom panels: Comparing the linker control ligands CJL-1-116 and CJL-5-35-5 that 
comprise MUmBL CJL-1-124 (D), there is a notable difference in binding affinity (27-
fold difference). However, linker control ligands CJL-5-35-4 and CJL-1-132 that 
comprise MUmBL CJL-5-58, are much more balanced with only a 4-fold difference (C). 
Data is shown as mean ± SEM of at least two independent experiments.  
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Figure 5.9: Illustrations of the 125I-NDP-MSH competitive binding experiments with 
MUmBLs compared to monovalent tetrapeptide ligands separately and in a mixture at the 
mMC1R. For IC50 values see Table 2 or Supplemental Table 2.  
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Figure 5.10. Ligand induced response of bioluminescence resonance energy transfer 
(BRET) signal at the mMC4R-NanoLuc and MC4R-HaloTag homodimer. Maximal BRET 
signal (100%) was defined as the signal measured when assay buffer (A) was added. Each 
ligand was dosed at 10-5, 10-7 and 10-9 M. Significance was determined using a one-way 
ANOVA to determine overall significance upon treatment followed by a Bonferroni post-
hoc test to compare each ligand concentration to assay buffer control (A). * p<0.05, ** 
p=0.01, *** p<0.001. Data shown as the mean ± standard error of the mean (SEM) 
determined from three independent experiments. 
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Figure 5.11. The dose response effect of CJL-5-58 administered ICV on cumulative food 
intake in male and female wild type mice utilizing a fasting refeeding paradigm. The 
littermate age matched mice were fasted for 22 hours prior to treatment and the 
reintroduction of food. Data is shown as mean ± SEM. Data was analyzed using the SPSS 
(v23, IBM) using a multivariate general linear model followed by a Bonferroni’s post hoc 
test. *p<0.05, ** p=0.01, *** p<0.001 for CJL-5-58 compared to saline. For body weight 
information see Figure 5.12. 
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Figure 5.12. The dose response effect of CJL-5-58 administered ICV on change in body 
weight in male and female wild type mice utilizing a fasting refeeding paradigm. Data is 
shown as mean ± SEM. Data was analyzed using the SPSS (v23, IBM). *p<0.05, ** 
p=0.01, *** p<0.001 for CJL-5-58 compared to saline. For food intake information see 
Figure 5.11. 
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Figure 5.13. The effect of CJL-5-58 administered ICV on cumulative food intake in male 
and female wild type mice utilizing nocturnal feeding paradigm. Satiated mice were treated 
2 hours prior to lights out. Data is shown as mean ± SEM. Data was analyzed using the 
SPSS (v23, IBM) using a multivariate general linear model followed by a Bonferroni’s 
post hoc test.. *p<0.05, ** p=0.01, *** p<0.001 for CJL-5-58 compared to saline. 
  
215 
 
 
Figure 5.14 The effect of CJL-5-58 administered ICV on change in body weight (g) in 
male and female wild type mice utilizing nocturnal feeding paradigm. Data is shown as 
mean ± SEM. Data was analyzed using the SPSS (v23, IBM). *p<0.05, ** p=0.01, *** 
p<0.001 for CJL-5-58 compared to saline. 
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Figure 5.15. TSE metabolic cage parameters after ICV administration of 5 nmols of CJL-
5-58, or a combination of 5 nmols CJL-1-14 and 5 nmols CJL-1-80 (10 nmols total 
combined peptide) to male wild type mice in a fasting-refeeding paradigm. The littermate 
age matched mice were fasted for 22 hours. Data is shown as mean ± SEM. Data was 
analyzed using the SPSS (v23, IBM) using a multivariate general linear model followed by 
a Bonferroni’s post hoc test. *p<0.05, ** p=0.01, *** p<0.001 for CJL-5-58 compared to 
saline. %p<0.05, %% p=0.01, %%% p<0.001 for saline compared to co-administration of 
CJL-1-14 and CJL-1-80.   +p<0.05, ++ p=0.01, +++ p<0.001 for CJL-5-58 compared to 
co-administration of CJL-1-14 and CJL-1-80.  For all parameters from -18 to 24 hours, 
see Figure 5.16. 
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Figure 5.16 TSE metabolic cage parameters after ICV administration of 5 nmols of CJL-
5-58, or a combination of CJL-1-14 and CJL-1-80 (10 nmols total peptide) to male wild 
type mice in a fasting refeeding paradigm. The littermate age matched mice were fasted 
for 22 hours. Data is shown as mean ± SEM. Data was analyzed using the SPSS (v23, 
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IBM). *p<0.05, ** p=0.01, *** p<0.001 for CJL-5-58 compared to saline. %p<0.05, %% 
p=0.01, %%% p<0.001 for saline compared to co-administration of CJL-1-14 and CJL-
1-80.   +p<0.05, ++ p=0.01, +++ p<0.001 for CJL-5-58 compared to co-administration of 
CJL-1-14 and CJL-1-80.   
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Figure 5.17. TSE metabolic cage parameters after ICV administration of 5 nmols of CJL-
5-58, or a combination of CJL-1-14 and CJL-1-80 (10 nmols total peptide) to male wild 
type mice in a nocturnal feeding paradigm (no fasting). Satiated mice were treated 2 hours 
prior to lights out. Data is shown as mean ± SEM. Data was analyzed using the SPSS (v23, 
IBM) using a multivariate general linear model followed by a Bonferroni’s post hoc test. 
*p<0.05, ** p=0.01, *** p<0.001 for CJL-5-58 compared to saline. %p<0.05, %% p=0.01, 
%%% p<0.001 for saline compared to co-administration of CJL-1-14 and CJL-1-80.   For 
all parameters from 0 to 24 hours, see Figure 5.18.  
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Figure 5.18: TSE metabolic cage parameters after ICV administration of 5 nmols of CJL-
5-58, or a combination of CJL-1-14 and CJL-1-80 (10 nmols total peptide) to male wild 
type mice in a nocturnal feeding paradigm. Data is shown as mean ± SEM. Data was 
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analyzed using the SPSS (v23, IBM). *p<0.05, ** p=0.01, *** p<0.001 for CJL-5-58 
compared to saline. %p<0.05, %% p=0.01, %%% p<0.001 for saline compared to co-
administration of CJL-1-14 and CJL-1-80.   +p<0.05, ++ p=0.01, +++ p<0.001 for CJL-
5-58 compared to co-administration of CJL-1-14 and CJL-1-80.   
222 
 
 
Figure 5.19. TSE metabolic cage parameters after ICV administration of 5.0, 2.5, or 1.0 
nmols of CJL-5-58 to male MC3RKO mice in a nocturnal feeding paradigm. Data is shown 
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as mean ± SEM. Data was analyzed using the SPSS (v23, IBM). *p<0.05, ** p=0.01, *** 
p<0.001 for saline compared to 5 nmols CJL-5-58. +p<0.05, ++ p=0.01, +++ p<0.001 for 
saline compared 2.5 nmol CJL-5-58. Note: Some toxicity was observed that may confound 
these results. (See main text.) 
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Figure 5.20. TSE metabolic cage parameters after ICV administration of 1.0 or 0.5 nmols 
of CJL-5-58 to male MC3RKO mice in a fasting-refeeding paradigm. Data is shown as 
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mean ± SEM. Data was analyzed using the SPSS (v23, IBM). *p<0.05, ** p=0.01, *** 
p<0.001 for saline compared to 1.0 nmols CJL-5-58. +p<0.05, ++ p=0.01, +++ p<0.001 
for saline compared 0.5 nmol CJL-5-58. Note: Some toxicity was observed that may 
confound these results. (See main text.) 
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Figure 5.21. The effect of CJL-5-58 (5 nmols) administered ICV on cumulative food 
intake and body weight in male MC4RKO mice utilizing nocturnal feeding and fasting-
refeeding paradigm in conventional cages. Data is shown as mean ± SEM. Data was 
analyzed using the SPSS (v23, IBM). *p<0.05, ** p=0.01, *** p<0.001 for 5 nmol CJL-
5-58 compared to saline. Note: Some toxicity was observed that may confound these 
results. (See main text.)
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Figure 5.22. TSE metabolic cage parameters after ICV administration of 5.0 or 2.5 nmols 
of CJL-1-124 to male wild type mice in a nocturnal feeding paradigm. Data is shown as 
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mean ± SEM. Data was analyzed using the SPSS (v23, IBM). *p<0.05, ** p=0.01, *** 
p<0.001 for saline compared to 5 nmols CJL-5-58. %p<0.05, %% p=0.01, %%% p<0.001 
for saline compared 2.5 nmol CJL-5-58. Note: Some toxicity was observed that may 
confound these results. (See main text.)  
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Figure 5.23. TSE metabolic cage parameters after ICV administration of 5.0 or 2.5 nmols 
of CJL-1-124 to male MC3RKO mice in a nocturnal feeding paradigm. Data is shown as 
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mean ± SEM. Data was analyzed using the SPSS (v23, IBM). *p<0.05, ** p=0.01, *** 
p<0.001 for saline compared to 5 nmols CJL-5-58. %p<0.05, %% p=0.01, %%% p<0.001 
for saline compared 2.5 nmol CJL-5-58. Note: Some toxicity was observed that may 
confound these results. (See main text.) 
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Figure 5.24. The effect of CJL-1-124 (5.0 and 2.5 nmols) administered ICV on cumulative 
food intake and body weight in male MC4RKO mice utilizing nocturnal feeding paradigm 
in conventional cages. Data is shown as mean ± SEM. Data was analyzed using the SPSS 
(v23, IBM). %p<0.05 for 2.5 nmol CJL-5-58 compared to saline. Note: Some toxicity was 
observed that may confound these results. (See main text.) 
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  cAMP 
Signaling 
β-Arrestin 
Recruitment 
Compound Structure EC50 (nM) EC50 (nM) 
  Mean±SEM Mean±SEM 
NDP-MSH Ac-Ser-Tyr-Ser-Nle-Glu-His-DPhe-Arg-Trp-Gly-Lys-Pro-Val-
NH2 
0.06±0.01 120±50 
MTII Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2 0.03±0.005 1.6±0.8 
CJL-1-14 Ac-His-DPhe-Arg-Trp-NH2 1.8±0.2 290±150 
CJL-5-35-4 Ac-His-DPhe-Arg-Trp-(PEDG20)-NH2 0.67±0.03 55±16 
CJL-1-116 (PEDG20)-His-DPhe-Arg-Trp-NH2 2.0±0.3 140±70 
CJL5-35-1 Ac-His-DPhe-Arg-Trp-(Pro-Gly)6-NH2 5.5±0.7 1600±600 
CJL-1-41 (Pro-Gly)6-His-DPhe-Arg-Trp-NH2  1.1±0.07 1500±500 
CJL-1-31 Ac-His-DPhe-Arg-Trp-(Pro-Gly)6-His-DPhe-Arg-Trp-NH2  0.95±0.08 1900±600 
CJL-1-87 Ac-His-DPhe-Arg-Trp-(PEDG20)-His-DPhe-Arg-Trp-NH2 0.57±0.05 130±30 
CJL-5-72 Ac-His-DPhe-Arg-Trp-(PEDG20)-(PEDG20)-His-DPhe-Arg-
Trp-NH2 
1.2±0.3 280±40 
CJL-1-80 Ac-His-DNal(2')-Arg-Trp-NH2 50% at 10 µM 30% at 10 µM 
CJL5-35-5 Ac-His-DNal(2')-Arg-Trp-(PEDG20)-NH2 55% at 10 µM 15% at 10 µM 
CJL-1-132 (PEDG20)-His-DNal(2')-Arg-Trp-NH2 50% at 10 µM 20% at 10 µM 
CJL-5-35-2 Ac-His-DNal(2')-Arg-Trp-(Pro-Gly)6-NH2 55% at 10 µM 30% at 10 µM 
CJL-1-140 Ac-His-DNal(2’)-Arg-Trp-(PEDG20)-His-DNal(2')-Arg-Trp-
NH2 
70% at 10 µM 10% at 10 µM 
CJL-1-63 Ac-His-DNal(2')-Arg-Trp-(Pro-Gly)6-His-DPhe-Arg-Trp-NH2 1.9±0.2 55% at 10 µM 
CJL-5-58 Ac-His-DPhe-Arg-Trp-(PEDG20)-His-DNal(2')-Arg-Trp-NH2 1.9±0.5 45% at 10 µM 
CJL-1-124 Ac-His-DNal(2')-Arg-Trp-(PEDG20)-His-DPhe-Arg-Trp-NH2 4.7±1.0 20% at 10 µM 
CJL-5-74 Ac-His-DNal(2')-Arg-Trp-(PEDG20)-(PEDG20)-His-DPhe-
Arg-Trp-NH2 
5.9±3.2 25% at 10 µM 
CJL-1-14+ 
CJL-1-80 
Ac-His-DPhe-Arg-Trp-NH2 and Ac-His-DNal(2')-Arg-Trp-NH2 1.9±0.2 40% at 10 µM 
Table 5.1: Functional data at the hMC4R. The cAMP signaling potency was determined 
by AlphaScreen™ assays. The β-arrestin recruitment potency was determined by 
PRESTO-Tango assays.202 The reported errors are the standard error of the mean (SEM) 
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determined from at least three independent experiments. Changes less than 3-fold were 
considered to be within the inherent experimental assay error. The % symbol represents 
amount of maximal signal observed at 10 µM compared to control NDP-MSH maximal 
signal. 
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  HPLC k' HPLC k' Mass Mass Purity 
Comp. Structure (Syst. 1) (Syst. 2) (calcd.) (obs.) % 
CJL-5-35-2 Ac-His-DNal(2')-Arg-Trp-(Pro-Gly)6-NH2 5.3 9.7 1660.9 1660.0 >96% 
CJL-1-63 Ac-His-DNal(2')-Arg-Trp-(Pro-Gly)6-His-DPhe-Arg-Trp-NH2 5.3 8.6 2287.6 2287.3 >95% 
CJL-5-58 Ac-His-DPhe-Arg-Trp-(PEDG20)-His-DNal(2')-Arg-Trp-NH2 5.4 9.7 1680.9 1680.6 >95% 
CJL-1-124 Ac-His-DNal(2')-Arg-Trp-(PEDG20)-His-DPhe-Arg-Trp-NH2 6.0 9.5 1680.9 1681.0 >97% 
CJL-5-74 Ac-His-DNal(2')-Arg-Trp-(PEDG20)-(PEDG20)-His-DPhe-Arg-Trp-NH2 5.7 10.2 1999.3 1999.2 >95% 
Table 5.2. The analytical data for peptides synthesized currently. HPLC k' = (peptide retention time - solvent retention time) / solvent 
retention time. System 1 is a 10% to 90% gradient of acetonitrile in water containing 0.1% trifluoroacetic acid over 35 minutes at a flow 
rate of 1.5 mL/min, and system 2 is the same but with methanol replacing acetonitrile. Product purity was determined by HPLC purity 
in the solvent system which showed the least purity and integrating the area under the curves of the chromatograms collected at 214 nm. 
Mass observed was calculated from the M+1 or (M+2)/2 peak.
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 mMC1R mMC3R mMC4R mMC5R 
Comp. ID cAMP   
EC50 (nM) 
Binding  
IC50 (nM) 
cAMP    
EC50 (nM) 
Binding  
IC50 (nM) 
cAMP         
EC50 
(nM) 
Binding  
IC50 (nM) 
cAMP  
EC50 (nM) 
 Mean± 
SEM 
Mean± 
SEM 
Mean± 
SEM 
Mean± 
SEM 
Mean± 
SEM 
Mean± 
SEM 
Mean± 
SEM 
CJL-1-14a 14.1±2.6 390±50 55.5±12.2 60% @100 
µM 
13.7±1.9 210±60 9.8±2.7 
CJL-1-31a 4.4±0.6 27.5±2.2 20.2±4.0 3300±800 9.2±1.0 33.3±5.1 3.8±0.9 
CJL-1-87a 6.4±1.5 68.6±5.3 10.1±2.5 3500±500 3.6±0.5 9.9±2.9 3.1±0.6 
CJL-5-72a 12.6±3.8 130±20 22.7±3.7 10200±1300 7.3±2.1 53.8±14.1 4.0±0.2 
CJL-1-80a 98.4±32.2 1630±120 15% at 10 
µM 
1400±200 15% at 
10 µM 
26.0±3.4 50% at 10 
µM 
CJL1-140a 560±140 430±40 60% at 10 
µM 
350±80 45% at 
10 µM 
10.4±0.03 790±190 
CJL-1-63 16.1±3.5 57.3±10.5 14.9±5.7 170±40 13.0±1.6 15.3±0.7 5.49±0.85 
CJL-5-58 10.1±1.5 70.8±7.2 22.4±6.5 590±125 13.5±6.3 14.0±2.5 8.09±3.27 
CJL-1-124 13.7±3.5 110±20 18.6±3.8 360±30 70% at 
10 µM 
7.3±1.5 11.7±3.1 
CJL-5-74 44.2±13.6 93.0±9.6 30.4±3.3 570±110 55% at 
10 µM 
9.6±5.6 8.1±1.8 
CJL-1-14+ 
CJL-1-80 
12.7±1.9 ND 75% at 10 
µM 
6810±330 50% at 
10 µM 
18.4±5.6 4.7±1.3 
Table 5.3: Summary of cAMP functional experiments and competitive binding 
experiments at the mMC1R, mMC3R, mMC4R, and mMC5R. The cAMP signaling 
potency was determined by AlphaScreen® assays in at least three independent 
experiments. In ALPHAScreen™ cAMP functional experiments, % represents amount of 
maximal signal observed at 10 µM compared to control NDP-MSH maximal signal. IC50 
values were determined by competitive binding in which experimental compounds were 
used to displace 125I-NDP-MSH in a dose-response manner. In competitive experiments, 
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% symbol represent the amount of 125I-NDP-MSH signal reduction at 10 µM. ND means 
the value was not determined. The reported errors are the standard error of the mean (SEM). 
Changes less than 3-fold were considered to be within the inherent experimental assay 
error. The a indicates that the synthesis and pharmacology was already reported in Lensing, 
C.J. et al J. Med Chem. 2016, and is included here for comparison. A full summary table 
of results can be found in the Table 5.4 and 5.5.   
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 mMC1R mMC3R mMC4R mMC5R 
Comp. Agonist EC50 
(nM) 
Agonist 
EC50 (nM) 
Antagonist 
(pA2) 
Agonist EC50 
(nM) 
Antagonist 
(pA2) 
Agonist 
EC50 (nM) 
 Mean±SEM Mean±SEM Mean±SEM Mean±SEM Mean±SEM Mean±SEM 
NDP-MSH 0.03±0.01 0.24±0.01  0.46±0.04 
 
0.31±0.03 
α-MSH 0.15±0.05 0.76±0.05  4.0±0.9 
 
0.59±0.03 
ɣ-MSH 1090±300 34.6±4.0  869±66 
 
35.1±18.7 
CJL-1-14 14.1±2.6 55.5±12.2  13.7±1.9  9.8±2.7 
CJL-5-35-4 26.2±9.9 47.4±12.7  5.7±2.9  2.1±0.3 
CJL-1-116 24.9±5.9 30.9±7.5  18.5±2.9  3.9±1.3 
CJL5-35-1 5.7±.7 107±66  74.1±14.1  52.4±10.3 
CJL-1-41 16.4±4.7 27.2±5.2  14.5±2.7  4.9±1.2 
CJL-1-31 4.4±0.6 20.2±4.0  9.2±1.0  3.8±0.9 
CJL-1-87 6.4±1.5 10.1±2.5  3.6±0.5  3.1±0.6 
CJL-5-72 12.6±3.8 22.7±3.7  7.3±2.1  4.0±0.2 
CJL-1-80 98.4±32.2 15% at 10 µM 6.04±0.09 15% at 10 µM 8.09±0.04 50% at 10 
µM 
CJL5-35-5 112±19 25% at 10 µM 6.14±0.06 10% at 10 µM 8.39±0.08 PA, 70% at 
10 µM 
CJL-1-132 139±17 PA, 45% at 10 
µM 
6.07±0.18 15% at 10 µM 7.97±0.29 PA, 50% at 
10 µM 
CJL-5-35-2 153±73 10% at 10 µM 6.88±0.19 5% at 10 µM 7.20±0.9 60% at 10 
µM 
CJL-1-140 563±142 15% at 10 µM 6.08±0.11 45% at 10 µM 7.68±0.37 786±185 
CJL-1-63 16.1±3.5 14.9±5.7  12.99±1.60  5.49±0.85 
CJL-5-58 10.1±1.54 22.4±6.5  13.54±6.34  8.09±3.27 
CJL-1-124 13.7±3.5 18.56±3.8  70% at 10 µM  11.71±3.13 
CJL-5-74 44.2±13.6 30.4±3.3  55% at 10 µM  8.09±1.75 
CJL-1-14+ 
CJL-1-80 
12.71±1.9 75% at 10 µM  50% at 10 µM  4.66±1.28 
Table 5.4: Functional data at the mMC1R, mMC3R, mMC4R, and mMC5R with data from 
Chapter 3 for comparison. The cAMP signaling potency was determined by AlphaScreen® 
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assays. The reported errors are the standard error of the mean (SEM) determined from at 
least three independent experiments. PA represents partial agonist. The % symbol 
represents amount of maximal signal observed at 10 µM compared to control NDP-MSH 
maximal signal. Changes less than 3-fold were considered to be within the inherent 
experimental assay error. The synthesis and pharmacology was already reported in 
Lensing, CJ et al J. Med Chem. 2016, 59, 3112-3128 for some compounds.25 
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Table 5.5: Summary of competitive binding experiments at the mMC1R, mMC3R, and 
mMC4R with data from Chapter 3 for comparison. IC50 values were determined by 
competitive binding in which experimental compounds were used to displace 125I-NDP-
MSH in a dose-response manner. In competitive experiments, % represent the amount of 
 
 mMC1R mMC3R mMC4R  
 IC50 (nM)  IC50 (nM)  IC50 (nM)  
Published Compound 
Name 
 
Mean± SEM n Mean±SEM n Mean±SEM n 
 
NDP-MSH 0.31±0.08 6 4.18±0.61 14 1.09±0.12 19 
Published CJL-1-14 388±52 2 60% @100 µM 2 214±55 6 
Published CJL-5-35-4 178±4 2 13400±5100 2 83±14 4 
Published CJL-1-116 705±6 2 78% @100 µM 3 292±67 4 
Published CJL-5-35-1 225±63 2 85% @100 µM 2 841±290 2 
Published CJL-1-41 1090±110 3 8430±230 2 258±27 2 
Published CJL-1-31 27.5±2.2 2 3250±760 2 33±5.1 3 
Published CJL-1-87 68.6±5.3 3 3470±510 2 9.9±2.9 4 
Published CJL-5-72 131±18 2 10200±1300 2 54±10 2 
Published CJL-1-80 1630±120 2 1430±190 2 26.0±3.4 2 
Published CJL-5-35-5 997±190 2 1310±120 2 10.7±0.6 2 
Published CJL-1-132 1870±220 4 999±290 2 21.8±1.9 3 
 CJL-5-35-2 633±128 2 350±60  39.2±1.0 2 
Published CJL-1-140 430±40 3 350±80 5 10.4±0.03 2 
 CJL-1-63 57.3±10.5 2 167±36.1 2 15.3±0.7 2 
 CJL-5-58 70.8±7.2 2 592.3±123.5 2 14.0±2.5 2 
 CJL-1-124 106.69±20.8 2 364.5±28.6 2 7.3±1.5 4 
 CJL5-74 93±9.6 2 566.1±110 2 9.6±5.6 2 
 CJL-1-14+ 
CJL-1-80 
ND  6810±330 2 18.4±5.6 2 
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125I-NDP-MSH signal reduction at 100 µM. The reported errors are the standard error of 
the mean (SEM). Changes less than 3-fold were considered to be within the inherent 
experimental assay error. The Pub. Indicates that the synthesis and pharmacology was 
already reported in Lensing, CJ et al J. Med Chem. 2016, 59, 3112-3128.25 
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Paradigm Housing Wild-type MC3RKO MC4RKO 
Fasting TSE Adverse;  
Sig. Effect 
Adverse;  
Sig. Effect 
N.D 
Nocturnal Conventional No Adverse;  
Sig. Effect 
N.D Adverse;  
Sig. Effect 
Fasting TSE Adverse;  
No Effect 
Adverse;  
Sig. Effect 
N.D. 
Nocturnal Conventional No Adverse;  
No Effect 
N.D No Adverse;  
No Effect 
Table 5.6. Table of adverse reactions observed in the current experiments with CJL-5-58 
in wild-type mice, MC3RKO mice, and MC4RKO mice. Adverse means that adverse 
reactions were observed in the experiments as described in the text. Sig. Effect means that 
a significant effect on food intake was observed. N.D. means not determined indicating 
that the experiment was not performed.  
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Chapter 6: Progressing the Structure Activity Relationship (SAR) of Bivalent 
Ligands: Evaluating the Effects of the Linker Length and Pursuing a Retro-Inverso 
Approach 
All peptides were designed, synthesized, purified, and analytically characterized by 
Cody Lensing under the supervision of Carrie Haskell-Luevano. Katlyn Fleming helped 
with mass determination by MALDI-TOF. The in vitro pharmacology studies were 
performed by Cody Lensing, Katie Freeman, and Sathya Schnell, all members of the 
Haskell-Luevano lab group. Radiolabeled 125I-NDP-MSH was prepared by Robert Speth. 
Serum stability studies were performed by Cody Lensing and Adam Zarth. 
6.1 Chapter Overview 
 The previous chapters provide evidence that melanocortin bivalent ligands have 
unique effects that are distinct from their monovalent counterparts in both in vitro and in 
vivo assay paradigms. This work validates further pursuit of melanocortin bivalent ligand 
design as pharmacological probes for both in vitro and in vivo exploratory studies. 
However, there is much work to be done to further explore the medicinal chemistry space 
around melanocortin bivalent ligand design. In this chapter, we describe two different 
approaches that were pursued to further study melanocortin bivalent ligands’ structure 
activity relationship (SAR). Homobivalent ligands were designed with 13, 16, 19, 20, and 
22 atom linkers to explore the effects of linker length. Overall, these studies resulted in a 
“flat” SAR in which the compounds all have similar potencies and efficacies. Bivalent 
ligands were also designed to include the retro-inverso tetrapeptide scaffold DTrp-DArg-
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Phe-DHis. Although this scaffold lacked high binding affinity and potency, it was very 
metabolically stable. The incorporation of this scaffold into bivalent ligands yielded 
ligands with varying potency and metabolic stabilities. The SAR trends observed from this 
design and their future implications are discussed in this chapter. 
6.2 Introduction  
 Although the main focus of the current thesis was to establish the effects of bivalent 
ligands at multiple melanocortin receptors in vitro and to understand their effects in vivo, 
we did initiate preliminary medical chemistry campaigns to optimize the melanocortin 
bivalent ligand design. These medicinal chemistry design strategies were attempts to better 
understand the structure activity relationship (SAR) of the bivalent ligands as well as 
circumvent foreseeable problems. The two main strategies that will be discussed in this 
chapter include: 1) testing the effects of linker length using polyethylene glycol (PEG)-
based linkers and 2) incorporating a retro-inverso scaffold into the bivalent ligands. 
The current approach of testing the effects of linker length was based on work 
performed by Portoghese and coworkers. They have previously observed that bivalent 
ligands are quite sensitive to linker length.10, 11, 224, 225  Small extensions in the length of the 
linker can significantly change activity.10, 11, 224, 225 Single atom linker extensions 
previously resulted in noteworthy changes (>500-fold) in the in vivo potency in a series of 
bivalent ligands tested for antinociception.10 A two-atom linker extension in a bivalent 
ligand previously increased potency by 1100-fold.225 Therefore, based on the previous 
results presented in Chapter 3 and Chapter 4 that the PEDG20 linker when incorporated 
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into compound CJL-1-87 resulted in increased binding affinity at the mMC4R and was 
metabolically stable,25, 132 we choose to explore the chemical space around this linker. 
Homobivalent ligands similar to CJL-1-87 were designed that utilized the His-DPhe-Arg-
Trp tetrapeptide scaffold. The ligands were designed to include PEG-based linkers that 
were 13, 16, 19, and 22 atoms long and connected two His-DPhe-Arg-Trp scaffolds 
(Figure 6.1). A MUmBLs series similar to CJL-5-58 in Chapter 5 was also designed with 
the 19 and 22 atom PEG-based linkers connecting a His-DPhe-Arg-Trp scaffold and a His-
DNal(2’)-Arg-Trp  scaffold (Figure 6.1). 
Another feature of the melanocortin bivalent ligands presented in Chapter 3- 5 is 
that all of these ligands, even the homobivalent ligands, are asymmetric.25, 132  This is due 
to the standard solid phase peptide synthesis convention utilized in which ligands are 
synthesized from the C-terminus to the N-terminus in a linear fashion. This results in a Trp 
residue connected to the linker on the N-terminus and a His residue connected to the linker 
on the C-terminus. Depending on how each receptor in a melanocortin dimer orientates 
itself, the asymmetry of the bivalent ligands could positively or negatively affect binding. 
The previous results of increased binding affinity and changes in pharmacology of the 
melanocortin bivalent ligands compared to their monovalent counterparts suggests that the 
asymmetric design utilized in Chapter 3-5 does bridge melanocortin dimers.25, 132  
However, to explore more thoroughly the effects of pharmacophore orientation on bivalent 
ligand design, we sought a design strategy that could be utilized to study this quickly and 
efficiently. Ideally, we wanted familiar and optimized chemistry that would give us access 
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to all four possible orientations rapidly. As these ligands were designed prior to the 
metabolic studies performed in Chapter 4 and Chapter 5, we also had some concern at 
this point about metabolic stability of the peptidic ligands. We sought to optimize 
metabolic stability simultaneously with the design strategy. One known strategy that fit all 
these requirements was to incorporate a retro-inverso scaffold in the bivalent ligands.312-314 
In a retro-inverso isomer, the direction of the sequence is reversed and the chirality 
of each sidechain are switched [e.g. levo (L) to dextro (D)]. In making both changes 
simultaneously the orientation of each side chain would be the same in theory, but with the 
directionality of the backbone reversed (Figure 6.2A). The retro-inverso strategy has 
previously been used to increase metabolic stability of peptides, while retaining or even 
increasing the activity of the original pharmacophore.312, 313 It should also be noted that 
although the paper chemistry appears to be a “golden goose” and is successful in some 
systems, the retro-inverso strategy has also been reported to have detrimental effects on 
activity.312, 313 Nonetheless, we persisted in hopes of both increasing the bivalent ligands’ 
metabolic stabilities and increasing their potencies. The retro-inverso tetrapeptide scaffold 
DTrp-DArg-Phe-DHis was incorporated into the bivalent ligand design by standard solid 
phase synthesis to create pseudo-symmetric bivalent ligands (Figure 6.2B). All the 
different orientations of the retro-inverso bivalent ligands with different linker lengths were 
designed and synthesized in parallel (Table 6.1).  
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6.3 Results and Discussion 
6.3.1 Synthesis  
The retro-inverso and linker length libraries were envisioned and synthesized at the 
same the time in parallel. Resin was split at various points as described in Chapter 2 and 
Chapter 3 (Scheme 2.1). Specifically, the common C-terminal tetrapeptide scaffolds were 
synthesized in bulk for each ligand and the resin was split before adding the linker and N-
terminus tetrapeptide scaffold. Compounds CJL-5-119-1, CJL-5-119-2, CJL-5-119-3, 
CJL-5-119-4, CJL-5-119-6, CJL-9-22-1, and CJL-9-22-2 were synthesized from 
common resin that had the His-DPhe-Arg-Trp scaffold added. Compounds CJL-5-127-1, 
CJL-5-127-2, CJL-5-127-3, CJL-5-127-4, CJL-5-127-5, CJL-5-127-6, CJL-5-127-7, 
CJL-5-127-8 were synthesized from common resin that had the DTrp-DArg-Phe-DHis 
scaffold added. Compounds CJL-9-22-3, CJL-9-22-4, and CJL-9-22-5 were synthesized 
from common resin that had the His-DNal(2’)-Arg-Trp scaffold added. All ligands were 
cleaved from resin and purified to >95% by RP-HPLC. Their masses were confirmed by 
MALDI-TOF (Table 6.1). 
6.3.2 In Vitro Biological Characterization 
As previously described in Chapter 2-5, the ability of compound to induce cAMP 
signaling was measured by the AlphaScreen® cAMP Assay Technology in live HEK293 
cells stably expressing the mMC1R, mMC3R, mMC4R, and mMC5R. Competitive 
binding affinity studies with the experimental ligands were also performed utilizing 125I-
NDP-MSH as previously described in Chapters 2-5. Data from CJL-1-14 was previously 
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reported in Chapter 3.25 Compound CJL-5-119-2 is the same structure as compound CJL-
1-87, but was remade during parallel synthesis as a control. It was observed to be slightly 
more potent in the cAMP functional AlphaScreen assay than previous results in Chapter 
3 (i.e. 2-fold at the mMC1R, 4-fold at the mMC3R, 2-fold at the mMC4R, and 6-fold at 
the mMC5R).25 This may have been due to changes that the manufacture PerkinElmer 
made to their AlphaScreen kit as control peptide NDP-MSH was also observed to be 
slightly more potent (i.e. 3-fold at the mMC1R, 4-fold at the mMC3R, even at the mMC4R, 
and 5-fold at the mMC5R) compared to those achieve previously in Chapter 3.25 A 
PerkinElmer sales representative emailed us the following about the changes in the 
AlphaScreen kit: “There were two things that were changed in the kit.  The antibody was 
changed, because our sole supplier discontinued that antibody and we also changed the 
tracer, which is the same as the AlphaLISA.  You should see better signal with the new 
kit.  Everything should be the same, but if you need help, please do not hesitate to let me 
know.”  
It should be noted that the IC50 values of CJL-5-119-2 and CJL-1-87 calculated 
from competition with 125I-NDP-MSH were within experimental error at the mMC1R, 
mMC3R, and mMC4R. This suggests the compounds were indeed the same, and the 
changes in cAMP functional potency were due to the manufacture’s changes in the 
AlphaScreen Kit. Compound CJL-9-22-4 is the same structure as CJL-5-58 reported in 
Chapter 5, but was also remade during parallel synthesis as a control. Similar to CJL-1-
87 and NDP-MSH, it showed increased potency (i.e. 2-fold at mMC1R, 3-fold at the 
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mMC3R, 3-fold at the mMC4R, and 4-fold at the mMC5R). Because all control 
compounds had increased functional potency in the “new” AlphaScreen® cAMP Assay 
after PerkinElmer made changes (but binding affinity was unaffected), it seems likely that 
the changes in potency are due to the AlphaScreen assay components. Because all 
compounds appear more potent, comparison internally with the “new” AlphaScreen kit 
should not be affected. However, direct comparison to previous cAMP AlphaScreen results 
should be avoided. Therefore, only results from the current studies are included in this 
chapter for AlphaScreen data. 
6.3.2.1 Linker Length Analogs  
The homobivalent ligands based on the His-DPhe-Arg-Trp tetrapeptide with 
varying linker lengths showed a “flat” SAR in the AlphaScreen assay (Table 6.2). This 
suggests that the linker lengths tested did not measurably affect cAMP signaling at least in 
this particular assay paradigm. At the mMC1R, the EC50 values ranged from 2.1 to 3.1 nM. 
At the mMC3R, the EC50 values ranged from 1.3 to 2.7 nM. At the mMC4R, the EC50 
values ranged from 1.1 to 1.7 nM. At the mMC5R, the EC50 values ranged from 0.39 to 
0.63 nM. The linker length for MUmBL analogs CJL-9-22-3, CJL-9-22-4, and CJL-9-
22-5 also appeared to have a “flat” SAR (Table 6.2).  The lack of SAR in the functional 
cAMP assays was not surprising considering that we and others have reported only small 
gains in functional signaling when measuring a single assay parameter with melanocortin 
bivalent ligands.25, 26, 132 28 In fact the results are very consist with the hypothesis presented 
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in Chapter 5 of asymmetrically signaling homodimers in which only one binding event of 
the melanocortin bivalent ligands results in cAMP signaling (Figure 5.1). 
To further evaluate the homobivalent linker length analogs, competitive binding 
affinity experiments were performed (Table 6.3). The competitive binding experiments of 
the linker length analogs competing against 125I-NDP-MSH also showed relatively flat 
SAR. At the mMC1R, the IC50 values ranged from 34 to 58 nM. At the mMC3R, the IC50 
values ranged from 1170 to 2140 nM. At the mMC4R, the IC50 values ranged from 10 to 
15 nM. The lack of SAR observed in the competitive binding assay paradigms following 
linker length extensions was surprising, but may be explained in several ways. First, 
detecting small disturbances in already highly potent ligands can be difficult. It has 
previously been observed that high potency (or affinity) pharmacophores incorporated into 
bivalent ligands can potentially mask multivalent interactions.27, 122, 223 This was discussed 
in detail in Chapter 3 to rationalize the lack of increased binding affinity observed with 
compound CJL-1-140 at the mMC4R.25  
A second possibility for the lack of improvement observed may be due the kinetics 
of the assay. In the current binding assay paradigm, a one-hour compound incubation was 
used. The purposed bivalent binding mode increases binding affinity by increasing the local 
concentration of the second pharmacophore and by lowering the dissociation of the 
bivalent ligand from the receptor (Figure 3.4). However, bivalent ligand design should not 
dramatically affect the entropic costs of the first binding event with the first 
pharmacophore. This means that the bivalent binding mode has a strong kinetic component 
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that may be affected by time. It could be hypothesized that our current one hour endpoint 
in the assay paradigm may not be optimal for measuring changes in the bivalent binding 
mode due to linker length, and therefore, no effects are observed currently. Also different 
melanocortin ligands have been reported to have different kinetics of binding, and different 
radiolabeled probes have been reported to give different IC50 or Ki values for the same 
experimental ligands in competitive binding assays.27, 132, 205, 219, 315 Therefore, 125I-NDP-
MSH may not be the optimal probe for detecting bivalent ligand effects due to its slow 
dissociation.205, 315 If NDP-MSH has a faster on-rate than the bivalent ligands and a slow 
dissociation, it may be difficult to detect small changes in binding affinity due to bivalent 
ligand design. However, more dramatic changes would be detectable such as the 
differences between the 20 atom PEDG20 linker in CJL-1-87 and the 40 atom PEDG20-
PEDG20 linker in CJL-5-72 observed in Chapter 3.25 
A third possibility is that the currently used PEG-based linkers are too flexible to 
detect small changes in linker length. If may be that with small 3 atom changes in linker 
length segments, the flexible PEG-based linker can “bend” to the appropriate length to 
bridge the receptor dimers. It may be necessary to use a more rigid linker system. Or a 
wider range of linker lengths could be used. Again, evidence of this hypothesis may be 
observed in the results presented in Chapter 3 in which the 20 atom PEDG20 was doubled 
to the 40-atom PEDG20-PEDG20 and resulted in observable changes in binding affinity 
(3-5 fold).25 
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 Finally, it must be mentioned that it is possible that the hypothesized bivalent 
binding mode has not been realized. This seems unlikely given the increased binding 
affinity observed with bivalent ligands compared to their monovalent counterparts that has 
been described in Chapter 3-5.25, 132 Also in strong support of the bivalent binding mode 
is the data that the linkers with bigger differences in length (i.e. 20-atom PEDG20, 36-atom 
(Pro-Gly)6, and 40 atom PEDG20-PEDG20) did result in differential effects on binding 
affinity in Chapter 3.25 Finally, if the bivalent ligands were binding in a monovalent 
fashion, it would be difficult to rationalize the unique in vitro and in vivo functional 
pharmacologies described in Chapter 4 and Chapter 5 with CJL-1-87 and CJL-5-58.132 
However, since no direct structural data of melanocortin bivalent ligand binding exists to 
date, it cannot be completely ruled out that some other mechanism is at play to explain the 
complex pharmacology that has been observed throughout current thesis work. Further 
work into characterizing the pharmacology and probing the SAR of bivalent ligands will 
provide further evidence to prove or disprove the hypothesized bivalent binding mode. But 
in order to gain confirmation of bivalent ligand binding, most likely a crystal structure of 
a bivalent ligand binding a melanocortin receptor dimer will be necessary.  
6.3.2.2 Retro-Inverso Analogs 
The first set-back while assessing the retro-inverso analogs was the discovery that 
both CJL-5-127-7 (Ac-DTrp-DArg-Phe-DHis-NH2) and CJL-5-127-8 (DTrp-DArg-Phe-
DHis-NH2) showed minimal agonist cAMP functional activity (<35% at 100 µM at any 
receptor subtype) (Table 6.2). Furthermore, compound CJL-5-127-7 showed little ability 
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to displace 125I-NDP-MSH in competitive binding assays (Table 6.3, Figure 6.3). At a 
concentration of 100 µM, CJL-5-127-7 reduced signal from 125I-NDP-MSH binding by 
30% at the mMC1R, 25% at the mMC4R, and showed no detectable result at the mMC3R. 
Although concerning, this lack of binding affinity may not be too problematic in the 
bivalent ligands that contain the His-DPhe-Arg-Trp scaffold considering the hypothesized 
bivalent binding mode. This is because the His-DPhe-Arg-Trp scaffold may act as a 
“targeting moiety” for the poorly-binding DTrp-DArg-Phe-DHis, tethering it in the precise 
location where it needs to be to bind the second receptor. Considering the greatly reduced 
entropic cost of binding for this second pharmacophore, it can still be hypothesized that 
the retro-inverso scaffold in a bivalent ligand will bind the second receptor in a dimer pair 
even with its poor binding affinity. Evidence of “targeting moiety” effect was presented in 
Chapter 5 in which the MUmBLs’ binding affinities increased 130 to 480-fold compared 
to the weaker binding tetrapeptide scaffold. In fact, the weak binding affinity of the retro-
inverso pharmacophore scaffold may aid in the detection of the synergistic effects of the 
purported bivalent binding mode. 
All bivalent compounds that contained the His-DPhe-Arg-Trp scaffold had EC50 
values less than 10 nM in the cAMP AlphaScreen assay at all receptor subtypes even when 
containing the DTrp-DArg-Phe-DHis scaffold (Table 6.2). This is consistent with the 
hypothesis of asymmetric signaling homodimers presented in Chapter 5 in which only one 
pharmacophore in a bivalent ligand is responsible for the cAMP signaling. This means the 
lack of functional activity of the DTrp-DArg-Phe-DHis scaffold would not affect cAMP 
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signaling assay results. No discernable SAR was observed at the mMC1R, mMC3R, and 
mMC5R for these compounds. At the mMC4R, there was a trend that placement of the 
His-DPhe-Arg-Trp scaffold in the N-terminus and the DTrp-DArg-Phe-DHis on the C-
terminus was slightly more potent than the opposite orientation. This can be observed with 
the 3-fold increased potency of CJL-5-127-3 compared to CJL-5-119-6 that both contain 
the 19 atom PEG-based linker. There is also a 3-fold increased cAMP potency of CJL-5-
127-2 compared CJL-5-119-5 that both contain the PEDG20 linker (Table 6.2).  
The ligands that contained only the DTrp-DArg-Phe-DHis (i.e. CJL-5-127-4, CJL-
5-127-5, and CJL-5-127-6) had greatly reduced ability to induce cAMP signaling. 
Compound CJL-5-127-5 was the most potent compound and was a full agonist at the 
mMC4R (EC50 = 3200 nM). This was as significant improvement in cAMP signaling 
potency at the mMC4R compared to its monovalent counterpart CJL-5-127-7 that showed 
only 20% activity at 100,000 nM. This suggests that the bivalent ligand design can 
dramatically increase the functional potency of the retro-inverso monovalent tetrapeptide. 
The full agonism observed with CJL-5-127-5 suggests that retro-inverso scaffold may still 
be useful for targeting the melanocortin receptors, but further optimization of the scaffold 
will be necessary. This also recapitulates the previous trend established in Chapter 3 that 
the PEDG20 linker is an optimal linker for targeting the mMC4R.25 Even more 
interestingly, it shows trends in the cAMP functional activity that are based on the length 
of the linker connecting the two tetrapeptide scaffolds (i.e. 20 atom PEDG20 > 22 atom 
PEG > 19 atom PEG). These trends were not observed above with the more potent linker 
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length analogs. This supports the hypothesis explained above that the high potency of His-
DPhe-Arg-Trp is masking the subtler effects of linker length in the analogs above.  
It was decided to focus on only the retro-inverso bivalent ligands that contained the 
PEDG20 linker for competitive binding experiments at the mMC1R, mMC3R, and 
mMC4R (Figure 6.3, Table 6.3). Bivalent ligand CJL-5-127-5 that contains two DTrp-
DArg-Phe-DHis pharmacophores had the lowest binding affinity of the retro-inverso 
bivalent analogs, but it did show improvement compared to the monovalent ligand CJL-
5-127-7 (Ac-DTrp-DArg-Phe-DHis-NH2) at all three subtypes tested. Both the bivalent 
ligands that contained one DTrp-DArg-Phe-DHis scaffold and one His-DPhe-Arg-Trp 
scaffold had improved binding affinity compared to both their monovalent counterparts 
CJL-1-14 (Ac-His-DPhe-Arg-Trp-NH2) and CJL-5-127-7 (Ac-DTrp-DArg-Phe-DHis-
NH2). At the mMC1R, CJL-5-119-5 and CJL-5-127-2 were both c.a. 3-fold more potent 
than the monovalent ligand CJL-1-14. At the mMC3R, CJL-5-119-5 and CJL-5-127-2 
was estimated to have 12-fold and 21-fold increased binding affinities, respectively, 
compared to CJL-1-14. At the mMC4R, CJL-5-127-2 had 7-fold increased binding 
affinity compared to CJL-1-14.  
Two important trends were observed in the binding experiments with the retro-
inverso analogs. First, the increased binding affinity of the retro-inverso scaffold 
containing bivalent ligands CJL-5-119-5 and CJL-5-127-2 compared to CJL-1-14 (Ac-
His-DPhe-Arg-Trp-NH2) supports the hypothesized bivalent binding mode. It is unlikely 
that the addition of the very weakly binding DTrp-DArg-Phe-DHis would be able to 
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increase binding affinity beyond CJL-1-14 alone without some sort of reduction in 
entropic cost, presumably through the bivalent binding mode. If monovalent binding of the 
His-DPhe-Arg-Trp pharmacophore was the only factor in binding, it would be expected 
that CJL-5-119-5 and CJL-5-127-2 would be the same as CJL-1-14. It can be proposed 
that the His-DPhe-Arg-Trp scaffold acts as a “targeting” region to bring the DTrp-DArg-
Phe-DHis scaffold very close to the second binding pocket in a melanocortin dimer (Figure 
3.4). This increases the local concentration of the DTrp-DArg-Phe-DHis scaffold 
dramatically, resulting in the increased binding affinity of the bivalent ligands. This also 
helps explain the high potency of these ligands in the cAMP functional assays. Second, 
based on the observation that CJL-5-127-2 had greater fold enhancements than CJL-5-
119-5, it can be hypothesized that the orientation having the Trp and DTrp residues 
connected to the linker, and therefore closer together, was favored at the mMC3R and 
mMC4R. This may have future design implications if completely symmetric bivalent 
ligands are synthesized.  
6.3.3 In Vitro Mouse Serum Stability Assays 
In order to assess the metabolic stability of both the linker length analogs and retro-
inverso analogs, in vitro mouse serum stability assays were performed as described 
previously in Chapter 2 (Figure 6.4).132 The linker length analogs CJL-5-119-1, CJL-5-
119-2, and CJL-5-119-3 all had similar metabolic stability in mouse serum (Figure 6.4A). 
Considering CJL-1-87 (which is the same as CJL-5-119-2) has adequate metabolic 
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stability for in vivo studies as reported in Chapter 4,132 this suggests that all these linker 
systems may be used in future design strategies.  
 The retro-inverso tetrapeptide CJL-5-127-7 was very metabolically stable in 
mouse serum. There was 90% of the parent peptide intact after 24 h. (Figure 6.4B) and 
80% intact after 72 h (Figure 6.4C). It can be estimated that the half-life of CJL-5-127-7 
would be 210 h. The most stable bivalent ligand assayed was CJL-5-127-5 that is 
comprised of two DTrp-DArg-Phe-DHis pharmacophores. The parent peptide was still 
45% intact at 24 h. This was approximately the same stability reported in Chapter 4 for 
compound CJL-1-14.132 The two bivalent ligands that contained both the His-DPhe-Arg-
Trp and DTrp-DArg-Phe-DHis had slightly increased metabolic stability than CJL-5-119-
2 (that is the same as CJL-1-87). The half-life of CJL-5-119-5 and CJL-5-127-2 were 8.6 
h and 7.5 h, respectively. The half-life of CJL-5-119-2 was 6.0 h. 
6.4 Conclusions 
 Although the current SAR campaigns described in this chapter were less than ideal, 
we hope it serves as a guide for future melanocortin bivalent ligand SAR campaigns. The 
studies focused on linker length analogs show that further confirmation of the bivalent 
binding mode will be necessary. Specifically, it can be hypothesized that the current 
binding assay paradigm utilized will need optimization to be sensitive enough to detect 
small changes in binding affinity that result from linker length adjustments. It may be 
necessary to do kinetic binding assays, or some other type of assay that allows real-time 
monitoring. It may also be necessary to utilize a more rigid linker so that the flexibility of 
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the linker cannot compensate for changes in linker length. This may allow for further 
optimization of melanocortin bivalent ligand design.  
The retro-inverso design strategy currently presented was thought-provoking to 
develop and push forward, but the loss in affinity and efficacy with the retro-inverso 
tetrapeptide scaffold was undesirable. Interestingly, we did accomplish increased 
metabolic stability with this scaffold. It was almost inversely proportional that with 
decreased binding affinity and functional potency, there was increased metabolic stability. 
It still seems tempting to hypothesize that the retro-inverso tetrapeptide scaffold, given its 
dramatically increased metabolic stability, may be a valuable scaffold for future 
melanocortin ligand design. Starting with a metabolically stable tetrapeptide scaffold 
combined with the years of knowledge on how to create potent and high affinity 
melanocortin ligands may allow for the creation of a metabolically stable and high affinity 
peptidic melanocortin ligands.  
While there are a variety of possibilities to explain the lack of SAR observed in the 
linker length analogs, it still may raise questions about the purported bivalent binding 
mode. Interestingly, the gain in binding affinity of retro-inverso containing bivalent 
analogs CJL-5-119-5 and CJL-5-127-5 beyond that of the monovalent ligand Ac-His-
DPhe-Arg-Trp-NH2 provides strong evidence of the presumed bivalent binding mode. It is 
almost paradoxical that these two libraries that were idealized, design, synthesized, and 
assayed in parallel provide a strong argument for and a strong argument against the bivalent 
binding mode. However, given all we have learned throughout this thesis work,25, 132 I 
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believe there is more evidence in support of the bivalent binding mode than against it. More 
exploration into bivalent ligand SAR will be necessary to understand more thoroughly the 
complex pharmacology that has been observed in the current thesis work.  
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Figure 6.1. The chemical structures of selected scaffolds and linkers used in Chapter 6. 
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Figure 6.2. Design of melanocortin bivalent ligands containing retro-inverso scaffolds. A) 
By reversing the sequence and by switching the chirality of each side chains, a retro-inverso 
isomer has the same side chain orientations but with the directionality of the backbone 
reversed. B) Bivalent ligands can be synthesized with standard solid phase peptide 
synthesis that have pseudo-symmetry in their side change orientation. 
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Figure 6.3. Illustrations of the competitive binding experiments at the mMC1R (A), 
mMC3R (B), and mMC4R (C) looking at the effects of the retro-inverso scaffold DTrp-
DArg-Phe-DHis when it is incorporated in the bivalent ligands with the PEDG20 linker. 
CJL-1-14 is from previously reported data from Chapter 3.25  
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Figure 6.4. In vitro serum stability of linker length bivalent analogs at 24 h (A) and retro-
inverso analogs at 24 h (B) and 72 h (C). Ligands (10 µM) were incubated in mouse serum 
and monitored for degradation of the parent molecule by LC-ESI+-MS/MS as described in 
Chapter 2. 
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  HPLC k' HPLC k' Mass Mass Purity 
Compound Structure (Syst. 1) (Syst. 2) (calcd.) (obs.) % 
CJL-5-119-1 Ac-His-DPhe-Arg-Trp-(PEG)(22 atoms)-His-DPhe-Arg-Trp-NH2 5.26 10.08 1646.85 1646.9 >96% 
CJL-5-119-2 Ac-His-DPhe-Arg-Trp-(PEDG20)-His-DPhe-Arg-Trp-NH2 5.35 9.20 1629.83 2629.9 >95% 
CJL-5-119-3 Ac-His-DPhe-Arg-Trp-(PEG)(19 atoms)-His-DPhe-Arg-Trp-NH2 5.82 9.84 1602.82 1602.8 >97% 
CJL-9-22-1 Ac-His-DPhe-Arg-Trp-(PEG)(16 atoms)-His-DPhe-Arg-Trp-NH2 5.35 9.12 1558.79 1559.03 >96% 
CJL-9-22-2 Ac-His-DPhe-Arg-Trp-(PEG)(13 atoms)-His-DPhe-Arg-Trp-NH2 5.28 7.75 1514.77 1515.01 >98% 
CJL-9-22-3 Ac-His-DPhe-Arg-Trp-(PEG)2(22atoms)-His-DNal(2')-Arg-Trp-NH2 5.91 8.71 1696.86 1697.04 >98% 
CJL-9-22-4 Ac-His-DPhe-Arg-Trp-(PEDG20)-His-DNal(2')-Arg-Trp-NH2 5.74 8.59 1679.85 1680.05 >96% 
CJL-9-22-5 Ac-His-DPhe-Arg-Trp-(PEG)(19atoms)-His-DNal(2')-Arg-Trp-NH2 5.86 9.98 1652.84 1652.92 >98% 
CJL-5-127-7 Ac-DTrp-DArg-Phe-DHis-NH2 4.57 6.43 685.34 685.28 >97% 
CJL-5-127-8 DTrp-DArg-Phe-DHis-NH2 3.15 4.32 643.33 643.27 >98% 
CJL-5-119-4 Ac-DTrp-DArg-Phe-DHis-(PEG)(22 atoms)-His-DPhe-Arg-Trp-NH2 5.92 9.89 1646.85 1646.9 97% 
CJL-5-119-5 Ac-DTrp-DArg-Phe-DHis-(PEDG20)-His-DPhe-Arg-Trp-NH2 5.50 9.78 1629.83 1629.9 >95% 
CJL-5-119-6 Ac-DTrp-DArg-Phe-DHis-(PEG)(19 atoms)-His-DPhe-Arg-Trp-NH2 5.65 9.60 1602.82 1602.8 >98% 
CJL-5-127-1 Ac-His-DPhe-Arg-Trp-(PEG)(22 atoms)-DTrp-DArg-Phe-DHis-NH2 6.54 7.67 1646.85 1646.8 >95% 
CJL-5-127-2 Ac-His-DPhe-Arg-Trp-(PEDG20)-DTrp-DArg-Phe-DHis-NH2 5.66 9.90 1629.83 1629.8 >95% 
CJL-5-127-3 Ac-His-DPhe-Arg-Trp-(PEG)(19 atoms)-DTrp-DArg-Phe-DHis-NH2 5.94 10.11 1602.82 1603.04 >97% 
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Table 6.1. The analytical data for peptides synthesized currently. HPLC k' = (peptide retention time - solvent retention time) / solvent 
retention time. System 1 is a 10% to 90% gradient of acetonitrile in water containing 0.1% trifluoroacetic acid over 35 minutes at a flow 
rate of 1.5 mL/min, and system 2 is the same but with methanol replacing acetonitrile. Product purity was determined by HPLC purity 
in the solvent system which showed the least purity and integrating the area under the curves of the chromatograms collected at 214 nm. 
Mass observed was calculated from the M+1. 
CJL-5-127-4 Ac-DTrp-DArg-Phe-DHis-(PEG)(22 atoms)-DTrp-DArg-Phe-DHis-NH2 5.49 8.97 1646.85 1647.03 >98% 
CJL-5-127-5 Ac-DTrp-DArg-Phe-DHis-(PEDG20)-DTrp-DArg-Phe-DHis-NH2 5.92 10.60 1629.83 1630.10 >98% 
CJL-5-127-6 Ac-DTrp-DArg-Phe-DHis-(PEG)(19 atoms)-DTrp-DArg-Phe-DHis-NH2 5.48 9.03 1602.82 1602.87 >97% 
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 mMC1R mMC3R mMC4R mMC5R 
Compound Agonist EC50 
(nM) 
Agonist EC50 
(nM) 
Agonist EC50 
(nM) 
Agonist EC50 
(nM) 
 Mean±SEM Mean±SEM Mean±SEM Mean±SEM 
NDP-MSH 0.009±0.002 0.06±0.007 0.34±0.10 0.06±0.005 
CJL-5-119-1 2.1±0.4 2.3±0.6 1.7±0.8 0.48±0.01 
CJL-5-119-2 3.1±0.6 2.7±0.5 1.7±0.6 0.52±0.04 
CJL-5-119-3 2.8±0.5 2.4±0.4 1.7±0.7 0.63±0.06 
CJL-9-22-1 2.4±0.5 1.3±0.2 1.1±0.5 0.41±0.03 
CJL-9-22-2 2.2±0.2 1.5±0.3 1.1±0.5 0.39±0.03 
CJL-9-22-3 6.9±0.9 6.4±1.4 5.5±2.2 1.8±0.04 
CJL-9-22-4 6.4±1.2 9.0±2.1 4.8±1.7 2.1±0.2 
CJL-9-22-5 5.9±1.0 5.8±1.4 4.8±2.5 1.7±0.2 
CJL-5-127-7 5% at 100 µM 15% at 100 µM 20% at 100 µM 35% at 100 µM 
CJL-5-127-8 15% at 100 µM 15% at 100 µM 15% at 100 µM 1% at 100 µM 
CJL-5-119-4 7.2±1.6 3.6±1.1 5.7±2.5 1.3±0.05 
CJL-5-119-5 9.0±1.5 4.5±0.7 8.8±4.1 1.4±0.2 
CJL-5-119-6 8.8±1.3 4.9±1.9 7.1±4.3 1.5±0.4 
CJL-5-127-1 5.6±1.3 4.9±1.6 2.8±1.2 0.74±0.05 
CJL-5-127-2 7.2±0.6 5.9±1.4 3.2±1.1 1.0±0.05 
CJL-5-127-3 5.0±0.6 3.6±0.7 2.1±0.9 0.63±0.02 
CJL-5-127-4 25% at 100 µM 45% at 100 µM 80% at 100 µM 60% at 100 µM 
CJL-5-127-5 45% at 100 µM 55% at 100 µM 3200±1200 80% at 100 µM 
CJL-5-127-6 25% at 100 µM 45% at 100 µM 65% at 100 µM 50% at 100 µM 
Table 6.2: Functional cAMP signaling data at the mMC1R, mMC3R, mMC4R, and 
mMC5R. The cAMP signaling potency was determined by AlphaScreen® assays. The 
reported errors are the standard error of the mean (SEM) determined from at least three 
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independent experiments. Changes less than 3-fold were considered to be within the 
inherent experimental assay error.  
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 mMC1R mMC3R mMC4R 
 IC50 (nM) IC50 (nM) IC50 (nM) 
Compound 
Name 
 
Mean ± SEM n Mean±SEM n Mean±SEM n 
NDP-MSH 0.39±0.07 2 5.9±0.7 2 1.9±0.3 3 
CJL-1-14 388±52* 2 60% @100 µM* 2 214±55* 6 
CJL-5-119-1 45±4 2 1680±240 2 15±5 3 
CJL-5-119-2 58±16 2 2140±170 2 14±4 3 
CJL-5-119-3 37±1 2 1700±180 2 14±3 3 
CJL-9-22-1 37±8 2 1170±10 2 12±4 3 
CJL-9-22-2 34±7 2 1310±220 2 10±4 3 
CJL-5-127-7 30% @100 µM 2 NA 2 25% @100 µM 2 
CJL-5-119-5 150±20 2 6220±270 2 93±40 2 
CJL-5-127-2 110±34 2 3800±250 2 29±It 5 2 
CJL-5-127-5 6300±1000 2 55% @100 µM 2 80% @100 µM 2 
Table 6.3: Summary of competitive binding experiments at the mMC1R, mMC3R, and 
mMC4R. IC50 values were determined by competitive binding in which experimental 
compounds were used to displace 125I-NDP-MSH in a dose-response manner. In 
competitive experiments, % represents the amount of 125I-NDP-MSH signal reduction at 
100 µM. The reported errors are the standard error of the mean (SEM). Changes less than 
3-fold were considered to be within the inherent experimental assay error. NA means no 
displacement was observed at 100 µM. 
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Chapter 7: Advancements Made, Lessons Learned, and Future Directions 
The current thesis provides the field foundational work into the design of 
melanocortin bivalent ligands, characterization of their in vitro pharmacology, and 
evaluation of their in vivo effects. As proposed in the introductory chapter, it appears we 
have successfully utilized bivalent ligands to target GPCR oligomers to decrease the 
entropic cost of binding and elicit novel melanocortin signaling patterns. These bivalent 
ligands are lead probes that may help in the design of therapeutics to treat obesity and other 
metabolic disorders. 
 Lead ligand CJL-1-87 showed promising effects as an anti-obesity probe as 
described in Chapter 3 and Chapter 4.25, 132 Compared to its monovalent counterpart, it 
possessed increased binding affinity, increased in vitro functional potency, increased the 
duration of action in spite of decreased serum stability, decreased in vivo food intake, 
decreased mice’s body fat percentage, and differentially affected mouse hormone levels. 
25, 132 The design principles learned along the way about receptor subtype preference 
patterns, paradigm-specific in vivo effects, and more will hopefully help guide future 
development of bivalent ligands targeting not only melanocortin receptors, but also 
targeting other GPCRs. 
In Chapter 5, a design strategy to target asymmetric GPCR homodimers with 
unmatched bivalent ligands (UmBLs) is presented. Melanocortin bivalent ligands featuring 
one agonist pharmacophore and one antagonist pharmacophore for the same receptor are 
synthesized, characterized in vitro, and evaluated in vivo. Employing this design strategy, 
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we discovered first in class biased ligands at the hMC4R in which the cAMP signaling 
pathway was robustly activated at nanomolar concentrations (EC50 ~ 2 to 6 nM), but the β-
arrestin pathway was only partially activated at a concentration of 10 µM. We also provided 
competitive binding and BRET data that supported our proposed asymmetric homodimer 
targeting strategy. Administration of lead compound CJL-5-58 to mice affected the 
measured metabolic endpoints, but also resulted in some signs of adverse reactions which 
may be paradigm specific. This design strategy may find applications for other 
melanocortin-dependent physiological effects or in other GPCR systems as well. To our 
knowledge, this is the first single compound design strategy to target asymmetric 
homodimers that is easily amendable for use in both in vitro and in vivo assay paradigms. 
 In Chapter 6, the structure activity relationship (SAR) of bivalent ligands is 
investigated in more depth. Bivalent ligands with various linker lengths were designed, 
synthesized, and evaluated in vitro. Also, bivalent ligands that contained the retro-inverso 
scaffold DTrp-DArg-Phe-DHis were studied. The ligands synthesized were not selected 
for further in vivo work, but they do highlight the need for further in vitro SAR studies.  
Based on the foundational work provided in this thesis, there are many different 
design strategies that could be explored. More rigid linkers could be used to gauge more 
effectively the SAR of linker length. Truly symmetric bivalent ligands could be synthesized 
and evaluated. Heterobivalent ligands with selective pharmacophores for two different 
melanocortin subtypes could be designed. This may become even more relevant as MC3R-
selective tetrapeptides are reported in the literature.119 Given the discovery in Chapter 4 
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of the mMC3R-mMC4R heterodimer,132 heterobivalent ligands that feature one selective 
mMC4R pharmacophore and one selective mMC3R pharmacophore may be interesting 
pharmacological probes to study this heterodimer. Heterobivalent ligands targeting the 
melanocortin receptors and a different receptor system may also be of interest. For 
example, heterobivalent ligands targeting known heterodimers such as the MC3R-GHSR 
(i.e. growth hormone secretagogue receptor) and MC4R-GPR7 (i.e. G protein-coupled 
receptor 7) could be synthesized and evaluated.316 Another interesting design aspect would 
be bitopic ligands as allosteric modulators are discovered and reported. By tethering an 
allosteric modulator to a high affinity orthosteric ligand, it may provide unique and distinct 
pharmacologies. This would be especially useful if the allosteric modulators are low 
affinity, as the orthosteric agonist or antagonist can act as the targeting moiety and allow 
for high overall binding affinity (as discussed in Chapter 5 and Chapter 6).  
 It was once stated by sociologist and economist Thorsein Veblen that: “The 
outcome of any serious research can only be to make two questions grow where only one 
grew before.” This thesis appears to have followed this maxim. Throughout this thesis 
many different pieces of data led to further questioning. For example: “Why is there an 
incongruity between the gains in binding affinity (c.a. 20- to 25-fold) and the gains in 
functional potency (c.a. 3- to 5-fold) with lead bivalent ligands?” “What is responsible for 
the physiological differences between administering bivalent ligands to fasted mice versus 
normal feeding mice?” “What is the equilibrium between melanocortin receptor 
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monomers, dimers, and higher-order oligomers?” and “Why was no distinct effect on SAR 
observed with the linker length library in Chapter 6?” 
Although this thesis opens the door to many more questions and hypotheses, it is 
my hope that the discoveries herein provide a foundation of work for future studies of both 
melanocortin dimers and of bivalent ligands targeting them. This work provides novel 
applications of melanocortin bivalent ligands, and suggests physiological relevancy of 
melanocortin dimers. It also provides evidence of two novel drug targets (i.e. MC3R-
MC4R heterodimer and asymmetric MC4R homodimer). It appears likely to me that as 
more is elucidated about the melanocortin dimers and GPCR dimers in general, the 
strategies and lessons learned in this thesis will become increasingly valuable. GPCRs 
remain one of the most highly successful drug targets, and additional ways to 
pharmacologically target them will hopefully garner new opportunities to improve human 
health.  This dissertation will hopefully serve as a valuable resource for future researchers 
exploring “The Bivalent Advantage.”  
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Appendix: Summary of Analytical Information and Pharmacology of Compounds 
 Figure A-1 presents the chemical structures of bivalent ligands synthesized 
throughout the current thesis. Table A-1 presents the analytical information of each peptide 
synthesized. Table A-2 presents the functional cAMP AlphaScreen® Assay results at the 
mMC1R, mMC3R, mMC4R, and mMC5R. Table A-3 presents the summary of 
competitive binding experiments with 125I-NDP-MSH at the mMC1R, mMC3R, and 
mMC4R. 
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Appendix Figure A-1. The chemical structures of selected scaffolds and linkers used. 
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   HPLC k' HPLC k' Mass Mass Purity 
Publ? Comp Structure (Syst. 1) (Syst. 2) (calcd.) (obs.) % 
Pub CJL-1-14 Ac-His-DPhe-Arg-Trp-NH2 3.2 5.5 685.34 685.39 >99% 
Pub CJL-5-35-4 Ac-His-DPhe-Arg-Trp-(PEDG20)-NH2 4.6 8.3 1003.52 1003.70 >95% 
Pub CJL-1-116 (PEDG20)-His-DPhe-Arg-Trp-NH2 4.0 6.4 961.51 961.57 >96% 
Pub CJL-5-35-1 Ac-His-DPhe-Arg-Trp-(Pro-Gly)6-NH2 4.3 8.5 1609.79 1610.00 >97% 
Pub CJL-1-41 (Pro-Gly)6-His-DPhe-Arg-Trp-NH2 3.6 6.2 1567.78 1568.28 >95% 
Pub CJL-1-31 Ac-His-DPhe-Arg-Trp-(Pro-Gly)6-His-DPhe-Arg-Trp-NH2 4.9 7.4 2237.10 2237.18 >99% 
Pub CJL-1-87 Ac-His-DPhe-Arg-Trp-(PEDG20)-His-DPhe-Arg-Trp-NH2 4.0 7.9 1629.83 1629.80 >99% 
Pub CJL-5-72 Ac-His-DPhe-Arg-Trp-(PEDG20)-(PEDG20)-His-DPhe-Arg-Trp-NH2 5.2 9.5 1949.01 1949.00 >95% 
Pub CJL-1-80 Ac-His-DNal(2')-Arg-Trp-NH2 4.3 7.5 735.36 735.30 >98% 
Pub CJL-5-35-5 Ac-His-DNal(2')-Arg-Trp-(PEDG20)-NH2 4.7 8.6 1053.54 1053.70 >95% 
Pub CJL-1-132 (PEDG20)-His-DNal(2')-Arg-Trp-NH2 5.2 8.3 1011.53 1011.59 >98% 
 CJL-5-35-2 Ac-His-DNal(2')-Arg-Trp-(Pro-Gly)6-NH2 5.3 9.7 1660.9 1660.0 >96% 
Pub CJL-1-140 Ac-His-DNal(2’)-Arg-Trp-(PEDG20)-His-DNal(2')-Arg-Trp-NH2 6.4 10.9 1729.86 1730.03 >95% 
Pub CJL-1-20 Ac-His-DPhe(p-I)-Arg-Trp-NH2 3.4 6.1 811.2 811.4 >99% 
 CJL-5-35-6 Ac-His-DPhe(p-I)-Arg-Trp-(PEDG20)-NH2 4.7 8.7 1129.4 1129.6 >96% 
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 CJL-5-009 (PEDG20)-His-DPhe(p-I)-Arg-Trp-NH2 4.5 8.0 1087.4 1087.3 >98% 
 CJL-5-35-3 Ac-His-DPhe(p-I)-Arg-Trp-(Pro-Gly)6 -NH2 5.23 9.67 1735.7 1735.8 >97% 
 CJL-5-64 Ac-His-DPhe(p-I)-Arg-Trp-(PEDG20)-His-DPhe(p-I)-Arg-Trp-NH2 6.0 10.5 1881.6 1881.6 >97% 
 CJL-1-63 Ac-His-DNal(2')-Arg-Trp-(Pro-Gly)6-His-DPhe-Arg-Trp-NH2 5.3 8.6 2287.6 2287.3 >95% 
 CJL-5-58 Ac-His-DPhe-Arg-Trp-(PEDG20)-His-DNal(2')-Arg-Trp-NH2 5.4 9.7 1680.9 1680.6 >95% 
 CJL-1-124 Ac-His-DNal(2')-Arg-Trp-(PEDG20)-His-DPhe-Arg-Trp-NH2 6.0 9.5 1680.9 1681.0 >97% 
 CJL-5-74 Ac-His-DNal(2')-Arg-Trp-(PEDG20)-(PEDG20)-His-DPhe-Arg-Trp-NH2 5.7 10.2 1999.3 1999.2 >95% 
 CJL-1-53 Ac-His-(p-I)DPhe-Arg-Trp-(Pro-Gly)6-His-DPhe-Arg-Trp-NH2 5.50 9.75 2363.4 2363.4 >98% 
 CJL-1-108 Ac-His-DPhe(p-I)-Arg-Trp-(PEDG20)-His-DPhe-Arg-Trp-NH2 6.29 9.33 1755.7 1755.8 >96% 
 CJL-5-12 Ac-His-DPhe-Arg-Trp-(PEDG20)-His-DPhe(p-I)-Arg-Trp-NH2 5.47 9.63 1755.7 1755.8 >96% 
 CJL-5-15 Ac-His-DNal(2')-Arg-Trp-(PEDG20)-His-DPhe(p-I)-Arg-Trp-NH2 5.95 10.40 1806.8 1806.6 >95% 
 CJL-5-61 Ac-His-DPhe(p-I)-Arg-Trp-(PEDG20)-His-DNal(2')-Arg-Trp-NH2 5.95 10.71 1806.8 1806.6 >96% 
 CJL-5-119-1 Ac-His-DPhe-Arg-Trp-(PEG)(22 atoms)-His-DPhe-Arg-Trp-NH2 5.26 10.08 1646.85 1646.9 >96% 
Pub CJL-5-119-2 Ac-His-DPhe-Arg-Trp-(PEDG20)-His-DPhe-Arg-Trp-NH2 5.35 9.20 1629.83 2629.9 >95% 
 CJL-5-119-3 Ac-His-DPhe-Arg-Trp-(PEG)(19 atoms)-His-DPhe-Arg-Trp-NH2 5.82 9.84 1602.82 1602.8 >97% 
 CJL-9-22-1 Ac-His-DPhe-Arg-Trp-(PEG)(16 atoms)-His-DPhe-Arg-Trp-NH2 5.35 9.12 1558.79 1559.03 >96% 
 CJL-9-22-2 Ac-His-DPhe-Arg-Trp-(PEG)(13 atoms)-His-DPhe-Arg-Trp-NH2 5.28 7.75 1514.77 1515.01 >98% 
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 CJL-9-22-3 Ac-His-DPhe-Arg-Trp-(PEG)2(22atoms)-His-DNal(2')-Arg-Trp-NH2 5.91 8.71 1696.86 1697.04 >98% 
 CJL-9-22-4 Ac-His-DPhe-Arg-Trp-(PEDG20)-His-DNal(2')-Arg-Trp-NH2 5.74 8.59 1679.85 1680.05 >96% 
 CJL-9-22-5 Ac-His-DPhe-Arg-Trp-(PEG)(19atoms)-His-DNal(2')-Arg-Trp-NH2 5.86 9.98 1652.84 1652.92 >98% 
 CJL-5-127-7 Ac-DTrp-DArg-Phe-DHis-NH2 4.57 6.43 685.34 685.28 >97% 
 CJL-5-127-8 DTrp-DArg-Phe-DHis-NH2 3.15 4.32 643.33 643.27 >98% 
 CJL-5-119-4 Ac-DTrp-DArg-Phe-DHis-(PEG)(22 atoms)-His-DPhe-Arg-Trp-NH2 5.92 9.89 1646.85 1646.9 >97% 
 CJL-5-119-5 Ac-DTrp-DArg-Phe-DHis--(PEDG20)-His-DPhe-Arg-Trp-NH2 5.50 9.78 1629.83 1629.9 >95% 
 CJL-5-119-6 Ac-DTrp-DArg-Phe-DHis-(PEG)(19 atoms)-His-DPhe-Arg-Trp-NH2 5.65 9.60 1602.82 1602.8 >98% 
 CJL-5-127-1 Ac-His-DPhe-Arg-Trp-(PEG)(22 atoms)-DTrp-DArg-Phe-DHis-NH2 6.54 7.67 1646.85 1646.8 >95% 
 CJL-5-127-2 Ac-His-DPhe-Arg-Trp-(PEDG20)-DTrp-DArg-Phe-DHis-NH2 5.66 9.90 1629.83 1629.8 >95% 
 CJL-5-127-3 Ac-His-DPhe-Arg-Trp-(PEG)(19 atoms)-DTrp-DArg-Phe-DHis-NH2 5.94 10.11 1602.82 1603.04 >97% 
 CJL-5-127-4 Ac-DTrp-DArg-Phe-DHis-(PEG)(22 atoms)-DTrp-DArg-Phe-DHis-NH2 5.49 8.97 1646.85 1647.03 >98% 
 CJL-5-127-5 Ac-DTrp-DArg-Phe-DHis-(PEDG20)-DTrp-DArg-Phe-DHis-NH2 5.92 10.60 1629.83 1630.10 >98% 
 CJL-5-127-6 Ac-DTrp-DArg-Phe-DHis-(PEG)(19 atoms)-DTrp-DArg-Phe-DHis-NH2 5.48 9.03 1602.82 1602.87 >97% 
Appendix Table A-1. The analytical data for peptides synthesized in this thesis. HPLC k' = (peptide retention time - solvent retention 
time) / solvent retention time. System 1 is a 10% to 90% gradient of acetonitrile in water containing 0.1% trifluoroacetic acid over 35 
minutes at a flow rate of 1.5 mL/min, and system 2 is the same but with methanol replacing acetonitrile. Product purity was determined 
by HPLC purity in the solvent system which showed the least purity and integrating the area under the curves of the chromatograms 
collected at 214 nm. Mass observed was calculated from the M+1 or (M+2)/2 peak. The Pub. Indicates that the synthesis and 
pharmacology was reported in Lensing, CJ et al J. Med Chem. 2016. 25, 132
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 mMC1R mMC3R mMC4R mMC5R 
Compound Agonist 
EC50 
(nM) 
Agonist 
EC50 (nM) 
Antagonist 
(pA2) 
Agonist 
EC50 (nM) 
Antagonist 
(pA2) 
Agonist 
EC50 (nM) 
 Mean± 
SEM 
Mean±SEM Mean± 
SEM 
Mean±SEM Mean± 
SEM 
Mean± 
SEM 
NDP-MSH 0.03±0.01 0.24±0.01  0.46±0.04 
 
0.31±0.03 
α-MSH 0.15±0.05 0.76±0.05  4.0±0.9 
 
0.59±0.03 
ɣ-MSH 1090±300 34.6±4.0  869±66 
 
35.1±18.7 
CJL-1-14 14.1±2.6 55.5±12.2  13.7±1.9  9.8±2.7 
CJL-5-35-4 26.2±9.9 47.4±12.7  5.7±2.9  2.1±0.3 
CJL-1-116 24.9±5.9 30.9±7.5  18.5±2.9  3.9±1.3 
CJL5-35-1 5.7±.7 107±66  74.1±14.1  52.4±10.3 
CJL-1-41 16.4±4.7 27.2±5.2  14.5±2.7  4.9±1.2 
CJL-1-31 4.4±0.6 20.2±4.0  9.2±1.0  3.8±0.9 
CJL-1-87 6.4±1.5 10.1±2.5  3.6±0.5  3.1±0.6 
CJL-5-72 12.6±3.8 22.7±3.7  7.3±2.1  4.0±0.2 
CJL-1-80 98.4±32.2 15% at 10 µM 6.04±0.09 15% at 10 µM 8.09±0.04 50% at 10 
µM 
CJL5-35-5 112±19 25% at 10 µM 6.14±0.06 10% at 10 µM 8.39±0.08 PA, 70% at 
10 µM 
CJL-1-132 139±17 PA, 45% at 10 µM 6.07±0.18 15% at 10 µM 7.97±0.29 PA, 50% at 
10 µM 
CJL-5-35-2 153±73 10% at 10 µM 6.88±0.19 5% at 10 µM 7.20±0.9 60% at 10 
µM 
CJL-1-140 563±142 15% at 10 µM 6.08±0.11 45% at 10 µM 7.68±0.37 786±185 
CJL-1-20 12±2 55% at 100 µM 6.79±0.08 50% at 100 µM 8.57±0.08 2.75±1.15 
CJL-5-35-6 9.5±1.7 PA, 60% at 100 µM 7.30±0.07 PA, 45% at 100 
µM 
8.67±0.05 28±12 
CJL-5-009 30±6 PA, 60% at 100 µM 7.01±0.22 PA, 45% at 100 
µM 
8.49±0.24 4.5±1.6 
CJL-5-35-3 7.1±1.7 25% at 10 µM 7.05±0.13 30% at 10 µM 7.82±0.12 27.6±12 
CJL-5-64 NS NS NS NS NS NS 
CJL-1-63 16.1±3.5 14.9±5.7  12.99±1.60  5.49±0.85 
CJL-5-58 10.1±1.54 22.4±6.5  13.54±6.34  8.09±3.27 
CJL-1-124 13.7±3.5 18.56±3.8  70% at 10 µM  11.71±3.13 
CJL-5-74 44.2±13.6 30.4±3.3  55% at 10 µM  8.09±1.75 
CJL-1-14+ 
CJL-1-80 
12.71±1.9 75% at 10 µM  50% at 10 µM  4.66±1.28 
CJL-1-53 26.6±14 PA, 70% at 100 µM 6.54±0.16 PA, 80% at 100 
µM 
6.95±0.23 35±4.0 
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CJL-1-108 5.8±1.06 29.1±5.8  PA, 65% at 10 
µM 
 12.8±2.3 
CJL-5-12 14.1±2.3 56.5±11.8  9.6±3.5  14.9±1.8 
CJL-5-15 130±40 70% at 10 µM 6.63±0.12 60% at 10 µM 7.67±0.17 64.0±11.9 
CJL-5-61 88.7±21.8 60% at 10 µM 6.60±0.10 55% at 10 µM 7.65±0.32 120±40 
NDP-MSH 0.009±0.0
02 
0.06±0.007  0.34±0.095  0.06±0.005 
CJL-5-119-1 2.1±0.4 2.3±0.6  1.7±0.8  0.48±0.01 
CJL-5-119-2 3.1±0.62 2.7±0.5  1.7±0.6  0.52±0.04 
CJL-5-119-3 2.8±0.46 2.4±0.41  1.7±0.71  0.63±0.055 
CJL-9-22-1 2.4±0.50 1.3±0.22  1.1±0.46  0.41±0.034 
CJL-9-22-2 2.2±0.20 1.5±0.33  1.1±0.45  0.39±0.026 
CJL-9-22-3 6.9±0.88 6.4±1.4  5.5±2.2  1.8±0.04 
CJL-9-22-4 6.4±1.2 9.0±2.1  4.8±1.7  2.1±0.2 
CJL-9-22-5 5.9±0.97 5.8±1.41  4.8±2.5  1.7±0.15 
CJL-5-127-7 5% at 100 
µM 
15% at 100 µM  20% at 100 µM  35% at 100 
µM 
CJL-5-127-8 15% at 
100 µM 
15% at 100 µM  15% at 100 µM  1% at 100 
µM 
CJL-5-119-4 7.2±1.6 3.6±1.1  5.7±2.5  1.3±0.05 
CJL-5-119-5 9.0±1.5 4.5±0.69  8.8±4.1  1.4±0.16 
CJL-5-119-6 8.8±1.3 4.9±1.9  7.1±4.3  1.5±0.38 
CJL-5-127-1 5.6±1.3 4.9±1.6  2.8±1.2  0.74±0.045 
CJL-5-127-2 7.2±0.59 5.9±1.4  3.2±1.1  1.0±0.052 
CJL-5-127-3 5.0±0.61 3.6±0.71  2.1±0.91  0.63±0.017 
CJL-5-127-4 25% at 
100 µM 
45% at 100 µM  80% at 100 µM  60% at 100 
µM 
CJL-5-127-5 45% at 
100 µM 
55% at 100 µM  3213±1147  80% at 100 
µM 
CJL-5-127-6 25% at 
100 µM 
45% at 100 µM  65% at 100 µM  50% at 100 
µM 
Appendix Table A-2: Functional data at the mMC1R, mMC3R, mMC4R, and mMC5R. 
The cAMP signaling potency was determined by AlphaScreen® assays. The reported 
errors are the standard error of the mean (SEM) determined from at least three independent 
experiments. Changes less than 3-fold were considered to be within the inherent 
experimental assay error. NS means compound was not soluble in bioassay compatible 
solvent. PA means partial agonism was observed. The Pub. Indicates that the synthesis and 
pharmacology was already reported in Lensing, CJ et al J. Med Chem. 2016.25, 132 
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    mMC1R mMC3R mMC4R  
 IC50 (nM) IC50 (nM) IC50 (nM) 
Published? Compound 
Name 
 
Mean ± SEM n Mean±SEM n Mean±SEM n 
Pub NDP-MSH 0.31±0.08 6 4.18±0.61 14 1.09±0.12 19 
Pub CJL-1-14 388±52 2 60% @100 
µM 
2 214±55 6 
Pub CJL-5-35-4 178±4 2 13400±5100 2 83±14 4 
Pub CJL-1-116 705±6 2 78% @100 
µM 
3 292±67 4 
Pub CJL-5-35-1 225±63 2 85% @100 
µM 
2 841±290 2 
Pub CJL-1-41 1090±110 3 8430±230 2 258±27 2 
Pub CJL-1-31 27.5±2.2 2 3250±760 2 33±5.1 3 
Pub CJL-1-87 68.6±5.3 3 3470±510 2 9.9±2.9 4 
Pub CJL-5-72 131±18 2 10200±1300 2 54±10 2 
Pub CJL-1-80 1630±120 2 1430±190 2 26.0±3.4 2 
Pub CJL-5-35-5 997±190 2 1310±120 2 10.7±0.6 2 
Pub CJL-1-132 1870±220 4 999±290 2 21.8±1.9 3 
 CJL-5-35-2 633±128 2 350±60  39.2±1.0 2 
Pub CJL-1-140 430±40 3 350±80 5 10.4±0.03 2 
Pub CJL-1-20 190±10 2 780±90 2 6.0±1.2 2 
 CJL-5-35-6 130±10 2 550±10 2 2.7±0.4 2 
 CJL-5-009 460±170 3 230±70 2 13.5±5.0 3 
 CJL-5-35-3 63.5±12 2 175±17 2 9.8±1.9 2 
 CJL-5-64 NS  NS  NS  
 CJL-1-63 57.3±10.5 2 167±36.1 2 15.3±0.7 2 
 CJL-5-58 70.8±7.2 2 592.3±123.5 2 14.0±2.5 2 
 CJL-1-124 106.69±20.8 2 364.5±28.6 2 7.3±1.5 4 
 CJL5-74 93±9.6 2 566.1±110 2 9.6±5.6 2 
 CJL-1-14+ 
CJL-1-80 
ND  6810±330 2 18.4±5.6 2 
 CJL-1-53 140±50 3 220±60 2 36±10 2 
 CJL-1-108 19.5±0.5 2 69±14 3 3.0±0.2 3 
 CJL-5-12 29.3±3.2 2 115±24 3 7.2±0.02 2 
 CJL-5-15 96±3.8 2 64±16 2 7.1±0.9 2 
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 CJL-5-61 194±12 2 145±51 2 8.9±0.3 2 
Pub NDP-MSH 0.39±0.07 2 5.9±0.7 2 1.9±0.3 3 
 CJL-5-119-1 45.2±3.6 2 1680±240 2 15±4.5 3 
Pub CJL-5-119-2 58±16 2 2140±170 2 14±3.7 3 
 CJL-5-119-3 36.6±1.2 2 1700±180 2 14±3.1 3 
 CJL-9-22-1 36.5±8.3 2 1170±10 2 12±3.5 3 
 CJL-9-22-2 33.7±7.4 2 1310±220 2 10±3.9 3 
 CJL-5-127-5 6300±1000 2 55% @100 
µM 
2 80% @100 
µM 
2 
 CJL-5-127-7 30% @100 
µM 
2 NA 2 25% @100 
µM 
2 
 CJL-5-119-5 150±20 2 6220±270 2 93±40 2 
 CJL-5-127-2 110±34 2 3800±250 2 29±5.4 2 
Appendix Table A-3: Summary of competitive binding experiments with 125I-NDP-MSH 
at the mMC1R, mMC3R, and mMC4R. IC50 values were determined by competitive 
binding in which experimental compounds were used to displace 125I-NDP-MSH in a dose-
response manner. In competitive experiments, % represent the amount of 125I-NDP-MSH 
signal reduction at 100 µM. The reported errors are the standard error of the mean (SEM). 
Changes less than 3-fold were considered to be within the inherent experimental assay 
error. NA means no activity observed up to 100 µM. NA means no displacement was 
observed at 100 µM. NS means compound was not soluble in bioassay compatible solvent. 
The Pub. Indicates that the synthesis and pharmacology was already reported in Lensing, 
CJ et al J. Med Chem. 2016.25, 132 
 
